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1 SUMMARY 
 
The aim of this work was to search for new active compounds which regulate lipid 
synthesis in vitro in SZ95 sebocytes. More than 200 extracts and fractions derived 
from plants, microorganisms, Bothrops moojeni snake venom as well as peptides 
were tested in a newly established screening model to identify active ingredients, 
which act on neutral and polar lipid synthesis in SZ95 sebocytes. The clinical 
background for this work was the fact that during the ageing process sebocytes 
reduce lipid production. The relationships between ageing effects and lipid reduction 
on a molecular level and ways to influence them are not fully identified. For this 
reason, after identification of active lipid regulating compounds, this work further 
focused on lipid stimulation in SZ95 sebocytes by Bothrops moojeni snake venom gel 
filtration fractions (Botmo GF).  
 
Botmo GF increased lipid synthesis in SZ95 sebocytes without apparent toxic or 
apoptotic effects in applied concentrations. Partly purified Botmo GF fractions were 
identified as fraction with phospholipase (PLA2) activity (Botmo GF 11-117) and 
another fraction without enzymatic PLA2 activity (Botmo GF 11-101). Botmo GF 11-
101 (1 g/ml) enhanced neutral lipid synthesis by up to 150% and polar lipid 
synthesis by up to 120%. The enzymatically active PLA2 Botmo GF 11-117 (1 g/ml) 
increased synthesis of neutral lipids by up to 310% and polar lipid synthesis by up to 
120% compared to untreated SZ95 sebocytes. The present data surprisingly indicate 
that lipid synthesis stimulation by Botmo GF 11-101 and Botmo GF 11-117 was 
independent of PLA2 enzymatic activity in Botmo GF 11 subfractions.  
It is hypothesized that SZ95 sebocyte treatment with PLA2 fractions lead to the 
production of fatty acids and eicosanoids which activate PPAR. Interestingly, Botmo 
GF 11-101 was not able to activate any PPAR and Botmo GF 11-117 significantly 
activated PPAR (p < 0.001) in PPAR,  or 2 transiently transfected SZ95 
sebocytes.  
 
Phospholipase activates the arachidonic acid (AA) metabolism. AA metabolised with  
cyclooxygenase (COX) and lipoxygenase (LOX) to prostaglandins as well as 
leukotrines. To get more knowledge about the lipogenesis pathway, we pre-
stimulated SZ95 sebocytes with arachidonic acid and treated sebocytes with 
cyclooxygenase-2 inhibitor (NS398), LOX inhibitor (NDGA), 5-LOX inhibitor (MK886) 
and PLA2 inhibitor (AACOCF3). Interestingly, most of the inhibitors stimulated neutral 
lipid synthesis in SZ95 sebocytes. Only, PLA2 inhibitor showed no neutral lipid 
stimulation. 
Additionally, SZ95 sebocytes transiently expressing PPAR were pre-stimulated with 
arachidonic acid. Treatment with NS398 reduced the level of PPAR isotype activation 
which, however, remained higher than that of untreated control cells. Since NS398 is 
a known prostaglandin E2 (PGE2) inhibitor, this effect is assumed to be caused by a 
reduction of PGE2. The LOX inhibitor NDGA activated all transiently expressed PPAR 
in SZ95 sebocytes. The epidermal LOX products such as 15-HETE and HPETE may 
act on PPAR in a non specific manner. 
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In conclusion, the enzymatically active PLA2 may activate a pathway of arachidonic 
acid and mediators which activate lipid synthesis. Botmo GF 11-117 activated 
PPAR. PLA2 inactive Botmo GF 11-101 still significantly activated lipid synthesis, 
while no PPAR activation was measurable. Thus, it is suspected that both Bothrops 
moojeni fractions act via different mechanisms on lipid stimulation in SZ95 sebocytes. 
However, the exact pathway is still not identified. Botmo GF 11-101 and 11-117 
might be interesting tools for the investigation of sebocyte lipogenesis and may be 
helpful to the development of therapeutic concepts for the treatment of age-related 
skin dryness. 
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2 INTRODUCTION 
 
2.1 HUMAN SKIN 
 
The skin is the largest organ of the human body and is organized in three layers: 
epidermis, dermis and subcutis. The dermis includes epidermal appendages like 
sebaceous glands, hair follicles and sweat glands. Sebaceous glands and hair 
follicles form one unit (Figure 1). Each unit consists of bulge, hair bulge and 
sebaceous gland. Sebaceous glands are found all over the surface of the human 
body, except on palms, soles and dorsum of the feet. The largest and most active 
sebaceous glands are located in the face and on the scalp. The main functions of 
sebaceous glands are sebum production and secretion. 
The sebum is composed of different lipids which are produced by sebocytes in the 
sebaceous glands (for more details see chapter 2.5). Main function of these 
sebocytes is to produce lipids, which are released upon cell death. The sebum is 
degraded to pass through the duct to the epidermal surface. Sebum lubricates the 
skin to protect it against bacterial and fungal infections. A lipid film controls moisture 
loss and contributes to body odor. 
 
 
 
 
Figure 1 - Schematic illustration of the skin: Skin is composed of three layers; epidermis 1, 
dermis 2 and subcutis 3. In the inner part of the dermis there is the pilosebaceous unit which consists 
of: hair bulge 4, sebaceous gland 5, and sweat glands 6. 
 
In more detail, sebocytes are able to express hormones and functional receptors 
themselves. These receptors bind molecules which initiate pathways for inflammatory 
cytokines or chemokines, proliferation, differentiation, lipogenesis, and androgen 
metabolism.  
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Phenomena in which the pilosebaceous unit which consists of hair bulge, sebaceous 
gland, and sweat gland is involved are: Skin ageing or disorders like acne, 
seborrhea, psoriasis and atopic or dry skin. 
 
 
2.2 CORRELATION BETWEEN SKIN AGEING AND REDUCED 
SEBACEOUS GLAND ACTIVITY IN HUMAN SKIN 
 
Human life expectancy has increased during the last decades. In the future our 
society will grow older; the consequences of ageing have begun to gain particular 
attention. The lifespan of humans is determined by both environmental and genetic 
factors, and many of the mechanisms identified to increase lifespan are evolutionarily 
conserved across organisms. Diepgen hypothesizes that life expectancy will grow up 
to 83 years for woman and 76 years for men in 2025 [28]. It is expected that the 
group of people aged 65 and more will grow from 17% today to over 30% of Europe‟s 
population by 2050. 
 
Skin ageing is a complex process. It is associated with numerous significant gender-
related alterations in the lipid profiles secreted by human sebaceous glands. 
During ageing, sebaceous glands undergo different structural and functional 
alterations. Alteration of skin surface lipids is related to the sebaceous gland activity. 
Gland activity and sebum secretion decrease during the course of ageing (Figure 2). 
 
 
 
Age
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Figure 2 - Sebum secretion level in relation to ageing estimated during life span for women and 
men [187]. 
 
A strong increase in sebum excretion occurs a few hours after birth with a peak 
during the first week of life, followed by slow decrease thereafter. A next sebum rise 
takes place at an age of about 9 years and continues up to the age of 20 years, when 
the adult sebum level is reached. After an age of 60 years sebaceous glands 
produce reduced levels of lipids. Women show stronger ageing effects with dry skin 
0  1
st 
week        9                   20                60    100 years 
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after menopause, while men experience a minimal sebum decrease, usually after the 
age of 80 years.  
 
The number of sebaceous glands remains approximately unchanged throughout life; 
however their size increases with age [157]. Over time, sebaceous glands reduce 
sebum secretion. As a result of this skin slowly loses its ability to renew itself and 
becomes thinner and drier. Dryness is one important characteristic of aged skin. 
Changes in the connective tissue reduce the skin's strength and elasticity. 
Additionally, aged skin repairs itself more slowly than younger skin. Figure 3 
illustrates the visible changes occurring during skin ageing on the less sun exposed 
inner arm. 
 
 
Figure 3 - Aged skin in the inner less UV exposed area of the arm. Photos are taken from a 10- 
(A), 45- (B) and 70- (C) year old person [88]. 
 
 
2.3 SEBACEOUS GLANDS AND DEVELOPMENT OF SEBOCYTES 
 
Epidermal progenitor cells in skin give rise to multiple lineages: hair follicle, 
sebaceous gland, and overlying epidermis. The multi-potent stem cells reside in the 
bulge region of the hair follicle. These stem cells transform into keratinocytes 
(epidermis) as well as into associated structures such as sebaceous glands 
(sebocytes) and dermal papilla (dermal papilla cells) (Figure 4)  
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6 
 
 
Figure 4 - Model follicle showing the development of sebocytes, dermal papilla cells (hair bulge) 
and keratinocytes (epidermis). The stem cells reside in the bulge region of the hair follicle and 
differentiate to sebocytes in the sebaceous glands [128] 
 
Many of the molecules which regulate epidermal self renewal and differentiation have 
been identified. Several molecular networks and signaling pathways are important in 
balancing epidermal growth and differentiation. Some of these key compounds are 
NF-κB, Wnt/-catenin, sonic hedgehog/patched, p63, 14-3-3σ, -catenin and 1-
integrin [172]. However the signals involved in sebocyte development are poorly 
understood. 
 
The level of -catenin regulates lineage selection by stem cell progeny in mammals. 
High levels of -catenin stimulate the formation of hair follicles while low levels lead 
to creation of epidermis and sebaceous glands. Intracellular signaling molecules like 
transcription factor 3 (Tcf3) and Lymphoid-enhancing factor-1 (∆NLef-1), a DNA 
binding molecule, control lineage differentiation. Overexpression of ∆NLef-1 blocks -
catenin signaling. Niemann et al. propose that ∆NLef-1 and Indian Hedgehog (IHH) 
cooperate to control proliferation and differentiation of sebocyte progenitors [104]. 
Sonic hedgehog (SHH) is a signaling molecule for the regulation of progenitor cells of 
hair lineage differentiation and proliferation. SHH is not required for terminal 
differentiation of the hair lineage, which is controlled by the Wnt signaling pathway 
[42, 105]. Inhibition of Wnt target genes using a dominant negative ∆NLef-1 promotes 
sebocyte development while inhibiting differentiation of the hair lineage [97, 103] 
(Figure 5). 
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Figure 5 - Model of interaction between ∆NLef-1, -catenin and hedgehog signaling in 
epidermal stem and progenitor cells. The high level of -catenin is necessary to develop papilla 
cells, ∆NLef-1 blocks -catenin for sebocytes, keratinocytes development [104]. 
 
The hedgehog pathway and other molecules are suggested to be implicated in 
sebocyte development, including activation of c-Myc, PPAR and COX-2 [5]. 
Activation of c-Myc stimulates epidermal proliferation and induces differentiation of 
sebocytes within the interfollicular epidermis [17]. 
 
 
2.4 HUMAN SEBACEOUS GLAND ISOLATION AND SEBOCYTE 
CULTIVATION 
 
Selective cultivation of sebocytes in vitro is essential for a better understanding of the 
pathophysiology of human skin, for drug development and investigation of drug 
pharmacokinetics. Data on sebaceous gland physiology initially emerged from the 
use of animal sebaceous gland models. Animal glands produce a higher amount of 
sebocytes than human sebaceous glands. The composition of intracellular lipids from 
hamster sebaceous gland-derived cells was very similar to human sebocytes, except 
that the hamster sebocytes did not contain any squalene and wax [62].  
In 1966, Kellum first described the isolation of sebaceous glands from human skin. 
However his experiments did not allow the maintenance of viable sebaceous glands 
in vitro [70]. In 1982, Karasek and Charlton reported the cultivation of human 
sebocytes, obtained from dermal slices rich in sebaceous gland tissue, to be used as 
a model for the investigation of human sebaceous glands [66]. Kealey et al. and Xia 
et al. introduced the maintenance of the sebaceous gland ex vivo and the cultivation 
of sebaceous gland cells in vitro, respectively [68, 174]. Several modifications of the 
technique of Xia et al., including sebocyte isolation and cultivation, have facilitated 
the reproducible cultivation of human sebocytes in vitro [174, 201]. 
However, human sebocytes are predisposed to differentiate by accumulating neutral 
fat droplets until they burst and die. Therefore, adequate cell numbers for large scale 
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experiments can only be obtained from multiple donors, while prolonged experiments 
are hindered by the short life span of the cells. Normal human sebocytes can only be 
grown for 3 to 6 passages. To overcome this problem, Zouboulis and colleagues 
cultured human facial sebocytes from an 87-year-old woman and transfected them 
with the Simian Virus-40 large T antigen. This gave rise to the immortalized cell line 
SZ95, allowing prolonged survival of the cells in vitro [199]. Several studies have 
shown that SZ95 sebocytes retain major characteristics of normal human sebocytes, 
such as differentiation with increased cell volume and lipid synthesis as well as 
subsequent apoptosis, expression of characteristic origin- and function-specific 
proteins of human sebaceous glands, and expected biological response to 
androgens and retinoids [173, 199]. Differentiation markers for fully differentiated 
sebocytes are keratin 7, keratin 19 and epidermal membrane antigen [201]. 
Since the first development of a standardized human sebaceous gland cell line 
(SZ95) [199], sebaceous gland research has experienced a new area with numerous 
research groups including sebocytes in their scope, whereas animal models have 
almost been abandoned. With the help of human sebocyte cultures research on acne 
and other sebaceous gland associated diseases is getting closer to the human in 
vivo situation [185]. 
In 2003, Thiboutot and colleagues applied the transfection system used by Zouboulis 
et al. to develop a second immortalized human facial sebaceous gland cell line, 
termed SEB-1. SEB-1 was established from sebaceous glands from normal skin of 
the predauricular area of a 55-year-old male [159]. Like SZ95 sebocytes, SEB-1 
sebocytes express characteristic sebaceous gland proteins and induce lipid droplets. 
Gene array studies showed that genes characteristic of sebaceous glands and those 
involved in lipid and steroid metabolism were expressed in SEB-1 sebocytes [185]. 
A third immortalized sebaceous gland cell line, Seb-E6E7, has been generated from 
adult human facial skin [81]. Human sebocytes were immortalized by introduction of 
HPV16 E6 and E7 genes. Seb-E6E7 sebocytes were transduced by co-culture with 
mitomycin C-treated packaging cells in the presence of 3T3-J2 cells. Seb-E6E7 
sebocytes, like SZ95 sebocytes, express both keratin 7 and involucrin [81]. 
 
2.5 SEBUM AND SEBOCYTE LIPIDS 
 
One of the main functions of sebocytes is sebum production. The major role of 
sebum and its lipid content is skin surface protection from environmental influences 
like UV, hazardous chemicals and microbes.  
Human sebum is a lipid mixture composed of glycerides, wax esters, squalene, 
cholesterol, cholesterol esters and free fatty acids. The composition of the 
intracellular lipids from mammalian sebaceous gland derived cells is similar to human 
sebaceous gland derived cells, except that mammalian sebocytes do not contain any 
squalene [62, 112]. Wax esters and squalene are only synthesized by human 
sebocytes [112]. 
Fatty acids and fatty alcohols are natural and direct precursors of wax esters. A fatty 
acid transport protein (FATP4) is strongly expressed by sebaceous glands. This 
trans-membrane protein enhances the uptake of long chain fatty acids into sebocytes 
[139]. As a consequence, wax ester biosynthesis is raised in human sebaceous 
gland cells [112]. The ability of sebocytes to synthesize wax esters correlates with 
the activity of -oxidation in these cells. Linoleic acid undergoes -oxidation to -
linoleic acid. It seems that -oxidation of linoleic acid is specific for sebocytes and 
associated with their differentiation [112]. 
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Ge et al. identified ∆-6 desaturase/FADS2 as the major fatty acid desaturase in 
human sebaceous glands, which synthesizes very long chain fatty acids. 
Desaturases add double bonds between carbon 6 and 7 of linolenate and -
linolenate to generate the polyunsaturated fatty acids -linolenate and stearidonate. 
Palmitate is elongated to the monounsaturated fatty acid sapienate. Sapienic and 
sebaleic acids are the predominant fatty acids, which are unique in humans 
compared to other hair bearing mammals [45, 102, 112, 156]. 
 
Table 1 - Lipid composition of sebaceous glands and cultured sebocytes in (%) 
 
 
Adult sebaceous 
glands 
Freshly isolated 
sebaceous glands 
Primary sebocytes 
Squalene 9.3 – 12 20 - 29 2 
Sterol/wax ester 24 - 27.1 6.5 - 7.1 4 
Triacyl glycerides 23 – 41 23 - 54  40 
Free fatty acids 14 – 27 0.8 - 1.2 20 
Cholesterol 1.4 - 4.2 1.5 - 2.1 2 
Diglycerides - 2.5 7 
Others 2 – 20 38 25 
Data from Nikkari, Cassidy and Ridden [18, 106, 127, 200] 
 
In vitro sebocytes synthesize less squalene, wax esters and cholesterol esters than 
sebaceous glands in vivo, but they are still capable of producing the natural lipid 
composition [133, 200]. Squalene may serve as a marker for terminal sebocyte 
differentiation [200] (Table 1). 
 
Table 2 - Lipid content in treated and untreated hamster sebocytes in (%) 
 
 Untreated  Oleic acid treated 
Squalene 33 49 
Phospholipids 59.7 30.1 
Free cholesterol 4.1 - 
Free fatty acids 0.97 12.2 
Triglycerides 0.58 6.0 
 
Analysis of extracted hamster sebocyte lipids revealed differences in lipid 
composition after addition of oleic acid to the culture medium [100]. After oleic acid 
treatment the concentration of squalene, fatty acids and triglycerides was largely 
increased and phospholipids concentration was decreased [100] (Table 2).  
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Figure 6 - Nile Red fluorescence staining of SZ95 sebocytes: Polar lipids (red) such as 
phospholipids containing organelles and membrane lipids are visualized at 540 / 620 nm. Unpolar or 
neutral lipids (yellow) such as triglycerides and wax esters are visualized at 485 / 528 nm [138]. 
 
Sebocyte lipids can be visualized with Nile Red or Oil Red staining (Figure 6) [50, 
199]. Nagai found that cultured hamster-cloned and rat primary sebocytes contain 
membrane vesicles, defined as sebosomes, containing squalene condensed lipid 
particles and enriched with histone H3, a cationic protein [100]. The presence of 
these vesicles suggests a cell function associated with secretion of antibacterial 
proteins, sterol regulation and a possible role in protecting the skin surface [100]. 
Additionally, perilipin A has been shown to be present on the surface of intracellular 
lipid droplets in differentiated hamster sebocytes in vitro [2]. Perilipin A is a protein in 
mammals which envelops lipid droplets in fat cells and protects the cell from the fat 
burning enzyme lipase. 
 
 
2.5.1 INTRACELLULAR LIPIDS IN SEBOCYTES 
 
In sebocytes, intracellular lipids are stored in lipid droplets. Neutral lipids play a major 
role as moisturizers and in the protection of human skin. Lipid synthesis in SZ95 
sebocytes is increased by androgens and fatty acids, whereas it is inhibited by 
hydrocortisone, retinoids, and estrogens [191]. 
 
The free fatty acids in sebum have been considered to participate in the inflammatory 
process. Linoleic acid and arachidonic acid are necessary for the first steps in the 
production of proinflammatory cyclooxygenase products, but they stimulate lipid 
synthesis in sebocytes as well. Furthermore, arachidonic acid up-regulates the 
secretion of IL-6 and IL-8 in sebocytes [4]. Arachidonic acid is an activating ligand of 
peroxisome proliferator-activating receptors (PPAR) which play a role in regulating 
lipogenesis in sebocytes [196]. 
In SZ95 sebocytes treated with arachidonic acid, lipid accumulation and apoptosis 
are enhanced. Terminal differentiation and apoptosis are two different programmed 
cell events, which both result in cell death. Terminal differentiation of sebocytes is a 
part of lipid synthesis. It begins with the accumulation of lipid droplets in the 
cytoplasm and results in apoptosis induction and bursting of the cell [173].  
Kontrolle 
Introduction 
 
 
11 
There is evidence that epidermal growth factor and 1-25-dihydroxyvitamin D3 act as 
suppressors in the regulation of lipogenesis in hamster sebocytes in vitro [134]. 
Epidermal growth factor, transforming growth factor- and fibroblast growth factor 
have mitogenic activity on hamster sebocytes and act as anti lipogenic factors. 
Moreover, it is likely that the formation of intracellular lipid droplets is independent of 
cell proliferation in hamster sebocytes [3]. The most understood compounds that 
down regulate lipid synthesis in vitro are the retinoids, such as isotretinoin (13-cis 
retinoic acid), tretinoin (all-trans retinoic acid), 9-cis retinoic acid, etretinate, and 
acitretin. Isotretinoin is the most potent component which suppresses sebum 
production and significantly decreases lipogenesis, thereby reducing proliferation and 
differentiation of sebocytes [108, 192, 193]. Isotretinoin and tretinoin reduce 
proliferation of cultured sebocytes in a dose- and time-dependent manner; however 
the complete mechanism of action remains unknown. Marked decreases in wax 
esters, a slight decrease in squalene and a relative increase in cholesterol level were 
measured. 
Hydrocortisone stimulates the proliferation of sebocytes in a dose-dependent 
manner. Cortisone reduces lipid production and anti-inflammatory effects when the 
cells are grown to confluency [200]. 
 
Table 3 - Neutral lipid synthesis regulating compounds 
 
Compounds 
Effect on neutral lipid 
synthesis 
Reference 
Androgen ↑ [90, 131, 134] 
Arachidonic acid ↑ [4] 
Linoleic acid ↑ [90] 
1-25-Dihydroxyvitamin D3 ↓ [134] 
All-trans retinoic acid ↓ [108, 192, 193] 
Epidermal growth factor ↓ [134] 
Estrogens  ↓ [187] 
Hydrocortisone ↓ [200] 
Transforming growth factor- ↓ [3] 
Legend: ↑ up regulation ↓ down regulation 
 
 
2.5.2 CELL MEMBRANE LIPIDS  
 
There are three classes of cell membrane lipids: phospholipids, cholesterol and 
glycolipids (Table 4). Human cells contain large amounts of cholesterol and a wide 
spectrum of different phospholipases with diverse functions. There are four main 
types of phospholipids: phosphatidylcholin, sphingomyelin, phosphatidylserine and 
phosphatidylethanolamine. Half of the lipid content in most membranes is a mixture 
of these four phospholipids. 
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Table 4 - Functions of polar membrane lipids 
 
Membrane 
lipids 
Functions Reference 
Phospholipids  Cell proliferation 
 Membrane homeostasis 
 Membrane repair through 
deacylation/reacylation 
 Induction of inflammation 
 Barrier function 
[175] 
Cholesterols  Prevention of hydrocarbon crystallization and 
phase shifts in the membrane 
 Required for permeability barrier homeostasis 
 Membrane structure 
 Regulation of ion pumps 
[91, 175] 
Glycolipids  Barrier function 
 Interaction between cells and cell surroundings 
 
[59] 
 
Cholesterol prevents crystallization of hydrocarbons and phase shifts in the 
membrane. It immobilizes the first few hydrocarbon groups of the phospholipid 
molecules, thus making the lipid bilayers less deformable and decreasing their 
permeability to small water-soluble molecules. 
Glycolipids are located in the outer layer of the membrane bilayers. Their sugar 
groups are exposed on cell surface. Assumedly glycolipids are involved in 
interactions between the cell and its surrounding. Glycolipids seem to be functionally 
linked to cholesterol [59]. 
 
2.5.3 PHOSPHOLIPASE IN THE EPIDERMIS 
 
The presence of phospholipase A2 (PLA2) activity was demonstrated several years 
ago, however the precise location of the different PLA2 in the epidermis and its 
appendages has still to be determined. Further studies have shown that these 
enzymes are expressed in various layers of the epidermis. Phospholipids in 
eukaryotic membranes do not only play a structural role, but are also involved in 
many metabolic processes. 
Phospholipase A2 (PLA2) catalyzes hydrolysis of the sn-2 fatty acid substituent from 
glycerophospholipid substrates to yield a free fatty acid, e.g., arachidonic acid and a 
2-lysophospholipid (Figure 7) [152] that have intrinsic mediator functions [125] and 
can initiate synthesis of other mediators, such as prostaglandins, leukotrienes, 
epoxy-eicosatrienoates, and platelet-activating factor (PAF) [11]. 
Haas et al. and Gurrieri et al. observed different PLA2 expressions levels in skin cells. 
The specifically secreted phospholipase A2 expression profile in the skin suggests a 
distinct function for each enzyme in the epidermis. The PLA2 expression from 
keratinocytes and primary keratinocytes from healthy patients compared to psoriasis 
patients were investigated [51, 54]. In short, immunofluorescence studies showed 
that PLA2 IB, IIF, and X were predominantly expressed in suprabasal layers, whereas 
sPLA2 V and IID were detected in the basal and spinous layers. Secreted PLA2 IIA 
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was weakly identified and sPLA2 IIE and XIIA were not detectable. In differentiated 
primary keratinocytes the expression of sPLA2 IB, IIF, X was increased, whereas 
sPLA2 V and IID were markedly decreased. In psoriatic skin sPLA2 X was 
dramatically down-regulated in the epidermis, while increased amounts of sPLA2 X, 
IIA, IID and IB appeared in the dermis [54]. 
 
 
Figure 7 - Phospholipase metabolism: Phospholipases A2 are enzymes that catalyze the hydrolysis 
of glycerophospholipids at the sn-2 position, generating free fatty acids and lysophospholipids [35].  
 
At present, the PLA2 family consists of 12 groups. PLA2 are involved in many 
physiological processes such as barrier function, eicosanoid production, and 
inflammation. They are connected to inflammatory diseases of the skin like psoriasis, 
eczema, and atrophy. Their differential localization suggests different roles for each 
PLA2 in skin physiology and during inflammation [96]. 
The secreted PLA2 (sPLA2) group, in which 10 isozymes have been identified, 
consists of low-molecular-weight, Ca2+-requiring, secreted enzymes that are known 
to be involved in a number of biological processes, such as modification of 
eicosanoid generation, inflammation, host defense and atherosclerosis. The cytosolic 
PLA2 (cPLA2) group consists of three enzymes, among which cPLA2 plays an 
essential role in the initiation of arachidonic acid metabolism. Intracellular activation 
of cPLA2 is tightly regulated by Ca
2+ and phosphorylation. The Ca2+ independent 
PLA2 group contains two enzymes and may play a major role in membrane 
phospholipid remodeling. Platelet-activating factor acetylhydrolase (PAF-AH) 
represents a unique group of PLA2 that contains four enzymes exhibiting unusual 
substrate specificity toward PAF and/or oxidized phospholipids [99]. 
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2.6 EXPRESSION OF PROTEINS AND HORMONES BY SEBOCYTES 
AND THEIR BIOLOGICAL ACTIVITIES 
 
Human skin is an endocrine organ which synthesizes hormones. Hormones are 
biochemically active messengers and coordinate activity in different cell types in 
multi-cellular organisms. The cells of the skin are able to metabolize, activate, and 
inactivate hormones. Human sebocytes themselves produce corticotrophin-releasing 
hormone (CRH), androgens, estrogens, all trans retinoic acid, cortisol, calcitriol 
(vitamin D3) and eicosanoids [183, 187]. Sebocyte proliferation, differentiation and 
lipid synthesis (accumulation of neutral lipids) are controlled by this complex 
endocrine hormone system. CRH activates proliferation and induces lipid synthesis in 
sebocytes. 
Androgens affect several functions of human skin, such as sebaceous gland growth 
and differentiation. In cell culture, androgens promote sebocyte differentiation as well 
as proliferation and show a lipogenic activity [134]. 
Estrogens, cortisol, and all trans retinoic acid down regulate differentiation, cell 
proliferation and intracellular accumulation of neutral lipids. The effects of estrogens 
can be explained by inhibition of gonadotropin secretion or by enhancement of 
testosterone binding. Cortisol also influences lipid metabolism, wound healing, and 
relieves stress. 
Calcitriol has various cellular functions including anti proliferative effects on SZ95 in 
logarithmic phase of cell growth and differentiation [141]. In addition, 1-25-
dihydroxyvitamin D3 decreases lipid synthesis in sebocytes [134]. 
 
 
2.7 HORMONE RECEPTORS AND THEIR PROPERTIES IN HUMAN 
SEBOCYTES 
 
Sebocytes express receptors for peptide hormones and neurotransmitters, which are 
mostly arranged on the cell surface. Steroid and thyroid receptors are found in the 
cytoplasm and nuclear compartment. Hormones (agonists) bind to the receptors with 
high affinity. This in turn triggers further pre-defined reactions (Figure 8). 
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Figure 8 - Interaction between membrane and nuclear recepto s in human sebocytes: Their 
influence on lipid accumulation is displayed. The release of various hormones, growth factors and 
mediators of inflammation can regulate lipogenesis in sebocytes. Activator (green), receptor (yellow), 
corticotrophin-releasing hormone (CRH), melanocyte-stimulating hormone- (MSH-), growth 
hormone (GH), insulin-like growth factor (IGF), epidermal growth factor (EGF), transforming growth 
factor- (TGF-), peroxisome proliferator-activated receptor (PPAR) [189]. 
 
Extracellular receptors regulate three kinds of intercellular communication pathways: 
The endocrine signaling pathway transports hormones to their receptors, the 
paracrine pathway absorbs, immobilizes and catabolizes local chemical mediators 
and the synaptic signaling pathway acts on the post synaptic part of cells. All cells in 
the human body express a defined combination of different receptor proteins which 
can interact with complementary signaling molecules to activate a characteristic cell 
response. 
Signal molecules can be classified according to their solubility in water. Most 
hydrophilic molecules bind to receptors on the cell surface, whereas hydrophobic 
molecules like steroid hormones pass through the plasma membrane of the cell and 
activate nuclear receptors in the cell cytoplasm. 
Introduction 
 
 
16 
 
Table 5 - Receptors and binding affinity of sebocytes  
 
Group Receptors Binding affinity Reference 
Extra 
cellular 
cell surface 
CRH-1R,-2R, MC-1R, 
MC-5R, -opinate-R, IGF-
1R, GHR, Substance P, 
CGRPR,VPAC-2, NYR, 
Integral membrane proteins 
bind to an extracellular 
domain and activate a 
tyrosine specific protein 
kinase in the cytoplasm 
[14, 143, 
186, 189, 
198]  
Nuclear 
receptor  
AR, ER, ß, PRA, PRB, 
RAR, RXR, PPAR, /,  
1,  2 
 
They are activated by 
distinct lipophilic small 
molecules such as 
glucocorticoids, estrogens, 
androgen, progesterone, 
retinoid and fatty acid 
derivatives. 
[8, 186]  
This table summarizes all known receptors which are active in human sebocytes and their binding 
affinity: Corticotrophin-releasing hormone 1-receptor (CRH-1R), corticotrophin-releasing hormone 2- 
receptor (CRH-2R), melanocortin-1 receptor types (MC-1R), melanocortin-5 receptor types (MC-5R), 
-opiate receptor (-opiate-R), vasoactive intestinal polypeptide receptor type 2 (VPAC-2), 
neuropeptide Y receptor (NYR), calcitonin gene-related peptide receptor CGRPR, insulin-like growth 
factor receptor (IGFR), growth hormone receptor (GHR), androgen receptor (AR), estrogens receptor-
alpha (ER), estrogens receptor-beta (ERß), substance P, retinoid acid receptor (RAR), retinoid x 
receptor (RXR), peroxisome proliferator-activated receptor (PPAR, /, ), progesterone receptor  A 
(PRA), progesterone receptor B (PRB). 
 
 
2.7.1 EXTRACELLULAR RECEPTORS OF SEBOCYTES 
 
Water soluble signaling molecules (neurotransmitters, protein hormones, and growth 
factors) as well as some soluble lipid signaling molecules bind specific receptor 
proteins on the surface of target cells with a high affinity. The receptor then 
transforms the extracellular signal into an intracellular response which alters the 
behavior of the target cell.  
Neuropeptides do not only act in the central nervous system, they are also active and 
expressed in skin cells. Neuropeptides have a neuroendocrinic regulatory effect on 
sebocytes and are the link between emotional stress and acne [15, 187, 198]. 
Corticotrophin-releasing hormone (CRH) and its receptors are expressed in 
sebaceous glands. The expression of CRH, CRH-binding protein, and CRH receptors 
(CRH-R) in SZ95 sebocytes was investigated at the mRNA and protein level [198]. 
CRH is an important autocrine hormone, with a pro differentiation and lipid synthesis 
inducing activity. CRH enhances mRNA expression of ∆5-3 hydroxysteroid 
dehydrogenase and formation of testosterone in human sebocytes [41, 198]. CRH 
directly induces lipid synthesis and enhances mRNA expression of Δ5-3-
hydroxysteroid dehydrogenase, an enzyme which converts dehydroepiandrosterone 
to testosterone in human sebocytes. Testosterone and growth hormone (GH) 
antagonize CRH through modulation of its receptor. GH switches the predominant 
CRH receptor-1 in SZ95 sebocytes to CRH receptor-2 [101, 194]. 
Melanocortin receptors (MC-1R, MC-5R) and their ligands melanocyte-stimulating 
hormone (MSH) and adrenocorticotrophin hormone (ACTH) have been shown to 
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influence physiological functions of cells and organs, including exocrine glands. MC-
Rs are located at the cell surface of sebocytes. MC-1R in SZ95 sebocytes and in 
primary sebocytes was first described by Böhm et al. [189]. MC-1R is expressed to 
higher levels than MC-5R. In SZ95 sebocytes, MC-5R expression is not detectable 
[15]. In 2006, Zhang examined the expression of MC-5R in human sebocytes in vivo 
and in vitro. MC-5R was only detected in differentiating, lipid-laden sebaceous glands 
but not in basal undifferentiated cells. Zhang et al. suggest that MC-5R is a marker of 
human sebocyte differentiation [180]. The immunomodulatory actions of -
melanocyte stimulation include regulation of expression and secretion of 
chemokines, down regulation of proinflammatory signal induced NF-κ3 activation and 
adhesion molecule expression PGE2 synthesis as well as induction of IL-10 [15]. 
The human sebocyte is a direct cellular target of -melanocyte-stimulating hormone 
(-MSH), which appears to regulate lipogenesis and the production of 
proinflammatory cytokines. It is unclear, whether -MSH or adrenocorticotropin 
(ACTH) is produced by sebocytes. Experiments in animals showed a stimulatory 
effect of -MSH and ACTH on sebum production. However, -MSH in human 
cultured sebocytes inhibited the IL-1 induced release of IL-8 [194]. A lipogenic effect 
on sebocytes also occurs after -endorphin stimulation [194].  
The -opiate receptor is expressed in human SZ95 sebocytes and sebaceous glands 
[14] and binds -endorphin. This stimulates lipogenesis and specifically increases the 
amount of C16:0, C16:1, C18:0, C18:1 and C18:2 fatty acids to a similar extent as 
linoleic acid stimulation of sebocytes [14].  
Insulin-like growth factor receptor (IGF-R) is expressed on the sebocyte cell surface 
and can be activated by IGF or a high dose of insulin [86]. In vitro studies have 
shown IGF-1 dependent stimulation of sebocyte proliferation and differentiation 
especially in combination with growth hormone (GH) [25]. IGF enhances lipid 
production in human SZ95 sebocytes in a dose-dependent manner.  
The activation of IGF-1R induces lipogenesis in SEB-1 cells via both the sterol 
response element binding proteins dependent and independent pathway. Sterol 
response element binding proteins are nuclear transcription factors and regulate the 
synthesis of cholesterol and fatty acids. They are produced as precursors stored in 
the endoplasmic reticulum [154].  
The growth hormone  also up-regulates sebocyte differentiation and augments the 
effect of 5-dihydroepiandrosterone on sebum synthesis [169]. Growth hormone 
binds to a membrane bound receptor and thus has a direct effect on sebocytes. Its 
activation is mediated by IGF [25]. 
Substance P can be released through stress; it promotes the development of 
cytoplasmic organelles in sebaceous cells and stimulates sebaceous germinative 
cells. It also increases the size of individual sebaceous cells and the number of 
sebum vacuoles for each differentiated sebaceous cell, all of which suggest that 
substance P promotes both the proliferation and the differentiation of sebaceous 
glands [165]. Neutral endopeptidase, an enzyme that degrades substance P and 
thus reduces the pro-inflammatory effect of substance P, is highly expressed in the 
sebaceous glands of acne patients. Finally, an increase in the number of nerve fibers 
is noted around the sebaceous glands of acne patients and sometimes inside the 
glands. The latter is related to an increased expression of nerve growth factor in acne 
prone sebaceous glands [13]. Substance P often co-localizes with calcitonin gene 
related peptide [155]. Calcitonin gene related peptide signaling in keratinocytes is 
involved in c-AMP induction and Ca2+ mobilization [117]. IL-6 produced by mast cells 
induces production of nerve growth factors in sebocytes [14]. Neuropeptides are 
transmitter substances produced by neuronal and non neuronal cells of the skin. 
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Seiffert et al. showed that the expression of calcitonin gene related peptide receptors, 
vasoactive intestinal polypeptide receptors and neuropeptide Y receptors are present 
in human sebocytes; their agonists activate cytokine production [143]. 
 
 
2.7.2 NUCLEAR RECEPTORS OF SEBOCYTES 
 
Hydrophobic ligands are able to pass cell membranes to activate receptor proteins or 
nuclear receptors in the cytoplasm.  
Azzi et al. show gender differences in mouse sebocytes. Androgen receptors (AR) in 
male mice are exclusively localized in the nuclei of basal and mature sebocytes. In 
females there are present in a lower level in both the nuclei and the cytoplasm [8]. 
ARs are ligand activated intracellular transcription factors, are stabilized by ligand 
binding, which in turn leads to up regulation of lipid synthesis in sebocytes. Five 
enzymes are involved in activation and inactivation of androgens. 
Dehydroepiandrosterone sulfate (DHEA-S) is metabolized with steroid sulfatase to 
dehydroepiandroestrone (DHEA). DHEA and androtestosterone are converted to 
testosterone and later to 5 DHT by intracellular enzyme 5-reductase in human 
skin. Sebocyte studies of Akamatsu et al. show a dose-dependent induction of 
sebocyte proliferation by testosterone treatment [1] and no effect on lipid stimulation 
[199]. Additional investigations by Rosenfield present evidence that the effect of 
testosterone is regulated by PPAR ligands [130]. All PPAR isotype are present in 
sebocytes and regulate multiple lipid metabolic genes [19, 87, 131]. In a study of 
Makrantonaki testosterone leads to a significant increase of polar lipid production. 
This lipid production can be used as a marker for sebocyte proliferation. 
Estrogens play an important role in tissue of both sexes. Estrogen receptor  (ER-) 
is expressed in basal and partially differentiated sebocytes. Estrogen receptor  (ER-
) and AR are both expressed in basal and early differentiated sebocytes [162]. 
Estrogens, estradiol and testosterone are formed by oxidative reduction of 4-
androsten-3, 17-dion. An experiment with 17 sterol sebocyte treatments show an 
effect on polar lipid production but no lipid-stimulating effect on neutral lipids in 
sebocytes. Other in vitro results demonstrate the influence of estrogens on the 
biological activity in sebaceous glands [53]. 
Progesterone receptor (PR) was found in nuclei of basal sebocytes in sebaceous 
glands [114]. There were no significant differences in PRA, PRB and AR 
immunoreactivity between non-pathological sebaceous gland and its neoplasm [67]. 
 
Two retinoid receptors are expressed in sebocytes. The retinoid acid receptor (RAR) 
modulates cell proliferation and the retinoid x receptor (RXR) influences cell 
differentiation. The natural ligands for RAR and RXR have been identified as all trans 
retinoic acid and 9-cis retinoic acid, respectively. 13-cis retinoid inhibits proliferation 
in sebocyte cell line SZ95. It was found that 13-cis retinoic acid is metabolized to all 
trans retinoic acid [130]. All trans retinoic acid binds to retinoic acid binding protein II, 
which in turn binds and activates nuclear receptor RAR [101]. 
The retinoid x receptor is a ligand dependent transcriptional regulator. RXR is known 
to form a heterodimer with PPAR. Several gene receptor studies have shown that 
either RXR ligand or PPAR ligand can activate the RXR-PPAR heterodimer [130].  
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RXR agonists stimulate sebocyte differentiation and proliferation. Kim reports dose-
dependent effects of the RXR agonist retinoid from an inactive to an active 
concentration in combination with specific PPAR agonists like, WY14643, 
troglitazone and cabaprostacyclin, on differentiation and growth in cultured primary 
sebocytes [72]. 
 
 
2.7.3 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS 
 
Peroxisome proliferator activated receptors (PPAR) belong to the nuclear hormone 
family. PPAR require heterodimerization with retinoid x receptors to allow their 
binding to DNA as ligand activated transcription factors. This regulates the 
expression of target genes encoding peroxisome proliferator‟s response elements 
within their promoter regions. PPAR have been shown to regulate multiple lipid 
metabolic genes in peroxisomes, microsomes and mitochondria by activating PPAR 
response elements (PPRE) (Figure 9) [48, 140].  
 
 
Figure 9 - Scheme for activation of PPAR: Activated PPAR act through PPAR response elements to 
up regulate multiple genes encoding enzymes involved in peroxisomal, microsomal and mitochondrial 
-oxidation, fatty acid ω-hydroxylation, ketone body formation, and fatty acid synthesis as well as fatty 
acid binding proteins, lipoprotein lipase and apolipoproteins. (L: PPAR ligand; RA: Retinoic Acid = 
RXR-activating ligand; PPRE: PPAR response element) [98, 129]. 
 
All PPAR subtypes are expressed in rat preputial sebocytes, SZ95 and SEB-1 
immortalized cell lines and the human sebaceous gland [19, 30, 132, 167]. PCR 
studies of Chen et al. and Alestas et al. demonstrated that all PPAR subtypes are 
present in the sebaceous gland and in the pilosebaceous ducts of healthy, acne 
involved and acne uninvolved skin [4, 19]. Kim showed a significant PPAR activity in 
preputial rat sebocytes. PPAR and  were also activated but to lower levels; 
however no other study verifies these results. Adult rat sebocytes express mRNA of 
PPAR, , 1, but PPAR2 mRNA was not detectable [72, 130]. In sebaceous gland 
cell line SZ95 PPAR, , 1, 2 expression was detectable by RT PCR [19]. 
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Table 6 - Peroxisome proliferator-activated receptor subtypes and their functions 
 
PPAR Function Reference 
 
 Skin barrier function 
 Lipid catabolism 
 Activation of -oxidation of fatty acids 
 Regulation of inflammation 
 Cell differentiation and proliferation 
 Skin wound healing 
[61, 78, 167] 
 
/ 
 Lipid anabolism 
 Regulation of late stage sebocyte differentiation 
 Control of inflammation 
[27, 78] 
1,2 
 Cell apoptosis 
 Lipid catabolism 
 Cell proliferation 
 Skin wound healing 
 Involvement in oxidative stress 
[61, 78, 181] 
 
 
PPAR, , 1, 2 were initially studied in skin because of their known role in regulating 
lipid metabolism. PPAR seems to contribute to the skin barrier function, activation of 
-oxidation of fatty acids as well as regulation of inflammation, and plays a role in 
sebocyte differentiation. PPAR (animals) /  (human) regulates the late stages of 
sebaceous cell differentiation and is described as the most effective isotype in 
stimulating lipid production [27]. PPAR activates sebocyte development 
(proliferation) and lipogenesis. PPAR is also involved in oxidative stress mediated 
prostaglandin E2 production and induces COX-2 expression in human SZ95 
sebocytes (Table 6) [181]. In SZ95 sebocytes PPAR is expressed and activated by 
UVB irradiation. Tert-buthylhydroperoxide (TBH) is a lipid soluble oxidant, which 
activates PPAR. After sebocyte treatment with TBH or PPAR agonist an increased 
level of COX-2 protein, mRNA expression and prostaglandin E2 (PGE2) production 
were observed. By pre-treatment with PPAR antagonist GW 9662 the ability of 
PPAR and TBH to produce PGE2 and COX-2 in sebocytes was blocked [181]. 
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Table 7 – Effect of Peroxisome proliferator-activated receptor agonists on lipid synthesis in 
sebocytes 
 
PPAR PPAR ligands Lipid Rodent sebocytes Human sebocytes 
 
WY14643 ↑ [2, 19, 131, 132] [19] 
LA ↑ [72]  
GW 0742 ↑  [181, 191] 
GW 2433 ↑ - [181, 191]  
GW 7647 ↑ - [181, 191] 
cPGI2 - [72]  
AA ↑ - [4, 191] 
LTB4 ↑ - [4, 191] 
/ 
GW 0742 ↑ - [181] 
GW 2433 ↑ - [181] 
cPGI2 - [72, 131, 132] - 
LA ↑ [72, 131, 132] [4, 19, 191] 
 
TRO ↑ [2, 63, 72, 131, 132] - 
BRL ↑ [2, 72, 131, 132] - 
CIG - - [181] 
GW 4148 - - [147, 167] 
Pioglitazone - - [167] 
15-HETE ↑ - [4] 
∆15-PGJ2 ↑ [63] - 
This table summarizes the activating ligands for all PPAR isotypes. No data (-), linoleic acid (LA), 
arachidonic acid (AA), leukotriene B4 (LTB4), WY14643, ciglitazone (CIG), carbaprostacyclin 
(cPGI2), troglitazone (TRO), hydroxyeicosatetraenoic acid (15-HETE), rosiglitazone (BRL), 
pioglitazone, 15-deoxy-delta(
12,14
)-prostaglandin J2 (∆15-PGJ2) synthetic ligands are GW 0742, GW 
7647, GW 2433 and GW 4148 
 
If cells express PPAR, they are not necessarily endogenously active; however, they 
can be activated by ligands depending on the differentiation stage of the cells. 
PPAR, PPAR and PPAR agonists have led to no differences in biological activity 
between SZ95 and SEB-1 sebocytes [19, 167]. 
Most natural and synthetic PPAR ligands induce lipogenesis in sebocytes in vitro and 
in vivo.  
Linoleic acid and carbaprostacyclin (cPGI2) are non-specific neutral PPAR and  
ligands. Arachidonic acid, whose 5-lipoxygenation metabolite leukotriene B4 is a 
natural PPAR ligand, was found to induce genes that are associated with -
oxidation. The intermediate metabolite 15-HETE is a PPAR ligand as well as cPGJ2. 
Lipid synthesis in human sebocytes is also stimulated by the prostaglandins PGE2 
and 15-deoxy-delta(12,14)-prostaglandin J2 (∆15-PGJ2), a neutral PPAR ligand. 
PPAR is down regulated by phytooestrogen and genistein. 17-Estradiol induces 
metabolism of PGD2 to ∆12-PGJ2.  
Sebocytes treated with synthetic PPAR ligands like WY14643, troglitazone or 
rosiglitazone significantly induced intracellular neutral lipids [2, 63, 162, 168]. 
Introduction 
 
 
22 
However, studies in cultured sebaceous glands led to controversial results. BRL 
49653 and WY14643 inhibited sebaceous lipogenesis [30] (Table 7).  
 
Rosenfield tested PPAR activators with and without androgen DHT on preputial rat 
sebocytes. Growth and maturation of sebocytes are influenced by steroids, 
testosterone, and the metabolite 5α-dihydrotestosterone (DHT). Rosenfield 
concluded that the activation of any PPAR seems to increase lipogenesis in the cells. 
PPAR seems to be significant in initiating the differentiation of sebocytes. DHT and 
BRL treatment has an additive effect on differentiation of sebocyte primary culture 
cells [84, 130]. 
Zileuton, a potent PPAR antagonist, is an inhibitor of leukotriene B4 synthesis, 
which reduces lipid synthesis [194]. The PPAR antagonist GW 0072 has the ability 
to inhibit thiazolidinedione induced adipocyte differentiation, but in a study with SEB-
1 sebocytes no statistically significant changes in total lipid production were observed 
[160]. 
 
 
2.8 INFLAMMATORY MECHANISMS IN SEBOCYTES 
 
Inflammation is characterized by the action of active lipid mediators, such as 
leukotrienes (LT), prostaglandins (PG) and 15-hydroxyeicosatetraenoic acids (15-
HETE). These molecules are metabolites from arachidonic acid or linoleic acid 
processed by the enzymes cyclooxygenase (COX) and lipoxygenase (LOX). 
Cyclooxygenase, a prostaglandin endoperoxide H synthetase, is a rate limiting 
enzyme complex for the production of prostaglandins [60, 164]. Cyclooxygenase has 
two isozymes, COX-1 and COX-2, which are expressed in human sebocytes in vitro; 
moreover, COX-2 expression was selectively up regulated in acne-involved 
sebaceous glands in vivo. COX expression was measured by examining mRNA and 
protein levels [4]. In a hamster sebocyte study of Iwata et al., COX-2 expression was 
detected, whereas COX-1 was not. 
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Figure 10 - Arachidonic acid metabolism. Arachidonic acid metabolites are PPAR ligands. PLA2 
activate the arachidonic acid synthesis. The COX-2 is a rate limiting enzyme complex for the 
production of prostaglandin. The LTB4 is catalyzed by LOX and LTA4 hydrolase. All these ligands 
activate free fatty acid synthesis and cytokine expression in sebocytes [183]. 
 
The biological pathway of prostaglandin plays an important role in sebaceous gland 
cells. Prostaglandin is responsible for the regulation of cellular functions under 
physiological and pathological conditions.  
Prostaglandins (PG) are associated with the development of sebaceous glands and 
sebocyte lipogenesis. In 1986, prostaglandin synthesis of prostaglandin D2 (PGD2) 
and prostaglandin E2 (PGE2) was discovered in mouse sebaceous gland cells [58]. 
Iwata et al. investigated the involvement of prostaglandins in the formation of 
intracellular lipid droplets in hamster sebaceous glands. In the augmentation of lipid 
droplet formation 15-desoxy-delta(12,14)-prostaglandin J2 (∆15-PGJ2) is a crucial 
factor, increasing triglycerol synthesis in sebocytes. COX-2 inhibitors reduce PGF2 
and PGE2 levels but increase ∆15-PGJ2 production and triacylglycol synthesis. 
Additionally the synthesis of ∆15-PGJ2 is mediated by COX-2 and cytochrome P-450 
dependent pathways [63]. Zouboulis proposed that for the future treatment of acne 
Iwata‟s study may provide insight into the inhibition of the proinflammatory and 
sebotropic activities. Additionally it shows that a possible regulation of PPAR may 
be more powerful than the inhibition of the prostaglandin pathway, including PPAR1 
regulation [188]. 
The recent study of Zhang et al. demonstrates that the production of PGE2 is induced 
by platelet-activating factor receptor (PAF-R) activation and mediated by COX-2 
expression. PAF-Rs seem to be involved in regulating the expression of inflammatory 
mediators, including COX-2, PGE2, and IL-8 [182].  
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Cultured SZ95 sebocytes express 5-lipoxygenase (LOX) and LTA4 hydrolase on the 
protein and mRNA level. These enzymes are essential for the formation of 
leukotriene B4 (LTB4). When SZ95 sebocytes were treated with arachidonic acid, 
LTB4 synthesis was increased. Treatment of human cultured sebocytes with 
arachidonic acid and calcium ionophore induced expression of 5-lipoxygenase 
detectable at mRNA and protein level [4, 76]. Immunohistochemical studies revealed 
weaker staining of 5-LOX and LTA4 hydrolase in healthy individuals and in 
uninvolved skin of acne patients than in acne lesions [4]. 
IL-6 and IL-8 were produced by SZ95 sebocytes in vitro and were up regulated in the 
presence of the 5-LOX activators, arachidonic acid and calcium ionophore [4]. It 
seems that 5-LOX activation induces cytokine secretion. Squalene peroxide induced 
the enzymatic activity of 5-LOX in cultured keratinocytes and increased the 
production of IL-6. Moreover squalene peroxide activated nuclear factor κB (NFκB), 
which also mediate proinflammatory signaling in cells [110]. 
Furthermore, sebaceous gland cells can produce cytokines without any mediation of 
other cells. IL-1 mRNA and protein are detectable in cultured sebocytes at steady 
state. IL-1, -6, -8 and TNF- are released by cultured human SZ95 sebocytes [4]. 
TNF-, IL-1 and  are detected at mRNA level by in situ hybridization in normal 
sebaceous glands [13] and IL-1 by immunohistochemistry in skin biopsies of 
healthy patients [64].  
Neuropeptides may also play an important role in induction of inflammatory 
processes. Toyoda and Morohashi reviewed the involvement of neuropeptides, 
neuropeptides degrading enzymes and neurotrophic factors in the inflammatory 
process of acne [166]. 
Substance P is associated with multiple cellular responses. It promotes proliferation 
and differentiation of sebaceous glands in vitro and the release of proinflammatory 
cytokines and chemokines. Toyoda and Morohashi examined the effects of 
substance P and neutral endopeptidase (NEP) on sebaceous glands in cultured skin. 
Immunohistochemical studies revealed that germinate sebocytes in acne patients 
express nerve growth factor [15]. 
Nuclear factor κB and activator protein-1 are active in acne lesions, leading to 
increased expression of their target genes such as inflammatory cytokines, enzymes 
and matrix-degrading metalloproteases .[65].  
Sebocytes and keratinocytes in culture secreted matrix metalloproteases (MMP) 
which have a predominant role in inflammation matrix remodeling and 
hyperproliferative skin disorders. SZ95 sebocytes secreted pro MMP-2 and pro MMP-
9 which was confirmed by microarray analysis [111]. 
 
Aim of the study 
 
 
25 
3 AIM OF THE STUDY 
 
The primary aim of this work was to search for extracts and fractions derived from 
plants, bacteria, Bothrops moojeni snake venom and peptides which influence lipid 
secretion in human sebocytes. If lipid regulating compounds could be discovered, the 
second goal was to gather more knowledge about these lipid synthesis interactions in 
SZ95 sebocytes. 
 
In detail, the aim of the study was:  
 
 To establish and optimize a SZ95 sebocyte drug screening model to search 
for new biologically active ingredients which regulate lipogenesis by 
measuring neutral lipid production, polar lipid production, cell vitality, and 
cytotoxicity. 
 To test the lipid regulating effects of new compounds on SZ95 sebocytes lipid 
synthesis three different pre-stimulations with arachidonic acid, linoleic acid 
and unstimulated should be used.  
 To identify lipid stimulating compounds. The active compounds should be 
discovered, purified and again tested for their lipid regulating activity in a dose-
dependent manner in SZ95 sebocytes.  
 To exclude apoptotic effects after lipid synthesis stimulation in SZ95 
sebocytes. An apoptosis assay could measure caspase-3/7 release in treated 
SZ95 sebocytes. Only compounds that would not affect viability of the cells 
should be further investigated. 
 To investigate how the lipid stimulating compounds interact in SZ95 
sebocytes. The lipid stimulating compounds could activate specific PPAR, 
/ or  in SZ95 sebocytes transiently expressing PPAR. A new PPAR 
receptor gene assay for SZ95 sebocytes had to be developed to identify new 
PPAR ligands. Cells could be transiently transfected with PPAR,  or  and 
treated with compounds to investigate the activation of PPAR,  and . 
 To test that treatment of sebocytes with lipid regulating compounds did not 
cause the expression of inflammatory mediators. Cytokine expression should 
be evaluated by Luminex 100 system. In addition to that, a cytokine 
expression profile from SZ95 sebocytes could be created.  
 To get more knowledge about the lipid synthesis activation and its pathway, a 
COX-2 inhibitor, a LOX inhibitor and a PLA2 inhibitor could be tested for their 
lipid regulating effects and cytokine expression in arachidonic acid pre-
stimulated human SZ95 sebocytes. 
 To obtain more knowledge about the specific or unspecific PPAR binding by 
PPAR ligands e.g. fatty acids. COX-2 and LOX inhibitors could be investigated 
on arachidonic acid pre-stimulated SZ95 sebocytes transiently expressing 
PPAR,  and . 
 
The findings should provide a better insight into lipid synthesis and cell signaling 
mechanism of sebocytes. Additionally, new active compounds and involved 
pathways should be identified. 
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4 MATERIALS AND METHODS 
 
4.1 MATERIALS 
 
4.1.1 REAGENTS 
 
Reagent Distributor 
Accutase Sigma, Munich, Germany 
Apoptose Reagent R&D System, Minneapolis, USA 
Arachidonic acid Sigma, Munich, Germany 
Bulk isolute® sorbent Hydromatrix Separtis GmbH, Grenzach Wyhlen, 
Germany 
Casiton Scharfe System GmbH, Reutlingen, 
Germany 
Cytosolic PLA2 Inhibitor (AACOCF3) US Biological, Massachusetts, USA 
DMSO Fluka, Steinheim, France 
Ethanol Alcosuisse, Delemont, Switzerland 
Gentamycin PAN Biotec GmbH, Aidenbach, Germany 
GHK Bachem, Basel, Switzerland 
Hoechst 33342 Invitrogen, Basel, Switzerland  
Hydrocortisone Sigma, Munich, Germany 
Linoleic acid Sigma, Munich, Germany 
Lipofectamine 2000 Invitrogen, Basel, Switzerland 
MK886  Cayman Chemical, Ann Arbor, USA 
NDGA Sigma, Munich, Germany 
Nile Red Sigma-Aldrich, Steinheim, Germany 
NS398 Merck, Darmstadt, Germany 
Optimem Invitrogen, Basel, Switzerland 
PBS PAN Biotec GmbH, Aidenbach, Germany 
Phospholipase A2, snake venom Sigma-Aldrich, Steinheim, Germany 
PLA2 bee venom Sigma-Aldrich, Steinheim, Germany 
PPAR Ligand (WY14643) ChemSyn laboratories, Lenexa, USA 
PPAR/ Ligand (L165041) Centre for Integrative Genomics, University 
Lausanne, Switzerland (Prof. Wahli) 
PPAR Ligand (Rosiglitazone) Alexis Biochemicals, Lausen, Switzerland 
Streptavidin-PE Prozyme, San Leandro, USA 
SuperFect® Transfection Reagent Qiagen, Basel, Switzerland 
Triton-X-100 Sigma-Aldrich, Steinheim, Germany 
Trypsin PAN Biotec GmbH, Aidenbach, Germany 
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4.1.2 TESTED COMPOUNDS 
 
Bothrops moojeni venom (snake venom, Pentapharm, Uberlândia, Minas Gerais, 
Brazil) was partly purified by HPLC and kindly provided by Anna Maria Perchuc at 
Pentapharm.  
 
 
Table 8 - Peptides  
 
Peptides Distributor 
GHK Bachem, Bubendorf, Switzerland 
GHK Pentapharm, Aesch, Switzerland 
TAT-GHK Pentapharm, Aesch, Switzerland 
Cu-GHK Pentapharm, Aesch, Switzerland 
GAA LJ 562-13 Pentapharm, Aesch, Switzerland 
GAA LJ 562-16 Pentapharm, Aesch, Switzerland 
GAA LJ 562-15 Pentapharm, Aesch, Switzerland 
HADGVF-OH 21-004 Pentapharm, Aesch, Switzerland 
SVSEIQLMHN 21-003 Pentapharm, Aesch, Switzerland 
179-145 Pentapharm, Aesch, Switzerland 
179-176 B Pentapharm, Aesch, Switzerland 
GAA LJ 562-14 Pentapharm, Aesch, Switzerland 
 
The used peptides were synthesized by Dr. Heidl, Dr. Fragale and Mr. Wikstroem. 
 
 
Table 9 - Marine microbial mats  
 
Microbial organism Distributor 
Biolip P 50 Biolip, Tahiti, French Polynesian islands 
Biolip P 51 Biolip, Tahiti, French Polynesian islands 
Biolip P 75 Biolip, Tahiti, French Polynesian islands 
Biolip P 90 Biolip, Tahiti, French Polynesian islands 
Biolip P 19 Biolip, Tahiti, French Polynesian islands 
Biolip P 2 Biolip, Tahiti, French Polynesian islands 
Biolip P 2 supernatant Biolip, Tahiti, French Polynesian islands 
Biolip P 51 supernatant Biolip, Tahiti, French Polynesian islands 
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Table 10 - Plants  
 
Family Plant Name Part of plant Distributor 
Ranunculaceae Actea racemosa  root Dixa AG, St. Gallen, Switzerland 
Rutaceae Aegle marmelos  root Treiber, Waibstadt, Germany 
Rubiaceae Asperula odoratae herb Chrüterhüsli, Basel, Switzerland 
Balanitaceae Balanites aegyptiaca  fruit/seed Treiber, Waibstadt, Germany 
Betulaceae Betula verrucosa leaf Treiber, Waibstadt, Germany 
Brassicaceae Brassica oleraceae sprout Ikeda Corporation, Tokyo, Japan 
Anacardiaceae Buchanania lanzan  seed Treiber, Waibstadt, Germany 
Fabaceae Butea monosperma flower Treiber, Waibstadt, Germany 
Compositae Calendula officinalis  flower Chrüterhüsli, Basel, Switzerland 
Fabaceae Cassia alata herb Friedrich Nature Discovery, Euskirchen, Germany 
Celastraceae Cassia glauca  root  Treiber, Waibstadt, Germany 
Apiaceae Centella asiatica leaf Chrüterhüsli, Basel, Switzerland 
Ranunculaceae Cimicifuga racemosa  rhizome, root Chrüterhüsli, Basel, Switzerland 
Asclepiadaceae Marsdenia condurango bark Friedrich Nature Discovery, Euskirchen, Germany 
Salicaceae Salix purpurea bark Treiber, Waibstadt, Germany 
Umbelliferae Crithmum maritinum herb Agrimer, Plouguerneau, France 
Loranthaceae Dendrophtoe pentandra leaf Treiber, Waibstadt, Germany 
Dioscoreaceae Dioscorea alata  herb Friedrich Nature Discovery, Euskirchen, Germany 
Dioscoreaceae Dioscorea esculenta  herb Friedrich Nature Discovery, Euskirchen, Germany 
Dioscoreaceae Dioscorea persimilis  herb Friedrich Nature Discovery, Euskirchen, Germany 
Dioscoreaceae Dioscorea persimilis  root Friedrich Nature Discovery, Euskirchen, Germany 
Dioscoreaceae Dioscorea tokoro  herb Friedrich Nature Discovery, Euskirchen, Germany 
Dioscoreaceae Dioscorea tokoro  root Friedrich Nature Discovery, Euskirchen, Germany 
Dioscoreaceae Dioscorea villosa root Chrüterhüsli, Basel, Switzerland 
Aspidiaceae Dryopteris filix-mas syn. rhizome Chrüterhüsli, Basel, Switzerland 
Compositae Elephantopus scaber root Friedrich Nature Discovery, Euskirchen, Germany 
Araliaceae Eleutherococcus senticosus root Chrüterhüsli, Basel, Switzerland 
Myrsinaceae Embelia ribes fruit Treiber, Waibstadt, Germany 
Chenopodiaceae Fredolia aretioides herb Friedrich Nature Discovery, Euskirchen, Germany 
Rubiaceae Galium mollugo  herb Treiber, Waibstadt, Germany 
Ginkgoaceae Ginkgo biloba  leaf Chrüterhüsli, Basel, Switzerland 
Fabaceae Glycyrrihza glabra stipe Chrüterhüsli, Basel, Switzerland 
Verbenaceae Gmelina arborea leaf Treiber, Waibstadt, Germany 
Euphorbiaceae Jatropha gossypifolia   root Dr. Gonzales, Santiago de Cuba,Cuba 
Lamiaceae Leonurus cardiaca leaf Chrüterhüsli, Basel, Switzerland 
Brassicaceae Lepidium meyenii  root Friedrich Nature Discovery, Euskirchen, Germany 
Sapindaceae Litchi  chinensis seed Ikeda Corporation, Tokyo, Japan 
Marsileaceae Marsilea quadrifolia leaf Treiber, Waibstadt, Germany 
Fabaceae Melilotus officinalis herb Friedrich Nature Discovery, Euskirchen, Germany 
Labiatae Mentha piperita leaf Chrüterhüsli, Basel, Switzerland 
Myrothamnaceae Myrothamnus flabellifolius herb Friedrich Nature Discovery, Euskirchen, Germany 
Nelumbonaceae Nelumbo nucifera  flower Treiber, Waibstadt, Germany 
Cactaceae Opuntia ficus indica fruit Friedrich Nature Discovery, Euskirchen, Germany 
Aaliaceae Panax gingseng root Chrüterhüsli, Basel, Switzerland 
Polypodiaceae Polypodium vulgare rhizome Chrüterhüsli, Basel, Switzerland 
Rosaceae Prunus persica  flower Friedrich Nature Discovery, Euskirchen, Germany 
Rosaceae Prunus spinosa  flower Friedrich Nature Discovery, Euskirchen, Germany 
Punicaceae Punica granatum fruit Friedrich Nature Discovery, Euskirchen, Germany 
Fagaceae Quercus suber bark Friedrich Nature Discovery, Euskirchen, Germany 
Rosaceae Rhodiola rosea radix. root Floros, Barnaul, Russia 
Rosaceae Rosa canina L. fruit Chrüterhüsli, Basel, Switzerland 
Rubiaceae Rubia cordifolia root Treiber, Waibstadt, Germany 
Rubiaceae Rubia cordifolia  stipe Treiber, Waibstadt, Germany 
Asparagaceae Ruscus aculeatus L. rhizome Chrüterhüsli, Basel, Switzerland 
Selaginellaceae Selaginellia lepydophylla herb Friedrich Nature Discovery, Euskirchen, Germany 
Compositae Silybum marianum fruit Friedrich Nature Discovery, Euskirchen, Germany 
Smilacaceae Smilax sarsaparilla  root Chrüterhüsli, Basel, Switzerland 
Caryopyllaceae Stellaria media herb Treiber, Waibstadt, Germany 
Boraginaceae Symphytum officinalis  root Chrüterhüsli, Basel, Switzerland 
Myrataceae Syzygium cuminii seed Treiber, Waibstadt, Germany 
Compositae Taraxacum officinalis leaf Chrüterhüsli, Basel, Switzerland 
Combretaceae Terminalia arjuna  bark Treiber, Waibstadt, Germany 
Leguminosae Trifolium pratense L. flower Chrüterhüsli, Basel, Switzerland 
Graminae Trisetum flavescens L. seed Chrüterhüsli, Basel, Switzerland 
Tropaeolaceae  Tropalolum majus  leaf Treiber, Waibstadt, Germany 
Scrophulariaceae Verbascum thapsus  leaf Treiber, Waibstadt, Germany 
Verbenaceae Verbena officinalis leaf Chrüterhüsli, Basel, Switzerland 
Violaceae Viola tricolor flower Chrüterhüsli, Basel, Switzerland 
Verbenaceae Vitex agnus castus fruit Chrüterhüsli, Basel, Switzerland 
Rhamanaceae Ziziphphus lotus  leaf Friedrich Nature Discovery, Euskirchen, Germany 
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4.1.3 PLASMIDS FOR TRANSFECTION 
 
Plasmid Origin 
PPRE-tk Luc The Salk Institute, La Jolla, USA  
(Dr. Evans)  
PPAR National Cancer Institute, Bethesda, 
USA (Dr. Gonzalez) 
PPAR/ Centre for Integrative Genomics, 
University Lausanne, Switzerland  
(Dr. Perroud) 
PPAR Centre for Integrative Genomics, 
University Lausanne, Switzerland  
(Dr. Perroud / Dr. Michalik) 
expression vector pSG5 
 
Promega, Southampton, United Kingdom 
 
 
Plasmid 
Depiction of the sequence of the C-
terminal ends 
PPAR  LLNVKPIEDIIQDNLLQALELQLKLNHPESSQLFAK
VLQKMTDLRQIVTEHVQLLHVIKKTETDMSLHPLL
QEIYKDLY505 
PPAR/ LMNVPQVEAIQDTILRALEFHLQVNHPDSQYLFP
KLLQKMADLRQLVTEHAQMMQWLKKTESETLLH
PLLQEIYKDMY440 
PPAR LLNIGYIEKLQEGIVEVLKLHLQSNHPDDTFLFPK
LLQKMVDLRQLVTEHAQLVIKKTESDAALHPLLQ
EIYRDMY468 
 
 
4.1.4 CELL CULTURE MATERIALS 
 
Material Distributor 
12-well plates Nunc, Wiesbaden, Germany 
96-well plates Nunc, Wiesbaden, Germany 
Cell culture flasks  Nunc, Wiesbaden, Germany 
Centrifuge tubes  Nunc, Wiesbaden, Germany 
Cover slip Menzel-Glaser, Braunschweig, Germany 
Culture slides Camber 6-8 BD Falcon, Becton Dickinson, USA 
Freezing vials Nunc, Wiesbaden, Germany 
Microscope slide Menzel-Glaser, Braunschweig, Germany 
MultiScreen® Solubility Filter Plate Millipore, Billerica, USA 
Serological Pipette Sarstedt, Nümbrecht, Germany 
Sterile filters (0.2 m) Corning, Acton, USA  
Tube Sarstedt, Nümbrecht, Germany 
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4.1.5 ACCESSORIES 
 
Accessories Distributor 
Teflon silicone septa Chase Scientific Glass, Tennessee, USA 
Filter Dionex GmbH, Idstein, Germany 
Fluoro Filter 544 nm Catalys AG, Wallisellen, Switzerland 
Fluoro Filter 555 nm Catalys AG, Wallisellen, Switzerland 
Fluoro Filter 620 nm Catalys AG, Wallisellen, Switzerland 
 
 
4.1.6 BUFFERS 
 
Buffer Distributor 
Reporter lysis buffer Promega, Madison, USA 
Passive lysis buffer  Promega, Madison, USA 
Luminex buffer Invitrogen, Basel, Switzerland 
Bio Rad buffer Bio Rad Laboratories, Hercules, USA 
 
 
4.1.7 CELLS 
 
Cells Origin 
SZ95 sebocyte cell line Dermato-endocrinology, Charité Berlin, 
Germany (Prof. Zouboulis) 
HeLa cell line Centre for Integrative Genomics, 
University Lausanne, Switzerland (Prof. 
Wahli) 
COS/7 cell line Centre for Integrative Genomics, 
University Lausanne, Switzerland (Prof. 
Wahli) 
 
"The SZ95 sebaceous gland cell line refers to a cell line resulting from the 
transfection of human sebaceous gland cells derived from isolated facial sebaceous 
glands with a PBR-322 based plasmid containing the coding region for the simian 
virus 40 large T gene. The cell line has been immortalized by Prof. Dr. Christos C. 
Zouboulis. Prof. Zouboulis owns the relevant patents EP1151082, DE59913210D, 
AT319813T, AU770518B, CN1344314T, DK1151082T, KR689120, PL194865 and 
has filed further patent applications in several countries (CA2360762, HU0200048, 
IL144683D, JP2002535984T, US2002034820 and others), which claim the cell line 
and uses thereof." 
 
All cells (SZ95, HeLa and COS/7) were maintained at 37°C, 5% CO2. 
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4.1.8 CELL CULTURE MEDIA AND SOLUTIONS 
 
Sebocyte HSG-Medium Distributor 
Sebomed® Basal Medium 500 ml Biochrom, Berlin, Germany 
10% fetal calf serum PAN Biotec GmbH, Aidenbach, Germany 
50 g/ml gentamycin PAN Biotec GmbH, Aidenbach, Germany 
1 mmol CaCl2 Sigma, Munich, Germany 
5 ng/ml epidermal growth factor (EGF) Sigma, Munich, Germany 
 
 
Sebocyte Medium for Transfection Distributor 
Sebomed® Basal Medium 500ml Biochrom, Berlin, Germany 
10% fetal calf serum without lipids PAN Biotec GmbH, Aidenbach, Germany 
50 g/ml gentamycin PAN Biotec GmbH, Aidenbach, Germany 
5 ng/ml epidermal growth factor (EGF) Sigma, Munich, Germany 
 
 
Medium for COS/7 and HeLa cells Distributor 
DMEM 500 ml Sigma-Aldrich, Steinheim, Germany  
10% fetal calf serum  PAN Biotec GmbH, Aidenbach, Germany 
 
 
Medium for COS/7 and HeLa cells for 
Transfection 
Distributor 
DMEM 500 ml Sigma-Aldrich, Steinheim, Germany  
 
 
4.1.9 MATERIALS OF CELL CULTURE TECHNIQUE 
 
Proliferation analysis Distributor 
Methyl-umbelliferyl-heptanoate Sigma, Munich, Germany 
 
Detection of cell lipids Distributor 
Nile Red Sigma, Munich, Germany 
 
Detection cell vitality  Distributor 
FDA Sigma, Munich, Germany 
 
Cytotoxicity detection Kit-Assay  Distributor 
LDH  Roche Diagnostics, Mannheim, Germany 
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Human Cytokine and Chemocine Assay: 
Multi-Plex System  
Distributor 
Bio-Plex human IL-1 Assay Bio Rad Laboratories, Hercules, USA 
Bio Plex human IL-6 Assay Bio Rad Laboratories, Hercules, USA 
Bio Plex human IL-8 Assay Bio Rad Laboratories, Hercules, USA 
Bio Plex human IL12 Assay Bio Rad Laboratories, Hercules, USA 
Bio Plex human IL13 Assay Bio Rad Laboratories, Hercules, USA 
Bio Plex human 8 Plex A Panel Bio Rad Laboratories, Hercules, USA 
Bio Plex Reaction Kit Bio Rad Laboratories, Hercules, USA 
 
 
Apoptosis - Caspase-3/7 Assay Distributor 
Apo ONETM Homogeneous Promega, Medison, USA 
Color Reagent A and Color Reagent B 
R&D System Cat DY999) 
R&D System, Minneapolis, USA 
 
 
Diverse Kits Distributor 
High speed Purification Kit  Qiagen AG, Hilden, Switzerland 
Dual luciferase® reporter assay system Promega, Medison, USA 
PLA2 activity assay  Assay Designs, Ann Arbor, USA 
Immunometric assay for sPLA2-IIA Cayman Chemical, Ann Arbor, USA 
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4.1.10 EQUIPMENT / INSTRUMENTS  
 
Instruments Distributor 
Cellcounter Casy1 Scharfe System GmbH, Reutlingen, 
Germany  
Centrifuge 5810R Eppendorf, Basel, Switzerland 
CO2 incubator AUTO-ZERO  Heraeus, Hanau, Germany 
Extractor (ASE100) DIONEX, Olten, Switzerland 
Fluorescence microscope BX51 Olympus, Tokyo, Japan 
Fluoroscan Ascent FL Thermo Labsystems, Helsinki, Finland 
Laminar flow (Skan VSE 2000-120) Skan AG, Basel, Switzerland 
Laminar flow (Gelaire BSB6A) Skan AG, Basel, Switzerland 
Libra  Mettler Toledo, Greifensee, Switzerland 
Luminex 100 system Luminex Corporation, Austin, USA 
Lumat, LB9501 Berthold, Regensdorf, Switzerland 
Chameleon Multilable Detection Pl. Hidex, Oy, Finland 
Lyophilizer (GT2) Lyovac, Rotkreuz, Switzerland 
Microplate Washer ASYS Hitech GmbH, Eugendorf, 
Austria 
Microscope camera (DP12) Olympus, Tokyo, Japan 
Microscope camera (DP70) Olympus, Tokyo, Japan 
Millipore Multi Screen Millipore, Billerica, USA 
Mixer  Telion AG, Schlieren, Switzerland 
Mulitidrop 384 Thermo Electron Cooperation, Vantaa, 
Finland 
Multiscan Ascent Thermo Labsystems, Helsinki, Finland  
Nanodrop ND Spectrometer  Witec AG, Fanghöfli Littau, Switzerland 
Phase contrast microscope Olympus, Tokyo, Japan 
Pipettes Eppendorf, Hamburg, Germany  
Rotavapor R-134 Büchli, Flawil, Switzerland 
Titramax 100 Heidolph Elektro GmbH&Co.KG, 
Kelheim, Germany 
Vacusan R Scan AG, Basel, Switzerland 
Vortexer Bender&Hobein AG, Zürich, 
Switzerland 
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4.2 METHODS 
 
4.2.1 SELECTION OF COMPOUNDS 
 
Natural products provide a greater structural diversity than standard combinational 
chemistry and thus offer major opportunities for finding novel low molecular weight 
structures that are active against a wide range of assay targets. This study focused 
on the discovery of natural products acting on lipogenesis or lipolysis. 
For this study, plants, microbial organism samples and Bothrops moojeni snake 
venom were selected. Most of the plants were chosen by literature search. The 
criterion for the search was wound healing, skin lipid regulation, and hormonal 
regulation. 
The microbial organisms were from the French Polynesian atoll. Until now, bioactivity 
and biodiversity of these samples were poorly investigated. However, these 
organisms might be a rich source for new drugs. These substances have to be 
identified for their pharmaceutical activity. The venom of the South American lance-
head viper, Bothrops moojeni may induce a wide spectrum of pharmaceutical effects. 
Peptides like GHK were selected by literature research (wound healing). Other 
peptides were developed at Pentapharm. 
 
 
4.2.1.1 EXTRACTION OF PLANT MATERIAL  
 
Numerous medicinal plants are used for disease treatment. Often not only one 
compound but a variety of them is responsible for pharmaceutical effects (of 
medicinal plants). Only in few cases the full metabolite profile of these extracts and 
the contributions of individual constituents to the overall pharmaceutical properties 
are known. 
 
Preparation procedure: 
 
A variety of plant herbs, fruits, barks, seeds, roots and rhizomes were collected. 
Dried leaves, roots, bark, flowers and seeds were ground. The blended sample, a 
mixture of 10 g pulverized plant samples and 5 g hydromatrix was put into an 
accelerated solvent extractor cell and extracted with polar (water) or non polar 
(ethanol) solvents in a Dionex ASE extractor.  
 
Table 11 - Extraction methods process 
 
Method 1: 
 
Solvent: Water 
 
Method 2: 
 
Solvent: Ethanol 
 
Temperature: 129°C 
Static time 5 minutes 
Flush volume: 60% 
Purge time 60 seconds 
Static cycles: 4 
Temperature: 90°C 
Static time 5 minutes 
Flush volume: 60% 
Purge time 60 seconds 
Static cycles: 4 
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It is known that ethanol has a proliferative effect on SZ95 sebocytes. For this reason 
the extracts were evaporated to dryness with a rotary evaporator at 40°C and 70 bar. 
Afterwards extracts were dissolved in water. After freezing all extracts a lyophilisation 
system that removes water and other solvents from frozen samples by sublimation 
was used. 
 
For profiling studies, dried ethanol extracts were dissolved in DMSO and water 
extracts in water, to a concentration of 10 mg/ml. These extracts were filtered through 
0.2 m filters for sterile cell culture conditions. All extracts were stored at 4°C.  
 
 
4.2.1.2 EXTRACTION OF MICROBIAL ORGANISMS 
 
Microbial mats from Polynesian islands are laminated communities, basically 
composed of phototropic and chemotropic prokaryotes. The vertical stratification of 
the community is a response of the organisms to the gradients of light, oxygen, 
sulfide and pH, according to their physiological requirements. Nitrogen fixation is 
essential for the development of many microbial mats. Mats from the French 
Polynesian atoll are characterized by a diversity in terms of physical and chemical 
parameters with pH ranging from 6 to 10.5, salinity ranging from 9 g/l to 42 g/l, 
temperature ranging from 42°C down to 20°C during the night and finally varying light 
intensity [7]. 
 
The used microbial organism samples contained bacteria like Pseudoalteromonas, 
Flavobacterium, Alteromonas, Paracoccus and Vibrio cyanobacteria. These 
organisms produce exopolysaccharides and pigments. 
 
Preparation procedure: 
 
Microbial samples consist of different bacterial pigments recovered from bacteria 
isolated from Polynesian microbial mats and their supernatant. Ten milligrams per 
milliliter of the lyophilized microorganisms were diluted in water. With the help of a 
pulsed ultrasonic device the cell membranes were disrupted to release the molecules 
such as bacterial pigments, bioactive molecules and polysaccharides. For cell culture 
conditions the samples were filtered through a 0.2 m filter wash. 
 
 
4.2.1.3 SYNTHESIS AND PREPARATION OF PEPTIDES  
 
Used peptides were synthesized at Pentapharm by Dr. Fragale, Dr. Heidl and 
Mr. Wikstroem. 
 
4.2.1.4 BOTHROPS MOOJENI - PROTEIN SEPARATION 
 
Bothrops moojeni (Botmo) crude venom was collected, pooled and dried at 
Pentapharm Brazil, Uberlândia. It was transported and stored in desiccated form until 
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it was reconstituted in deionized water at Pentapharm, Switzerland. A 30% solution 
was obtained and stored at -80°C (cf. 4.1.2; page 27). 
 
Size exclusion chromatography 
 
Crude venom from Bothrops moojeni was fractionated by gel filtration and HPLC. 
Crude, reconstituted venom was separated into 18 gel filtration (GF) fractions on two 
in-line Superdex-75 (Pharmacia) XK 26 columns. For the protein elution 50 mM 
CH3COONH4, 150 mM NaCl, pH 7.5 buffer at the flow rate of 2.2 ml/min was used 
and the absorbance was monitored at λ = 280 nm. Aliquots of 300 mg were loaded 
onto the system resulting in a good and reproducible separation. To ensure good 
reproducibility of the process, the columns were regenerated every 5 runs using 
0.5 M NaOH (flow rate 1 ml/min, over the period of 8 h). Collected fractions were 
called Botmo GF 1 - 18, stored at -80°C and used for further separation steps and 
various measurements [115]. 
 
RP-HPLC Botmo gel filtration fractions 11, 12 and 15 (about 10 mg of protein) were 
then submitted to Solid Phase Extraction by acidification with 0.1% TFA 
(trifluoroacetic acid) and loaded on Sep-Pak C18 classic cartridges (Waters™). 
Solvation, equilibrium, sample application and elution were performed according to 
the manufacturer´s instructions. The fractions eluted with 60% acetonitrile were 
enriched in peptides and proteins. They were freeze-dried under vacuum in a 
SC210A Speed Vac™ Plus from Savant™. The desalted fractions were processed 
by RP-HPLC on a Waters Alliance 2690 System using a semi preparative HPLC 
column (Vydac #218TP510 protein & peptide C18, 10 mm x 250 mm). Freeze-dried 
fractions were reconstituted in 0.1% TFA and centrifuged at 11,000 rpm before 
injections on column. Proteins and peptides were eluted using the gradient of 2-50% 
of 90% acetonitrile in 0.1% TFA for 75 min, then a gradient of 50 - 60% for 2 min and 
a gradient of 60 - 80% for the following 3 min, at a flow rate of 3 ml/min. The 
absorbance was monitored at λ = 225 nm and the fractions were collected manually, 
following peak absorbance.  
 
4.2.1.5 MEASUREMENT OF PHOSPHOLIPASE ACTIVITY 
 
Secretory phospholipases A (sPLA) is a group of enzymes that upon activation, 
cleave an acyl ester bond in the sn-2 position in glycerophospholipid. PLA2 generate 
arachidonic acid and eicosanoids from membrane phospholipids. For the 
determination of PLA2 activity a sPLA2 kit (Assay Designs) was used.  
 
Preparation procedure: 
 
Standards and samples (50 l) were pipeted in duplicate wells. Reaction buffer (100 
l) and substrate (50 l) were added and the plate was incubated at 37°C for 30 min. 
The specific substrates for PLA2 were converted into a sulfhydryl molecule, which 
was detected colorimetrically using 25 l of Ellman´s reagent which formed a yellow 
colored product with the sulfhydryl molecule.  
The amount of sPLA2 in the sample was compared to the amount of standard sPLA2 
supplied in the kit by comparison of the yellow color generated at 405 nm measured 
with a multiscan system.  
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4.2.1.6 IMMUNOMETRIC ASSAY FOR SECRETED PHOSPHOLIPASE A2 IIA 
 
Secretory PLA2 type IA, IIA and IIB are found in venom of snakes like vipers, cobras 
and rattlesnakes. Since 1994 the sPLA2 IIA are suggested to trigger the release of 
arachidonic acid in inflammatory processes [23].  
 
Preparation procedure: 
 
This immunometric assay is based on a doublet antibody immune sandwich 
technique which is specific for PLA2 IIA..The immunometric assay was used 
according to the manufacturer‟s instructions. In brief, each well on a 96-well plate is 
coated with a monoclonal antibody specific against PLA2 IIA. Samples and standards 
(100 l) were pipeted in duplicate wells. The immobilized antibody binds to any PLA2 
IIA introduced to the well. Then 100 l of acetylcholinesterase PLA2 Fab`conjugate 
was added to all wells except the blank and incubated overnight in the dark at 4°C. 
Acetylcholinesterase PLA2 Fab`conjugate binds selectivity on the other side of the 
PLA2 molecule, a sandwich layout is established. After washing five times to remove 
the unbound conjugates, 200 l of Ellman´s reagent was added and incubated for 30 
min. This reagent consists of acetylthiocholine and 5,5`-dithio-bis-(2-nitrobenzoic 
acid). Hydrolysis of acetylthiocholine by acetylcholinesterase reacts to thiocholine. 
The non enzymatic reaction of thiocholine with 5,5`-dithio-bis-(2-nitrobenzoic acid 
produces 5-thio-2-nitrobenzoic acid, which has a strong absorbance at 412 nm. The 
amount of sPLA2 IIA in the sample was compared to the amount of standard 
sPLA2 IIA supplied in the kit by comparison of the yellow color generated at 405 - 420 
nm measured at multiscan plate reader.  
 
 
4.2.2 CELL LINE – IMMORTALIZED HUMAN SZ95 SEBOCYTES  
 
Human sebocytes are cells of the sebaceous gland. Normal human sebocytes can 
only be grown for 3 to 6 passages. To overcome this problem, Zouboulis and 
colleagues cultured human facial sebocytes from a 87-year-old woman and 
transfected them with the Simian Virus-40 large T antigen [199]. 
Immortalized human sebocyte (SZ95) differentiation was characteristic for the 
intracellular accumulation of neutral lipids in cytoplasm.  
Cells used for experiments in this work were between passages 23 and 33. Work 
with the low passage cell stock was conducted in order to avoid selection of the cells, 
which may occur at high passage levels. 
 
Preparation procedure: 
 
Culture conditions 
 
SZ95 sebocytes were cultured in 175 square centimeters flasks and detached using 
trypsin as soon as possible by a standard procedure: The cells were washed twice 
with PBS without Ca2+ and Mg2+. Then fresh trypsin (3 ml) was added and incubated 
for 20 min at 37°C, 5% CO2. After cell detachment the reaction was stopped with 
approximately 6ml of HSG-medium containing fetal calf serum. The cells were 
pelleted by centrifugation (200 - 300g for 10 min) and then resuspended in HSG 
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medium. Then 3 million SZ95 sebocytes were transferred into a new flask. Sebocytes 
reached 90% of confluence after approximately one week. 
 
Thawing cells 
 
The frozen cells were thawed in a water bath at 37°C. The 1 ml cell suspension 
included in the delivered cryotube was diluted with HSG-medium in order to quickly 
decrease the concentration of DMSO included in the freezing medium to less than 
0.5%. Cell viability was assessed at this point; about 15 - 20% dead cells were 
present. The SZ95 sebocytes were placed in 175 square centimeters flasks 
(approximately 1.5 - 3 million cells per flask). The added medium was 0.2 - 0.5 ml 
medium per cm2 of growth surface. The medium was changed every second day. 
Confluency was reached after approximately one week.  
 
Freezing cells 
 
SZ95 sebocytes were detached for freezing at 70 - 80% of confluency using trypsin 
and resuspended in 1 ml Sebomed culture medium containing 10% DMSO. The 
cells, approximately 2 - 3 million per 1 ml, were frozen in a cryotube with a freezing 
speed of 1°C/min.  
 
 
4.2.3 SCREENING MODEL TO INVESTIGATE SZ95 SEBOCYTE LIPID 
SYNTHESIS 
 
Established treatments for sebaceous gland diseases act either on lipid production, 
hyperproliferation, inflammation, differentiation or a combination of these aspects. 
Depending of the research target the sebocyte culture design varies to investigate 
sebaceous gland functions, like lipogenesis. This cell culture model was developed to 
investigate the regulation of lipid synthesis. The screening model was used to search 
for new active compounds to inhibit or stimulate neutral lipid production in human 
sebocytes. 
Potential new drugs for treatment of acne or dry skin disorders can be identified by 
this newly developed screening model. Tests were carried out in three 96-well culture 
plates for each experiment, including Nile Red for staining neutral and polar lipids 
and FDA staining as viability markers for sebocytes. It was possible to determine 
multiple parameters from a single well.  
In this model a number of compounds were used in a pharmacological concentration 
range from 10-5 to 10-4 M, including known anti-acne and lipid stimulating drugs, and 
unknown compounds in 1/100 or 1/1000 dilutions that were potentially useful in the 
treatment of acne and dry skin. 
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Table 12 - Compound concentrations 
 
Compounds Diluents/Concentration 
Water Extracts 100-fold dilution 
DMSO Extracts 1000-fold dilution 
Hormones 10-8 M 
Fatty acids 10-5 to 10-4 M 
 
Preparation procedure: 
 
40,000 cells/well were seeded in 96-well plates and cultured for 24 h. After 24 h cells 
reached confluency and were pre-treated with 10-5 M arachidonic acid, 10-4 M linoleic 
acid or 50 l/well HSG medium. One hour later the treatment with negative control, 
hydrocortisone 10-4 M, and control medium containing 0.1% solvent (water or DMSO) 
started. Lipid synthesis in SZ95 sebocytes was decreased by hydrocortisone by 
about 10 - 20% and increased by fatty acids like arachidonic acid and linoleic acid 
0.1 mM by 40%. Compounds for the screening were prepared in deep well plates. 
The test substances were diluted in 1/100 and 1/1000 dilution steps.  
All compounds (pre-treatment and treatment) were cultured for 24 h at 37°C, 5% 
CO2.  
On the day of evaluation the medium was removed, and cells were washed twice 
with PBS and treated with Nile Red to stain intracellular polar and neutral cell lipids 
and FDA for cell vitality detection. After 15 min incubation at 37°C fluorescence was 
measured as described in chapters 4.2.5 and 4.2.6. 
 
 
4.2.4 FLUORESCENT LABELING OF MOLECULES AND ORGANELLES IN 
LIVING CELLS  
 
Fluorescence microscopy allows visualization of specific molecules that emit light 
when excited by light of a defined wavelength. For fluorescence microscopy, cells are 
stained with a dye and the dye is illuminated with filtered light at the absorbing 
wavelength; the light emitted from the dye is viewed through a filter that allows only 
the emitted wavelength to be seen.  
Fluorescence microscopy of living cells is a powerful tool to investigate labeled 
organelles or structure in living cells. The technique is used to study specimens, 
which can be made to fluoresce. The fluorescence microscope contains special 
filters, like DAPI, Texas Red and FITC. The filters are designed to isolate and 
manipulate two distinct sets of excitation and fluorescence wavelengths.  
 
Table 13 - Visualizing cell structures 
 
Filter Dye Cell structure 
Wavelength 
Ex/Em 
Texas red Nile Red PL 544 / 620 nm  
DAPI Hoechst 33342 DNA 385 / 420 nm 
FITC Nile Red NL 485 / 555 nm 
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Preparation procedure: Labeling of cells: 
 
Cells (20,000 cells/chamber) were seeded in chamber slides and cultured for 24 h. 
Wells were washed with PBS and treated with compounds for 24 h. Then, cells were 
cultured for another 48 h at 37°C and 5% humidity in the CO2 incubator.  
On the day of evaluation the medium was removed. Cells were washed twice with 
PBS and treated with a mixture of Nile Red 0.1mg/ml and Hoechst 33342 5 g/ml.  
Stock solution of Hoechst 33342 (10 g/ml) was prepared in distilled water, protected 
from light, and stored at 4°C; a 1000-fold dilution in PBS was prepared to be used for 
labeling.  
The Hoechst dye labels the nucleus DNA and emits light of the wavelength 
λ = 385/420 nm. Nile Red stained intracellular polar and neutral cell lipids for 
detection. The chamber slides were incubated in the labeling solution at 37°C, 5% 
CO2 for 15 -30 min.  
Before measuring the labeling medium was aspirated and cells were rinsed three 
times in PBS. Images were recorded in grey scale with a digital camera coupled to 
an Olympus fluorescence microscope equipped with band pass emission 
fluorescence filter optical blocks. 
 
 
4.2.5 NILE RED STAINING FOR CELL LIPID DETECTION 
 
The development of cytoplasmic lipid droplets is a normal cellular process in cells. 
The dye Nile Red (9-diethylamino-5 H-benzo[]phenoxazine-5-one) (Figure 11) can 
be applied as a fluorescent vital stain for the detection of intracellular lipid droplets by 
fluorescence microscopy [49, 50] (see also chapter 4.2.4). 
The production of lipids is assessed by the Nile Red fluorescence assay. This assay 
is based on the measurement of fluorescence by a fluorospectrometer after staining 
the cells with Nile Red, a dual emission lipid dye [198]. Fluorescence is a member of 
the ubiquitous luminescence processes, in which susceptible molecules emit light 
from electronically excited status by either a physical (for example, absorption of 
light), mechanical or chemical mechanism. After staining with Nile Red, the cells were 
viewed for gold-yellow neutral lipid fluorescence and for red polar lipid fluorescence.  
 
N
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Figure 11 - Structure of Nile Red (C20H18N2O2) 
 
Preparation procedure: 
 
Sebocytes (40,000 cells/well) were cultured in 96-well plates for 24 h. Then, medium 
was removed and the cells were treated for 24 h with compounds. After treatment the 
medium was removed, the wells were washed twice with PBS, and 100 l of a 
10 g/ml Nile Red solution in PBS was added to each well. The plates were then 
incubated at 37ºC for 15 min, and the released fluorescence was read on a 
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fluorospectrometer. The results were measured in absolute fluorescence units in 
comparison with the controls, using 485 nm excitation and 565 nm emission filters for 
neutral lipids and 540 nm excitation and 620 nm emission filters for polar lipids. 
Experiments were performed in triplicate with 10 wells evaluated for each data point 
in each experiment. 
 
 
4.2.6 FLUORESCEIN DIACETATE VITALITY MEASUREMENT 
 
Fluorescein diacetate (FDA) stains viable cells by uptake into these cells. In cells 
FDA is hydrolyzed by unspecific esterases which separate FDA in fluorescein and 
acetate. The dye is accumulated in viable and esterase active cells. Contrary to FDA, 
fluorescein is not able to pass the intact cell membrane and is stored in vital cells. A 
green fluorescence of the cell cytosol appears under the fluorescence microscope.  
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Figure 12 - Principle of fluorescein measurement.  
 
Preparation procedure: 
 
Cells (40,000 cells/well) were seeded in 96-well plates and cultured for 24 h. Wells 
were washed three times with PBS and afterwards treated with compounds for 24 h. 
Fluoresceindiacetate powder was diluted in DMSO (1 mg/ml).  
SZ95 sebocyte cell suspensions were treated and incubated at 37°C for 15 min with 
FDA (1 l/ml). The results were presented in absolute fluorescence units in 
comparison with the controls. The green fluorescence was measured using 485 nm 
excitation and 538 nm emission filters by fluorospectrometer. Experiments were 
performed in triplicate for each data point in each experiment. 
 
 
4.2.7 DETECTION OF CELL CYTOTOXICITY WITH LACTATE 
DEHYDROGENASE RELEASE ASSAY 
 
Dying cells release their cell content into the medium. The cytotoxicity detection is 
based on the measurement of lactate dehydrogenase (LDH) activity which is 
released from the cytosol of damaged cells into the supernatant.  
LDH catalyses oxidation at lactate to pyruvate in vivo. At the same time the reduction 
of NAD+ to NADH 1H occurs. The enzyme diaphorase and tetrazolium salt 2-[4 -
indophenyl]-3[4nitropheny]-5-phenyltetrazolium chloride (INT) are added. Diaphorase 
catalyzes reduction of INT to red formazan salt by simultaneous oxidation of NADH 
and H to NAD+ (Figure 13). 
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Figure 13 - Principle of lactate dehydrogenase activity. Lactate dehydrogenase (LDH) catalyzed 
reaction is followed by diaphorase catalyzed reaction. 
 
 
Preparation procedure: 
 
The LDH kit from Roche Diagnostics was used according to the manufacturer‟s 
instructions. In brief, cells (10 000 cells/well) were seeded in 96-well culture plates 
and cultured for 24 h. Wells were washed with PBS and treated for 24 h with 
compounds. After 4 - 24 h incubation cell microplates were centrifuged for 10 min at 
250 xg and 15 - 25°C. Subsequently cell free culture supernatant (100 l/well) was 
transferred to the plates. A reaction mixture of diaphorase, NAD+, INT and sodium 
lactate was added to the supernatant and incubated for approximately 15 to 30 min 
at 25°C protected from light. The resulting red formazan salt was quantified 
photometrically. Absorbance was measured at 490 nm (reference wavelength 690 
nm). 
The amount of accumulated formazan was proportional to LDH-activity in 
supernatant and correlated to number of dead cells. Cytotoxicity effects were clarified 
as significant if the increase of LDH was over 10% compared to control.  
 
4.2.8 APOPTOSIS ASSAY 
 
Apoptosis is defined as the controlled self destruction program of cells. The apoptotic 
modes of cell death are active and defined processes. Apoptosis is controlled by 
several factors like PLA2 pathway [151, 158] and activation of the caspase family [32, 
153]. 
 
In humans eleven caspases have been identified. There are two types of caspases: 
initiator caspases and effector caspases. Initiator caspases (e.g., caspase-8, 
caspase-9) cleave inactive pro-forms of effector caspases, thereby activating them; 
effector caspases (e.g., caspase-3, caspase-7) in turn cleave other protein 
substrates within the cell initiating in the apoptotic process. The initiation of this 
cascade reaction is regulated by caspase inhibitors. Caspase-3 and -7 play key 
effector roles in apoptosis in mammalian cells.  
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Preparation procedure: 
 
Cells (40,000 cells/well) were seeded in plates and cultured for 24 h. The wells were 
then washed three times with PBS and treated for 24 h with compounds.  
 
The apoptosis assay included a profluorescent caspase-3/7 consensus substrate, 
rhodamine 110 bis-(N-CBZ-L-aspartyl-L-glutamyl-L-valyl-aspartic acid amide) (Z-
DEVD-R110), and an optimized bifunctional cell lysis/activity buffer. The buffer 
efficiently lysed cultured mammalian cells and supported optimal caspase-3/7 
enzymatic activity. The substrate and buffer were combined to make the caspase-3/7 
reagent. Homogeneous caspase-3/7 reagent (100 l) was added to each well of a 
non transparent 96-well plate containing 100 l of blank, control cells in culture. 
Upon cleavage on the C-terminal side of the aspartate residue in the DEVD peptide 
substrate sequence by caspase-3/7 enzymes, rhodamine 110 becomes fluorescent 
when excited at a wavelength of 498 nm. The emission maximum was 521 nm. The 
amount of fluorescent product generated was representative for the amount of active 
caspase-3/7 present in the sample. Fluorescence was measured every 30 min for 
18 h with a fluorescence plate reader. 
 
 
4.2.9 CYTOKINE ASSAY USING A BIO-PLEX SUSPENSION ARRAY 
SYSTEM 
 
Cytokines are a group of proteinaceous signaling compounds that, like hormones 
and neurotransmitters, are used extensively for intercellular communication. 
They are critical to the functioning of both innate and adaptive immune responses. 
Apart from their importance in the development and functioning of the immune 
system, cytokines play a major role in a variety of immunological, inflammatory and 
infectious diseases.  
Cytokines are produced by a wide variety of cell types and can have effects on both 
nearby cells or throughout the organism, sometimes strongly dependent on the 
presence of other chemicals and cytokines. The cytokine family consists mainly of 
small water-soluble proteins and glycoproteins (proteins with an added sugar chain) 
with a molecular mass of 8 - 30 kDa. 
The multiplex bead array technology provided the means to measure multiple assays 
simultaneously. It allows the detection of soluble cytokines and chemokines in cell 
supernatant by capturing these to spectrally district beads and tagging the desired 
element with fluorescent-labeled markers for analysis. 
Multiplexed sandwich immunoassays for cytokines were used by coupling cytokine 
specific capture antibodies to beads with different emission spectra. The binding of 
biotinylated detection antibodies bound with a streptavidin-conjugated fluorochrome 
was analyzed [57].  
 
Preparation procedure: 
 
Sebocytes (40,000 cells/well) were seeded in 96-well microplates and cultured for 
24 h. Then cells were treated for 24 h with compounds.  
 
Materials and Methods 
 
 
44 
After overnight sebocyte incubation with Bothrops moojeni GF11, GHK, HC and 
Biolip 51 supernatant, 100 l of cell free supernatants were transferred into a new 
plate.  
In this study SZ95 sebocyte supernatant was investigated for IL-1, IL-2, IL-4, IL-6, 
IL-8, IL-10, IL-12, IL-13, GM-CSF, IFN-  and TNF-. Cytokine detection kits from Bio 
Rad Laboratories were used. The assay was performed in 96-well filter plates using 
all assay compounds provided in the kit. 
Standard curves were generated by using reference concentrations supplied by the 
manufacturer. The cytokine standard was reconstituted and diluted in the same 
medium in which the cells were prepared. 
The filter plate was pre-wetted with 70 l of Luminex buffer. The buffer was removed 
by vacuum filtration on a Millipore Multi Screen. Then 50 l of the prepared bead 
working solution was added to the respective wells, sucked dry by vacuum filtration 
and washed again with Luminex buffer. 
Samples were diluted in appropriate HSG medium (2-fold). Diluted standards and 
samples (50 l/well) were added to the respective wells and incubated in the dark for 
30 min on a shaker at 300 rpm at room temperature. Subsequently the microtiter filter 
plate was washed again three times with Luminex buffer (70 l). Buffer was removed 
by the Millipore Multi Screen system. The detection antibody was prepared to a 1x 
concentration. Detection antibody (25 l) was added to the respective wells and 
incubated in the dark at room temperature for 30 min on the shaker. 
Thereafter the wells were washed using the vacuum manifold and detector antibody 
conjugated to biotin was added. Streptavidin-RPE was diluted to a 1x concentration 
with Bio-Plex assay buffer and 50 l were added to each well and incubated as 
before. 
After washing to remove the unbound Streptavidin-RPE the beads (minimum 50 
beads per cytokine) were analyzed using the Luminex 100 instrument. Luminex 100 
monitored the spectral properties of the beads while simultaneously measuring the 
amount of fluorescence associated with R-phycoerythrin. Raw data (mean 
fluorescence intensity MFI) were analyzed by Bio-Plex Manager 4.1 software. 
 
 
4.2.10 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR 
LIGAND ACTIVITY MEASUREMENT WITH TRANSFECTION 
 
In transfection, foreign DNA is introduced into eukaryotic cells like HeLa, COS/7 and 
SZ95 cells. This is most often done as an instance of transient transfection, in which 
the transfected gene is expressed only transiently, that is in only the cells to which it 
was originally inserted and only for a short period of time. During cell mitosis the 
transient gene disappears.  
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Figure 14 - Receptor gene system: PPAR, /, 2 were transiently transfected in cells. Cells 
express more PPAR, /, 2 which were activated by PPAR, /, 2 ligands. The receptor activation 
was measured by luciferase enzyme activity. 
 
 
4.2.10.1 TRANSIENT TRANSFECTION WITH LIPOFECTAMINE 
 
The original method for cationic lipid-mediated DNA transfection was improved in 
1993 by replacing the monocationic lipid reagent with lipofectamine, a polycationic 
reagent. The reaction was based on an ionic interaction of DNA and liposomes to 
form a complex. This complex can deliver functional DNA into cultured cells [40]. 
 
Transfection procedure: 
 
With a coactivator dependent receptor ligand assay several natural compounds have 
been screened. Twelve-well culture plates were seeded with COS/7 or HeLa cells at 
a confluency of 50 - 60%. Incubation was overnight with DMEM medium and 10% 
FBS (fetal bovine serum) at 37°C, 5% CO2. The following day, the medium was 
replaced and cells were transfected with empty expression vectors (pSG5) and 
vectors containing PPAR, , 2.  
The transfection preparation began with mixing and incubating lipofectamine 
(2 l/well), Optimem (50 l/well), renilla (5 ng/well) and PPRE (250 ng/well).  
In another tube PPAR or pSG5 expression vector (400 ng/well) and Optimem (50 
l/well) were mixed. 
 
655 ng DNA total/well = 250 ng PPRE.TK.Luc/well + 5 ng pTK-renilla/well + 
400 ng PPAR or pSG5 empty vector/well 
 
The transfection mix was pooled carefully with DNA mixture, then gently 
homogenized and incubated for 20 min at room temperature without shaking. Cells 
were washed with DMEM medium without serum/antibiotics before transfection. 
DMEM medium without serum/antibiotics (500 l) was added to the transfection 
mixture (DNA/lipofectamine) and 600 l/well were distributed. Cells were transfected 
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in triplicates. After 3 h incubation at 37°C, 5% CO2 medium was replaced with DMEM 
with serum for 2 h. 
 
In the meantime DMEM without serum and with ligands or compounds were 
prepared. COS/7 or HeLa cells were treated with 600 l/well medium compositions. 
After 18 to 20 hours of culturing, cells were washed once with PBS. Lysis buffer 
(250 l) was added and plates were agitated at 4°C during 15 min on a shaker. Then 
cells were scraped and collected. Cell lysate (10 l) was transferred to 96-well 
opaque plates.  
Luciferase and renilla activity were measured 24 h after transfection using the Dual-
Luciferase Reporter Assay System, according to the manufacturer‟s instructions. 
Determination of normalized luciferase activity was plotted as fold activation relative 
to untreated cells. All experiments were performed in triplicates in at least three or 
more independent experiments. 
 
 
4.2.10.2 TRANSIENT TRANSFECTION OF SZ95 SEBOCYTES  
 
Transient transfection assays were performed using superfect transient reagent. This 
reagent assembles DNA into compact structures, to optimize the entry of DNA into 
SZ95 sebocytes. Once inside, superfect reagent buffers the lysosomes after fusion 
with the endosome, leading to pH inhibition of lysosomal nucleases and stability of 
superfect-DNA complexes. 
Chen et al. observed that sebocytes cultured with serum free medium produce more 
lipids than those cultured with medium containing 10% fetal bovine serum. However, 
the exact actions of ligands on lipid metabolism are relatively complex and vary in 
different cellular systems [19]. 
 
Preparation procedure: 
 
Sebocytes were trypsinized and transferred into 12-well culture plates, and incubated 
for 24 h to reach 40 - 50% (200,000 cells/well) confluency. 
 
Total DNA (1.5 g/well) (PPRE, pSG5 expression vectors and pSG5 expression 
vectors containing PPAR, , 2) was diluted in OptiMEM to a volume of 97 l/well. 
Then 3 l/well of superfect transfection reagent was added to the DNA solution. The 
samples were mixed and incubated for 5 - 10 min at room temperature to allow the 
complex formation.  
While complex formation took place, growth medium was aspirated from the plates 
and cells were washed with 2 ml of PBS. Then 400 l/well of Sebomed with 10% 
FCS without lipids was added to the reaction tube containing the transfection 
complexes. The transfection complex was mixed and immediately transferred to the 
SZ95 sebocytes for 2 h at 37°C, 5% CO2. Then the medium was removed and cells 
were washed with 2 ml/well PBS. Fresh medium with compounds was added and 
sebocytes were treated and incubated for 24 h at 37°C, 5% CO2. 
At the indicated time, cells were rinsed with phosphate buffer and lysed in reporter 
lysis buffer. Then firefly and renilla activity were measured with the Promega dual 
reporter kit, according to the manufacturer‟s instructions. PPAR activation was 
absorbed by measurement of luciferase activity. All assays were performed in 
triplicates in 12-well plates, and the results were analyzed with a t-test. 
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4.2.10.3 BACTERIAL TRANSFORMATION  
 
Bacterial transformation is a technique to introduce a foreign plasmid into bacteria. 
This method is based on the natural function of plasmid: to transfer genetic 
information vital to the survival of bacteria. A plasmid is a small circular piece of DNA 
that contains important genetic information for the growth of bacteria.  
 
Preparation procedure: 
 
Following the preparation procedure transformation of approximately 108 bacteria 
with 1 g of pUC should give rise to 1-5 106 colonies. 
Frozen competent Escherichia coli (E. coli) cells were thawed on ice, treated with 
beta-mercaptoethanol, mixed with a transforming plasmid, briefly heat shocked, and 
then transferred into 500 ml of LB medium with 50 g/l ampillicin. The E. coli culture 
was grown overnight at 37°C with vigorous shaking (300 rpm). 
The bacteria were then transferred into a sterile centrifuge bottle and spinned in a 
pre-cooled centrifuge (3000 rpm), for about 20 min, at 4°C; the supernatant was 
discarded.  
 
For purification of plasmid DNA, Qiagen Mini- and Maxi-prep columns were used 
according to the manufacturer‟s instructions, as follows: 
The plasmid purification was based on a modified alkaline lysis procedure, followed 
by binding of plasmid DNA to an anion exchange resin under appropriate low salt 
and pH conditions. RNA, proteins and low molecular weight impurities were removed 
by medium salt wash. Plasmid DNA was eluted in a high salt buffer and then 
concentrated and desalted. 
The bacterial pellet was resuspended in 10 ml of buffer P1. Immediately 10 ml of 
buffer P2 was added and mixed thoroughly but gently by inverting the tube several 
times, and incubated at room temperature for 5 min. Chilled buffer P3 (10 ml) was 
added and mixed as before. The sample was incubated on ice for 20 min and then 
centrifuged at 12000 rpm for 15 min; the supernatant was removed and stored on 
ice. A Qiagen-tip 500 was equilibrated with 10 ml of buffer QBT, and the supernatant 
was applied to the column and allowed to drain through under gravity. The column 
was washed twice with 30 ml of buffer QC. DNA was eluted with 15 ml of buffer QF, 
and precipitated by addition of 10.5 ml of isopropanol. The DNA pellet was washed 
with 5 ml ethanol of 70%. Finally the dried pellet, free of residual ethanol, was 
resuspended in 500 l of deionized water. The concentration of DNA was determined 
by measuring the absorbance at 260 nm of a diluted sample. DNA samples were 
stored at -20°C. 
 
 
4.2.11 STATISTICAL EVALUATION 
 
Values represent the mean values ± standard deviation (SD) of at least three 
experiments. Statistical significance was calculated by the student‟s t-test. Mean 
differences were considered to be significant when (p < 0.001 ***; p < 0.01 **; 
p < 0.05 *). Data and graphs were produced with MS Excel 2000.  
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5 RESULTS 
 
5.1 SCREENING FOR ACTIVE COMPONENTS TO REGULATE LIPID 
SYNTHESIS  
 
A new screening model using the human SZ95 sebaceous gland cell line was 
established in order to find new active compounds which affect the lipid synthesis in 
these cells. This model allowed measuring neutral lipids, polar lipids and cell vitality 
in one experiment for each well.  
 
Table 14 - Active compounds from SZ95 sebocyte screening  
 
 FDA  PL
NL in 
%
 NL FDA PL
NL in 
%
 NL
Microbial organism Biolib P 75 1 µg/ml - - 88 ↓* ↓* ↓* 77 ↓**
Microbial organism Biolib P 50 1 µg/ml - ↓* 86 ↓* - ↓** 76 ↓**
Microbial organism Biolib P 90 1 µg/ml - ↑* 127 ↑* ↓* ↑** 108 -
Microbial organism Biolib P 51 1 µg/ml - ↓** 76 ↓** ↓* ↓** 78 ↓**
Bothrops Moojeni. Protein fractions Botmo GF 1 1 µg/ml - - 117 ↑* - - 114 ↑*
Bothrops Moojeni. Protein fractions Botmo GF 2 1 µg/ml - - 127 ↑** - ↑* 135 ↑**
Bothrops Moojeni. Protein fractions Botmo GF 3 1 µg/ml - - 119 ↑* - - 111 -
Bothrops Moojeni. Protein fractions Botmo GF 4 1 µg/ml - - 137 ↑** - - 108 -
Bothrops Moojeni. Protein fractions Botmo GF 5 1 µg/ml - - 152 ↑** - - 131 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 6 1 µg/ml - - 165 ↑*** - - 125 ↑**
Bothrops Moojeni. Protein fractions Botmo GF 7 1 µg/ml - ↑* 215 ↑*** - ↑* 154 ↑**
Bothrops Moojeni. Protein fractions Botmo GF 8 1 µg/ml - ↑* 199 ↑** - ↑* 240 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 9 1 µg/ml - ↑* 240 ↑*** - ↑* 250 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 10 1 µg/ml - ↑* 217 ↑*** - ↑** 235 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 11 1 µg/ml - ↑* 202 ↑*** - ↑* 173 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 12 1 µg/ml - ↑* 215 ↑*** - ↑* 180 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 13 1 µg/ml - ↑* 168 ↑*** - ↑* 194 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 14 1 µg/ml - ↑* 136 ↑*** - ↑* 166 ↑***
Bothrops Moojeni. Protein fractions Botmo GF 15 1 µg/ml - ↑* 205 ↑*** - - 161 ↑***
Peptide Tat-GLY-HIS-LYS-OH 0.1 µg/ml - ↓* 84 ↓** - - 83 ↓**
Peptide H-GLY-HIS-LYS-OH 0.1 µg/ml - - 83 ↓** - - 102 -
Peptide Cu GLY-HIS-LYS-OH 0.1 µg/ml - - 90 ↓* - - 90 ↓*
Plant extract Prunus persica 1 µg/ml - - 111,5 ↑** - - 114 ↑*
Plant extract Jatropha gossypifolia 1 µg/ml - - 83 ↓** - - 76 ↓***
Plant extract Vitex agnus castus 0.1 µg/ml - - 82 ↓** - - 108 -
Plant extract Dioscorea villosa 0.1 µg/ml - - 119 ↑** - - 122 ↑**
LA, AA pre-treatment without pre-treatment
Source Name Conc.
 
 
Legend: NL neutral lipids, PL polar lipids, AA arachidonic acid, LA linoleic acid, glycyl-histidyl-lysine 
(Gly-His-Lys), FDA fluoresceine diacetate, (-) no significant effect. Yellow labeled compounds are 
considered for further studies. Data are shown as mean ± standard deviation of triplicates (n = 9). 
These data were analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *) 
was considered statistically significant. Lipid stimulation was marked with ↑ and lipid inhibition with ↓. 
Untreated control cells correspond to 100% neutral lipids. 
 
Table 14 displays 26 active substances of plant extracts, snake venom gel filtration 
fractions, bacteria extracts and synthetic peptides, which lead to lipid stimulation or 
reduction in sebocytes. The SZ95 sebocyte screening model has been carried out 
with two different methods.  
One method was sebocyte pre-treatment with arachidonic acid and linoleic acid 
which increases SZ95 sebocyte neutral lipid production and was used to find 
compounds which inhibit lipid production. After pre-lipid stimulation some 
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compounds, such as Bothrops moojeni venom gel filtration fractions, additionally 
stimulated the increased production of neutral and polar lipids. Compounds like 
glycyl-histidyl-lysine (GHK) and their derivatives, Jatropha gossypifolia, Vitex agnus 
castus reduced lipid production in SZ95 sebocytes. 
The other method tested the same compounds without arachidonic or linoleic acid 
pre-treatment. This method showed similar results compared to the experiments with 
arachidonic acid or linoleic acid pre-treatment.  
The remaining 175 compounds, which are not listed in Table 14 lead to no significant 
effects on neutral lipid regulation or were cytotoxic (cf. chapter 4.1.2). 
 
The plant extract Jatropha gossypifolia inhibited neutral lipid synthesis by about 17 - 
24% (p < 0.001 - p < 0.01). Vitex agnus castus blocked lipid expression by 18% 
(p < 0.01); however this effect was only observable with a fresh extract. Prunus 
persica and Dioscorea villosa boosted neutral lipid expression by 17 - 19% (p < 0.01) 
in cells. 
Bacteria extracts stimulated production of neutral lipids up to 10 - 27% in sebocytes, 
but a cell vitality reduction (p < 0.05) was also measurable, which is an indicator for 
cytotoxicity. In arachidonic and linoleic acid pre-stimulated SZ95 sebocyte cell vitality 
loss was not detectable. 
The three derivatives of GHK peptides reduced lipids in arachidonic or linoleic acid 
pre-treated SZ95 sebocytes. GHK and GHK derivatives inhibited pre-stimulated 
neutral lipids about 10 - 17%; p < 0.01 - p < 0.05. In non-stimulated cells GHK 
treatment had no measurable effect on SZ95 sebocyte lipids. 
Especially noticeable were the snake venom gel filtration fractions from Bothrops 
moojeni. All gel filtration fractions stimulated neutral lipid production in SZ95 
sebocytes significantly up to 140%; p < 0.001 without toxic effects. Even when 
sebocytes were pre-treated with arachidonic acid or linoleic acid, a lipid increase was 
observed.  
 
The objective of this screening was to identify active compounds influencing lipid 
metabolism in SZ95 sebocytes. Because Bothrops moojeni venom gel filtration 
fractions lead to the most promising results, the lipogenic influence of Bothrops 
moojeni venom gel filtration fractions were the main focus of this work.  
Three Botmo gel filtration fractions 11, 12 and 15, from the low molecular weight 
range were selected as the most interesting ones, showing best results in lipid 
stimulation. Botmo GF 11, 12 and 15 elute lately from the gel filtration column, having 
a lower molecular weight than earlier eluted fractions. Low molecular weight Botmo 
GF fractions are better suited for a complete identification of the fraction and for new 
possible topically used ingredients.  
Additionally, the inhibition of lipid production was investigated using GHK and Vitex 
agnus castus extract. 
 
 
5.1.1 LIPID REGULATION BY BOTHROPS MOOJENI VENOM 
 
The previous screening results showed for the first time ever that Bothrops moojeni 
venom fractions activated lipid synthesis in SZ95 sebocytes. In order to identify the 
right dose-response relationship of Botmo gel filtration fractions (Botmo GF) eight 
concentrations were tested. The three diagrams below show lipid stimulation in 
Botmo GF 11, Botmo GF 12 and Botmo GF 15 treated sebocytes (Figure 15). 
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Figure 15 - Lipids in SZ95 sebocytes incubated with Botmo gel filtration fractions 11, 12 and 15. 
Sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 h. On 
the next day SZ95 sebocytes without pre-treatment were treated with Botmo GF 11, Botmo GF 12 or 
Botmo GF 15 for 24 h in different concentrations. Neutral lipids (blue line ) and polar lipids (red 
line ) were measured with Nile Red dye. The fluorescence intensity of polar lipids and neutral lipids 
was shown in %. The fluorescence intensity of polar lipids is about 30,000 auto fluorescence units 
(AFU), neutral lipids about 100 AFU. Lipid production of control cells with no treatment was set to 
100%. These data are significant compared to control cells. Data are shown as mean ± standard 
deviation of triplicates (n = 6). These data were analyzed by two-tailed Student's t test, where (p < 
0.001 ***; p < 0.01 **; p < 0.05 *). 
*** 
* 
 
*** 
** 
*** 
* 
* 
*** 
*** 
** 
 
* 
 
* 
 
* 
 
** 
A – Botmo GF11 
C – Botmo GF15 
B – Botmo GF12 
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Graph A shows the measured lipid content of Botmo GF 11 treated SZ95 sebocytes. 
The concentration of Botmo GF 11 ranged from 0.0001 ng/ml to 1 g/ml. At a 
concentration of 1 g/ml neutral lipids were significantly increased to 173% 
(p < 0.001), at 0.1 g/ml to 150% (p < 0.001) neutral lipids and at 0.01 g/ml to 120% 
(p < 0.01) neutral lipids. Lower concentrations showed no significant effects. Only at 
1 g/ml polar lipid increase in SZ95 sebocytes demonstrated a low significance 
(p < 0.05).  
The measured lipid content of Botmo GF 12 treated SZ95 sebocytes was shown in 
graph B. A concentration of 1 g/ml resulted in 173% neutral lipid stimulation 
(p < 0.001), 0.1 g/ml 150% neutral lipid stimulation (p < 0.001) and 0.01 g/ml 120% 
neutral lipid stimulation (p < 0.05). Lower concentrations showed no significant 
effects. From 1 g/ml to 0.1 g/ml polar lipid synthesis was increased in SZ95 
sebocytes with a low significance (p < 0.05).  
 
Graph C displays Botmo GF 15 treated SZ95 sebocyte results. The neutral lipid 
production in SZ95 sebocytes was increased by 200% (p < 0.001) after stimulation 
with 1 µg/ml Botmo GF 15. A concentration of 0.1 g/ml Botmo GF 15 stimulated 
166% (p < 0.001) neutral lipids and 0.01 g/ml 122% (p < 0.05) neutral lipids. Lower 
concentrations showed no significant effects. At a concentration of 0.1 g/ml polar 
lipid increase in SZ95 sebocytes was significant (p < 0.05). For all these three figures 
the production of neutral lipids was more strongly stimulated than that of polar lipids. 
 
When neutral lipid production increased to significantly high levels, polar lipids were 
sometimes rising as well and reached a maximum of 118%; p < 0.05. Neutral lipid 
amounts were more significantly increased than polar lipids. Additionally, no toxic 
effects could be observed with LDH cytotoxicity assays (data not shown). 
Botmo GF 11, 12 and 15 showed comparable results on lipid synthesis and vitality in 
SZ95 sebocytes. 
 
 
5.1.2 APOPTOSIS – MEASUREMENT OF BOTMO GF11, 12 AND 15 
TREATED SZ95 SEBOCYTES 
 
Increased cell volume, accumulation of lipid droplets in the cytoplasm and nuclear 
degeneration are phenomena indicating terminal differentiation. Lipid stimulation in 
this range can be related to a late differentiation phase of SZ95 sebocytes. This 
differentiation state can lead to holocrine secretion and cell death [173]. SZ95 
sebocytes treated with Bothrops moojeni venom gel filtration fractions demonstrated 
increased neutral lipid accumulation, good cell vitality and no cytotoxic effects in all 
used concentration ranges.  
To verify these results and to rule out morphological processes of controlled cellular 
self-destruction (apoptosis), caspases 3/7 levels were measured (cf. chapter 4.2.8).  
Results 
 
 
52 
0
50
100
150
200
250
300
350
Control Stau 0,1µM HC 100µM GF11 1µg/ml GF11  0.1µg/ml
c
a
s
p
a
s
e
 3
/7
 a
c
ti
v
it
y
 %
0
50
100
150
200
250
300
350
Control Stau 0.1µM HC 100µM GF12 1µg/ml GF12  0.1µg/ml
c
a
s
p
a
s
e
 3
/7
 a
c
ti
v
it
y
 %
0
50
100
150
200
250
300
Control Stau 0.1µM HC 100µM GF15  1µg/ml GF15  0.1µg/ml
c
a
s
p
a
s
e
 3
/7
 a
c
ti
v
it
y
 %
 
Figure 16 - Caspase-3/7 activity measurement of SZ95 sebocytes treated with Botmo gel 
filtration fractions 11, 12 and 15. SZ95 Sebocytes were seeded at a density of 40,000 cells/well in a 
96-well plate and incubated for 24 h. On the next day cells were treated with Botmo GF 15 in two 
concentrations, hydrocortisone (HC) and a positive control staurosporin 10
-7
 M (Stau). Caspase-3/7 
measurement was carried out all 30 minutes for 18 h. Graph A shows Botmo GF 11, Graph B 
illustrates Botmo GF 12 and Graph C displays Botmo GF 15 treated SZ95 sebocyte results. All 
measurements show good consensus with no important changes. The diagram shows the final results. 
Data are shown as mean ± standard deviation of triplicates (n = 3). These data were analyzed by two-
tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
*** 
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Figure 16 shows results of SZ95 sebocytes which were treated with Botmo GF 11, 
12, 15 and staurosporin, Staurosporin induced apoptosis significantly (p < 0.001) and 
served as a control. No caspase-3/7 releases were measurable in all SZ95 
sebocytes treated with the three Botmo GF fractions in used concentration ranges.  
 
Parallel to the caspase-3/7 experiment, measurements of neutral, polar lipids and cell 
vitality were performed. Botmo GF 15 at 1 g/ml and 0.1 g/ml produced significant 
neutral lipids up to approximately 200% (p < 0.001) or 166% (p < 0.001), respectively 
as shown in Figure 15.  
To confirm the assumption that only Bothrops moojeni venom gel filtration fractions 
11, 12 and 15 are able to significantly stimulate neutral lipids, all buffers were 
included in this test. However, this test demonstrated no caspase-3/7 activity for 
Botmo GF 11, 12, 15, buffers and hydrocortisone.  
 
 
5.1.3 ACTION OF BOTMO GF 15 ON LIPID SYNTHESIS IN SZ95 
SEBOCYTES 
 
All Botmo GF 5 to 15 demonstrated highly significant neutral lipid accumulation in 
SZ95 sebocytes, but no toxic effects. Based on these results more investigations on 
Bothrops moojeni venom fractions followed. Botmo GF 15 was used for further 
separation steps and various measurements.  
 
 
 
 
Figure 17 - Semi preparative HPLC profile of Botmo GF 15. The desalted Botmo GF fraction 15 
was processed by RP-HPLC on an Waters Alliance 2690 System using a semi preparative HPLC 
column (Vydac #218TP510 protein & peptide C18, 10 mm x 250 mm) (cf. chapter 4.2.1.4) [115]. 
 
The semi preparative HPLC showed that Botmo GF 15 fraction still contained a lot of 
compounds which await their characterization (Figure 17). Since the HPLC 
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chromatograms showed relatively well separated fractions, they have been chosen 
for further experiments. HPLC fractions were collected and lyophilized (c.f. 4.1.2; 
page 27). The collected fractions were tested in 1 µg/ml concentrations using the in 
vitro SZ95 sebocyte model.  
 
Botmo GF fraction 15 subfractions 1 to 80 were tested on SZ95 sebocytes but did not 
lead to significant increase of lipid production. As seen in Figure 18, Botmo GF 15 
subfractions 76 to 80 showed no neutral and polar lipid stimulation in SZ95 
sebocytes. However Botmo GF 15-81 led to a lipid increase of 160% (p < 0.05). 
Botmo GF 15 subfraction 82 stimulated neutral lipids in sebocytes to 223% 
(p < 0.01), Botmo GF 15-83 and Botmo GF 15-84 about 240% - 245% (p < 0.001). In 
these tests polar lipids were increased up to 140% (p < 0.05), but neutral lipids were 
again more strongly stimulated. 
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Figure 18 - Lipids in SZ95 sebocytes incubated with Botmo gel filtration fraction 15. SZ95 
sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 h. On 
the next day cells were treated with hydrocortisone (HC) and Botmo GF 15 HPLC fractions (see Semi 
preparative HPLC profile). Neutral lipids (yellow bars) and polar lipids (grey bars) were measured with 
Nile Red dye. Lipid production of pos. control cells with no treatment was set to 100%. Data are shown 
as mean ± standard deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t 
test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
 
Semi preparative RP-HPLC separation of Botmo GF 11, 12 and 15 resulted in many 
different compounds (Figure 17). The compounds, which stimulated lipogenesis in 
SZ95 sebocytes, eluted late from HPLC column (Botmo GF 15 subfractions 82 - 84). 
Two selected fractions of Botmo GF 11-101, Botmo GF 11-117 and all active GF 15 
(GF 15-82 to GF 15-84) fractions were used for further investigations. There was not 
enough time to test Botmo GF 12.  
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5.2 GEL FILTRATION FRACTION OF BOTHROPS MOOJENI VENOM 
CONTAINING PHOSPHOLIPASE A2 
 
According to gel filtration measurements, Botmo GF 1 - 18 were divided into high 
(Botmo GF 1 - 8) and low (Botmo GF 9 - 18) molecular weight components. 
Compounds in the molecular mass range of sPLA2 (13 - 15 kDa) could be identified 
in the low molecular weight Botmo GF 9 - 15 [115]. 
 
Two tests were performed, one to identify the sPLA2 IIA and the other one to 
measure the PLA2 enzymatic activity.  
All fractions Botmo GF 15-76 to 85 were found to be sPLA2 IIA as tested by an 
immunometric assay. Botmo GF 15-81 to 84 (1 g/ml) which were able to increase 
(p < 0.001 - p < 0.05) neutral lipids significantly, showed sPLA2 enzymatic activity 
(PLA2 activity assay). Furthermore, fractions Botmo GF 15-76, Botmo GF 15-79, 
Botmo GF 15-80 and Botmo GF 15-85 also comprise sPLA2 structure, showing 
however no detectable PLA2 enzymatic activity.  
 
Additionally, two fractions of Botmo GF 11 were tested. As expected both fractions 
Botmo GF 11-101 and GF 11-117 were compounds of the PLA2 family, but only 
Botmo GF 11-117 was enzymatically active (p < 0.01). Snake venom fraction Botmo 
GF 11-101 with no detectable enzymatic activity significantly stimulated neutral lipid 
synthesis in SZ95 sebocytes (Table 15).  
 
Table 15 - HPLC fractions and their phospholipase A2 activity 
 
HPLC Fraction NL in % Significance sPLA2 IIA  PLA2 activity Significance 
GF15-76 115 - Yes 0,09 - 
GF15-79 111 - Yes 0,007 - 
GF15-80 111 - Yes 0,016 - 
GF15-81 160 * Yes 0,235 * 
GF15-82 223 ** Yes 1,894 *** 
GF15-83 240 *** Yes 1,980 *** 
GF15-84 245 *** Yes 1,865 *** 
GF15-85 100 - Yes .0,012 - 
GF11-101 150 *** Yes 0,034 - 
GF11-117 310 *** Yes 2,619 *** 
Legend: NL neutral lipids, sPLA2 IIA phospholipase type IIA, (-) no significant effect. Data are shown 
as mean ± standard deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t 
test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *) 
 
The following HPLC chromatograms A and B show that enzymatically inactive PLA2 
eluted earlier from HPLC column. Fractions later in the elution showed enzymatic 
activity. 
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Figure 19 - HPLC chromatograms of Botmo GF 11 (A) and 15 (B) with PLA2 active fractions. 
Blue area or arrow contains PLA2-molecules which are enzymatically inactive. Red area or arrow 
shows PLA2 enzymatically active molecules. These chromatograms are kindly provided by Anna Maria 
Perchuc. 
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After HPLC separation more material was available from Botmo GF 11-101 and GF 
11-117 compared to Botmo GF 15-76 and Botmo GF 15-83 or Botmo GF 15-84 
fractions. Because of their higher significant neutral lipid activity and more available 
material Botmo GF 11-101 (p < 0.01) and Botmo GF 11-117 (p < 0.001) were used 
for further investigation.  
 
 
5.3 REGULATION OF LIPIDS IN SZ95 SEBOCYTES 
 
5.3.1 LIPID STIMULATION IN BOTMO GF 11-101 AND BOTMO GF 11-117 
TREATED SZ95 SEBOCYTES 
 
Previous experiments in this work showed that Botmo GF 11-101 and Botmo GF 11-
117 contain molecules which belong to the sPLA2 family, but only Botmo GF 11-117 
was identified to be PLA2 enzymatically active. sPLA2 of Naja mossambica 
mossambica snake venom were tested on SZ95 sebocytes to compare these two 
Botmo GF 11-101 and GF 11-117 fractions with a defined and identified snake 
sPLA2.  
 
sPLA2 of Naja mossambica mossambica venom was used as positive control to 
compare with other sPLA2 from snake venoms. After 24 h treatment of SZ95 
sebocytes with Botmo GF 11-101, Botmo GF 11-117 and sPLA2 of Naja mossambica 
mossambica venom (positive control) a significant increase of neutral and polar lipids 
was observed. Botmo GF 11-101 up regulates neutral lipid synthesis by 150% 
(p < 0.01). Botmo GF 11-117 leads to significantly higher expression of neutral lipids: 
310% (p < 0.001). sPLA2  from Naja mossambica mossambica snake venom affects 
neutral lipid expression by 290% (p < 0.001).  
Botmo GF 11-117 and sPLA2 from Naja mossambica mossambica snake venom 
significantly increased polar lipids (p < 0.05).  
 
These secreted PLA2 were compared with honey bee sPLA2. Honey bee PLA2 
slightly stimulated neutral lipid production in SZ95 sebocytes, but was in all other 
experiments rather inactive compared to Botmo GF 11-101, Botmo GF 11-117 and 
sPLA2 from Naja mossambica mossambica (data not shown). 
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Figure 20 - Lipid content in Botmo GF 11-101, Botmo GF 11-117 and PLA2 of Naja mossambica 
mossambica treated SZ95 sebocytes. SZ95 sebocytes were seeded at a density of 40,000 
cells/well in a 96-well plate, incubated for 24 h. On the next day cells were treated with hydrocortisone 
(HC), Botmo GF 11-101, Botmo GF 11-117 and PLA2 from Naja mossambica mossambica (PLA2 naja 
m.). Data are shown as mean ± standard deviation of triplicates (n = 6). These data were analyzed by 
two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.3.2 CYCLOOXYGENASE-2 INHIBITOR AND LIPOXYGENASE INHIBITOR 
EFFECT ON LIPID SYNTHESIS 
 
The results so far suggested that Botmo GF11-101, Botmo GF11-117 and PLA2 
stimulated lipid synthesis by activating the arachidonic acid metabolism in SZ95 
sebocytes. To inhibit the lipid synthesis by arachidonic acid, general LOX inhibitor 
(NDGA) and COX-2 inhibitors (NS398) were tested for their ability to suppress lipid 
production in SZ95 sebocytes. 
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Figure 21 - Lipid content in general LOX inhibitor and COX-2 inhibitor treated SZ95 sebocytes. 
SZ95 sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 
h. On the next day cells were pre-stimulated with arachidonic acid and treated with hydrocortisone 
(HC), Naja mossambica mossambica sPLA2 (PLA2 naja m.), general LOX inhibitor (NDGA) and COX-2 
inhibitor (NS398). Data are shown as mean ± standard deviation of triplicates (n = 3). These data were 
analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *).  
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After treatment of SZ95 sebocytes with COX-2 inhibitor significant stimulation of 
neutral lipids 120% (p < 0.05) was observed. The general LOX inhibitor did not 
stimulated neutral lipids significantly. None of these inhibitors blocked or reduced 
neutral or polar lipid synthesis in SZ95 sebocytes when compared to stimulated or 
inhibited control cells (Figure 21). 
 
 
5.3.3 SZ95 SEBOCYTES TREATMENT WITH 5-LIPOXYGENASE 
INHIBITOR AND PHOSPHOLIPASE INHIBITOR 
 
The 5-LOX inhibitor (MK886) and PLA2 inhibitor (AACOCF3) were tested for their 
influence on the lipid content in SZ95 sebocytes; however there was no significant 
change in neutral or polar lipid production in SZ95 sebocytes. In detail, MK886 
demonstrated a low neutral lipid stimulation which was not significant and AACOCF3 
showed no effect compared to control cells. 
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Figure 22 - Lipid content in 5-LOX and PLA2 inhibitors treated SZ95 sebocytes. SZ95 sebocytes 
were seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 h. On the next 
day cells were pre-stimulated with arachidonic acid and treated with hydrocortisone (HC), Naja 
mossambica mossambica sPLA2 (PLA2 naja m.), 5-LOX inhibitor (MK886) and PLA2 inhibitor 
(AACOCF3). Data are shown as mean ± standard deviation of triplicates (n = 3). These data were 
analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *).  
 
 
5.3.4 PHOSPHOLIPASE PRE-STIMULATED SZ95 SEBOCYTES TREATED 
WITH CYCLOOXYGENASE-2 INHIBITOR, 5-LIPOXYGENASE 
INHIBITOR AND PHOSPHOLIPASE INHIBITOR 
 
To get more knowledge about the increased neutral lipid synthesis in SZ95 
sebocytes after PLA2 treatment, sebocytes were pre-stimulated with Naja 
mossambica mossambica PLA2 and 1 h later treated with Botmo GF 11-117, general 
LOX inhibitor (NDGA) and COX-2 inhibitor (NS398), 5-LOX inhibitor (MK886) and 
PLA2 inhibitor (AACOCF3). Additional lipid synthesis stimulation after Botmo GF 11-
117, general LOX inhibitor (NDGA), COX-2 inhibitor (NS398) and 5-LOX inhibitor 
(MK886) was observed (Figure 23). However, under these circumstances Botmo GF 
11-117 was not able to stimulate neutral lipids synthesis in SZ95 sebocytes 
significantly.  
Treatment with PLA2 inhibitor (AACOCF3) showed not significant lipid suppression 
(5%) in SZ95 sebocytes.  
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Figure 23 - Lipids in SZ95 sebocytes pre-incubated with Naja mossambica mossambica 
phospholipase. SZ95 sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and 
incubated for 24 h. On the next day cells were pre-treated with Naja mossambica mossambica sPLA2 
(PLA2 naja m.), for 1 h, and then treated with hydrocortisone (HC), Botmo GF 11-117, general LOX 
inhibitor (NDGA) and COX-2 inhibitor (NS398), 5-LOX inhibitor (MK886) and PLA2 inhibitor 
(AACOCF3). Neutral lipids (yellow bars) and polar lipids (grey bars) were measured with Nile Red 
staining. Lipid production of control cells with no treatment was set to 100%. Data are shown as mean 
± standard deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t test, 
where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.3.5 LIPID REGULATION IN SZ95 SEBOCYTES BY GLYCYL-HISTIDYL-
LYSINE 
 
Results from the SZ95 sebocyte screening demonstrated that glycyl-histidyl-lysine 
(GHK) and its derivatives reduced neutral lipid synthesis significantly by 15% 
(p < 0.01 - p < 0.05). A measurable lipid decrease in SZ95 sebocytes of more than 
10%, which is statistically significant, is interesting for further experiments. 
Cu GHK, GHK and Tat-GHK reduced neutral lipid content in arachidonic or linoleic 
acid pre-stimulated SZ95 sebocytes (p < 0.01 - p < 0.05). Without pre-stimulation Cu 
GHK and Tat-GHK inhibited neutral lipid production by 10 - 13%. GHK had no effect 
on the lipid content in unstimulated SZ95 sebocytes (see Table 14). This result was 
comparable to earlier observations with hydrocortisone treatment [145]. 
Part of the study was to investigate if GHK is able to influence the production of 
neutral lipids and the expression of cytokines in SZ95 sebocytes, in a similar way as 
hydrocortisone. 
In Figure 24, the effects of GHK on SZ95 sebocytes in vitro are shown. For this study 
SZ95 sebocyte lipid production was stimulated either with 0.1 mM linoleic acid or 
0.01 mM arachidonic acid. Both fatty acids led to similar results. After 1 h pre-
incubation with linoleic acid or arachidonic acid, cells were treated with 
hydrocortisone or GHK.  
Treatment with GHK (1 mM) significantly inhibited pre-stimulated neutral lipid 
synthesis by 15% (p < 0.01). A GHK concentration of 0.1 mM showed no effects on 
neutral and polar lipids. No lipid inhibition or lipolytic effect on SZ95 sebocytes was 
measured without pre-stimulating neutral lipids. Cell viability and proliferation 
remained unchanged. After 24 h treatment no cytotoxicity was detected with LDH 
(data not shown). 
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Figure 24 - Lipids in SZ95 sebocytes incubated with glycyl-histidyl-lysine. SZ95 sebocytes were 
seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 h. On the next day cells 
were pre-treated with arachidonic acid for 1 h, and then treated with GHK in different concentrations. 
Neutral lipids (yellow bars) and polar lipids (grey bars) were measured with Nile Red staining. Lipid 
production of control cells with no treatment was set to 100%. Data are shown as mean ± standard 
deviation of triplicates (n = 9). These data were analyzed by two-tailed Student's t test, where 
(p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.4 CYTOKINE ASSAY - BIO PLEX TECHNOLOGY 
 
5.4.1 DETECTION OF CYTOKINE LEVELS IN BOTMO GF 11 TREATED 
SZ95 SEBOCYTES 
 
To identify inflammatory mechanisms, this study determined the release of IL-1, IL-
2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, GM-CSF, IFN- and TNF- in treated SZ95 
sebocytes. More than 120 beads/well were measured with Bio Plex fluorescence 
technology (cf. 4.2.9). In the Bio Plex test system median fluorescence intensities 
(MFI) were measured. From the ratio between MFIs and standard dilution and their 
concentrations, the concentration of every measurement was derived. Diagrams 
show the effectively measured values in MFI, whereas the text references give the 
calculated amounts in pg/ml. 
 
SZ95 sebocytes grown in cell culture medium released IL-6 and IL-8 in higher 
statistically significant quantities. All other cytokines, IL-1, IL-2, IL-4, IL-10, IL-12, IL-
13, GM-CSF, IFN- and TNF-, were not measured in significantly high amounts. 
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Figure 25 - Cytokine measurements: IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, GM-CSF, IFN-
, and TNF-. SZ95 sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and 
incubated for 24 h. Fluorescence was measured in MFI (Median Fluorescence Intensity). SZ95 
sebocytes were treated for 24 h with Biolip P 51 (50 g/ml), hydrocortisone (HC) (100 M) and Botmo 
GF 11 (1 g/ml). Graph A shows IL-1 cytokine release in SZ95 sebocytes, graph B IL-2, graph C IL-
4, graph D IL-6, graph E IL-8, graph F IL-10, graph G IL-12, graph H IL-13, graph I GM-CSF, graph J 
IFN- and graph K TNF- release in SZ95 sebocytes. Data are shown as mean ± standard deviation 
of triplicates (n = 3). These data were analyzed by two-tailed Student's t test, where (p < 0.001 ***; 
p< 0.01 **; p < 0.05 *). 
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Biolip P 51 supernatant (50 g/ml) was used as stimulator of proinflammatory 
cytokines (positive control). Biolip P 51 supernatant induces significantly (p < 0.001) 
IL-1, IL-2, IL-4, IL-6, IL-8, GM-CSF, IFN-, and TNF- release.  
Hydrocortisone (100 M) was used as negative control, which suppressed significant 
IL-6 and IL-8 expression (p < 0.001). Additionally, IL-1 (p < 0.05), IL-4 (p < 0.05), 
IFN- (p < 0.05) and TNF- (p < 0.05) expression were reduced by hydrocortisone.  
 
Botmo GF 11 treatment stimulated significantly IL-6 (p < 0.01) and IL-8 (p < 0.05) 
expression compared to untreated SZ95 sebocytes. Botmo GF 11 treated SZ95 
sebocytes showed no significant IL-1, IL-2, IL-4, IL-10, GM-CSF, IFN- and TNF- 
cytokine release in comparison to control and untreated cells. No IL-12 and IL-13 
release was observed in any SZ95 sebocyte treatment (Figure 25). 
 
 
5.4.2 CYTOKINE RELEASE IN BOTMO GF 11-101 AND BOTMO GF 11-117 
TREATED SZ95 SEBOCYTES 
 
Botmo GF 11-101 (enzymatically inactive) and Botmo GF 11-117 (enzymatically 
active) were investigated for effect on cytokine release in SZ95 sebocytes. 
Additionally sebocytes were treated with the enzymatically active snake venom 
sPLA2 from Naja mossambica mossambica (positive control).  
Botmo GF 11-101 (1 g/ml) Botmo GF 11-117 (1 g/ml) and sPLA2 from Naja 
mossambica mossambica showed no significant IL-6 and IL-8 expression. 
Treatments induced expression of IL-8 in SZ95 sebocytes, which was higher 10% 
compared to untreated cells (Figure 26). 
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Figure 26 - IL-6 and IL-8 expression in Botmo GF 11-101, Botmo GF 11-117 and sPLA2 Naja 
mossambica mossambica treated SZ95 sebocytes. SZ95 sebocytes were seeded at a density of 
40,000 cells/well in a 96-well plate and incubated for 24 h. Fluorescence was measured in Median 
Fluorescence Intensity. SZ95 sebocytes were treated 24 h with Biolip P 51 (50 g/ml), hydrocortisone 
(HC) (100 M), Botmo GF 11-101 (1 g/ml), Botmo GF 11-117 (1 g/ml) and sPLA2 from Naja 
mossambica mossambica venom (PLA2 naja m.) (100 M). Graph A shows IL-6 cytokine release in 
SZ95 sebocytes and graph B illustrates IL-8 release in SZ95 sebocytes. Data are shown as mean ± 
standard deviation of triplicates (n = 6). These data were analyzed by two-tailed Student's t test, where 
(p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.4.3 CYTOKINE LEVELS AFTER LIPOXYGENASE INHIBITOR AND 
CYCLOOXYGENASE-2 INHIBITOR TREATMENT 
 
After treatment of SZ95 sebocytes with general LOX inhibitor (NDGA) and COX-2 
inhibitor (NS398) the IL-6 and IL-8 release was measured. In this concentration 
range no IL-6 or IL-8 expression was measurable in treated SZ95 sebocytes. 
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Figure 27 - IL-6 and IL-8 measurement of NDGA and NS398 treated SZ95 sebocytes. SZ95 
sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 h. 
Fluorescence was measured in Median Fluorescence Intensity. SZ95 sebocytes were treated for 24 h 
with Biolip P 51 (50 g/ml), hydrocortisone (HC) (100 M), Botmo GF 11-117 (1 g/ml), NDGA (10 M) 
and NS398 (10 M). Graph A shows IL-6 cytokine release in SZ95 sebocytes and graph B illustrates 
IL-8 release in SZ95 sebocytes. Data are shown as mean ± standard deviation of triplicates (n = 3). 
These data were analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.4.4 5-LIPOXYGENASE AND PHOSPHOLIPASE INHIBITOR 
SIGNIFICANTLY REDUCED CYTOKINE RELEASE 
 
After having treated SZ95 sebocytes with 5-LOX inhibitor (MK886) and PLA2 inhibitor 
(AACOCF3) in similar concentrations to those used in other experiments, both 
inhibitors showed significant suppression of IL-6 and IL-8 expression. 
MK886 reduced significantly IL-6 12% (p < 0.01) and IL-8 13% (p < 0.001) 
expression in SZ95 sebocytes. The PLA2 inhibitor, AACOCF3 inhibited IL-6 12% 
(p < 0.01) expression and decreased IL-8 32% (p < 0.001) significantly in SZ95 
sebocytes. AACOCF3 was a stronger suppresser of IL-8 expression than MK886 in 
SZ95 sebocytes  
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Figure 28 - IL-6 and IL-8 expression in Botmo GF 11-117, MK886 and AACOCF3 treated SZ95 
sebocytes. SZ95 sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and 
incubated for 24 h. Fluorescence was measured in Median Fluorescence Intensity. SZ95 sebocytes 
were treated for 24 h with Biolip P 51 (50 g/ml), hydrocortisone (HC, 100 μM), Botmo GF 11-117 (1 
μg/ml), MK886 (10 μM) and AACOCF3 (100 μM). Graph A shows IL-6 cytokine release in SZ95 
sebocytes and graph B illustrates IL-8 release in SZ95 sebocytes. Data are shown as mean ± 
standard deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t test, where 
(p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.4.5 INTERLEUKIN-6 AND INTERLEUKIN-8 RELEASE IN GLYCYL-
HISTIDYL-LYSINE TREATED SZ95 SEBOCYTES  
 
Hydrocortisone (0.1 mM) significantly reduced neutral lipid synthesis (p < 0.01) in 
SZ95 sebocytes and had antiinflammatory effects. Figure 29 demonstrates that 
hydrocortisone treatment decreased IL-6 and IL-8 release (p < 0.001) in SZ95 
sebocytes. Glycyl-histidyl-lysine (GHK) (1 mM) inhibited IL-6 expression significantly 
(p < 0.001); a low non significant reduction of TNF- and IL-8 expression could also 
be shown. At this concentration, GHK reduced IL-6 expression by about 20% and IL-
8 by about 14%. All other cytokines, IL-1, IL-2, IL-4, IL-10, IL-12, IL-13, GM-CSF, 
IFN- and TNF- were not measured in significant amounts after GHK treatment 
(data not shown). 
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Figure 29 - IL-6 and IL-8 measurements of glycyl-histidyl-lysine on SZ95 sebocytes. SZ95 
sebocytes were seeded at a density of 40,000 cells/well in a 96-well plate and incubated for 24 h. 
Fluorescence was measured in Median Fluorescence Intensity (MFI). SZ95 sebocytes were treated for 
24 h with glycyl-histidyl-lysine (GHK) (1 mM), hydrocortisone (HC) (0.1 mM) and Biolip P 51 (50 μg/ml) 
supernatant. Graph A shows IL-6 cytokine release in SZ95 sebocytes, graph B IL-8 release in SZ95 
sebocytes, and graph C TNF- release in SZ95 sebocytes. Data are shown as mean ± standard 
deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t test, where 
(p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
 
 
5.5 RECEPTOR BINDING STUDIES – TRANSIENT TRANSFECTION 
 
Bothrops moojeni snake venom contains PLA2. PLA2 plays a role in lipid mediator 
release [47], which may activate PPAR. PPAR receptor binding was investigated by 
transient transfection methods to identify PLA2 or PLA2 metabolites, as PPAR 
ligands. 
For this experiment, COS/7 and SZ95 cells were transfected with PPAR luciferase 
reporter plasmids specific for PPAR, , 2.  
 
COS/7 cells were used to learn the transient transfection method. Later on, the 
method was applied on SZ95 sebocytes.  
 
 
5.5.1 TRANSIENT TRANSFECTION OF COS/7 CELLS 
 
After transfection with promoter-luciferase reporter plasmids, treatments were added 
in serum free medium as indicated, and cells were incubated for further 24 h. Firefly 
and Renilla luciferase activities were measured using the dual luciferase kit. The 
firefly luciferase values of each sample were normalized by Renilla luciferase activity, 
and data were reported as relative light units. 
*** 
*** 
C 
Results 
 
 
77 
Promoter-luciferase reporter plasmids, PPAR reporter gene or PPAR response 
elements (PPAE) were transiently transfected into cells at the same time. This PPAR 
reporter gene is a gene that encodes an easily assayed product that is coupled to the 
upstream sequence of another gene and transfected into cells. The reporter gene 
can then be used to see which factors activate PPAR or PPAE response elements in 
the upstream region of the gene of interest.  
 
In Figure 30 increasing amounts of PPAR activation were measured in transfected 
cells with constant quantities of PPAR,  and 2 in the presence of the 
corresponding selective ligands. WY14643 (100 M) was used as specific PPAR 
ligand, L165041 (1 M) as specific PPAR/ ligand, and rosiglitazone (5 M) as 
specific PPAR2 ligand. 
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Figure 30 - Identification of PPAR ligands in transiently transfected PPAR, , 2 COS/7 cells. 
COS/7 cells were seeded at 50 - 60% cell confluency/well in a 12-well plate and incubated overnight. 
The next day cells were transfected with pSG5 expression vector or PPAR, , 2 and incubated with 
(-) medium (untreated COS/7 cells), (+) corresponding PPAR,  or 2 ligand (WY14643 (100 M), 
L165041 (1 M) and rosiglitazone (5 M)), arachidonic acid (AA) (50 M), linoleic acid (LA) (100 M), 
Botmo GF 11-101 (1 g/ml), Botmo GF 11-117 (1 g/ml) and Naja mossambica mossambica sPLA2 
(PLA2 naja m.) (100 M). Graph A shows COS/7 cells transfected with PPAR, B  PPAR transfected 
COS/7 cells and C  PPAR2 transfected Cos/7 cells. Data are shown as mean ± standard deviation of 
triplicates (n = 6). These data were analyzed by two-tailed Student's t test, where (p < 0.001 ***; 
p < 0.01 **; p < 0.05 *). 
 
Highest relative luciferase intensity was detected by PPAR transient transfected 
COS/7 cells. Arachidonic acid and linoleic acid were shown to regulate gene 
expression through direct and significant interactions with PPAR (p < 0.001) and 
PPAR2 (p < 0.01). Significant interactions with PPAR (p < 0.01) were observed with 
linoleic acid treatment.  
Botmo GF 11-101 (1 g/ml) did not activate any PPAR subtype. Botmo GF 11-117 
(1 g/ml) and Naja mossambica mossambica sPLA2 (100 M) were not required for 
statistically significant PPAR activation in transiently transfected COS/7 cells.  
 
 
5.5.2 TRANSIENT TRANSFECTION OF SZ95 SEBOCYTES 
 
In SZ95 sebocytes PPAR, /, 1, 2 expression was detected [19]. This study is 
based on the hypothesis that lipid synthesis stimulating compounds bind and activate 
PPAR subtypes directly or indirectly.  
Based on the knowledge gained from transient transfection of HeLa cells (data not 
shown) and COS/7 cells, a new transient transfection method for SZ95 sebocytes 
was developed. The concentrations of the compounds used for treatment of the cells 
were similar to those which were used in sebocyte screening. Figure 31 shows the 
data of a control experiment in order to check if PPAR ligands can activate 
endogenous PPAR receptors with and without PPAR transient transfection in SZ95 
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sebocytes. Additionally, these empty vector transiently transfected SZ95 sebocytes 
were measured and used to ensure that DNA concentrations were constant in each 
transfection. 
 
Figure 31 - Relative luciferase activity measurement of transfected and treated SZ95 sebocytes. 
SZ95 sebocytes were seeded at a density of 200,000 cells/well in a 12-well plate and incubated 
overnight. On the next day cells were transfected with pSG5 expression vector or PPAR, , 2 and 
activated with respective PPAR, , 2 ligand. (-) medium (untreated SZ95 sebocytes), (+) 
corresponding PPAR ligand (WY14643 (100 M), L165041 (1 M) and rosiglitazone (5 M)) Data are 
shown as mean ± standard deviation of triplicates (n = 3). These data were analyzed by two-tailed 
Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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As seen in Figure 31, SZ95 sebocytes showed an endogenous PPAR (p < 0.01) 
and PPAR activity (p < 0.01). These results act as negative control for PPAR, , 2 
transiently transfected SZ95 sebocytes.  
All three transiently transfected PPAR subtypes were activated significantly by 
PPAR, , 2 ligands (p < 0.001). SZ95 sebocytes transiently transfected with 
PPAR without PPAR ligand treatment showed a low luciferase activity. PPAR 
transfected SZ95 sebocytes treated with PPAR ligand WY14643 (100 M) led to a 
significant increase in luciferase activity (p < 0.001). Significant PPAR activation 
(p < 0.001) was observed after treatment with PPAR ligand L165041 (1 M). This 
PPAR activation was 5 times stronger compared to non treated control cells. The 
activation was similar to results in pSG5 expression vector (empty vector) transfected 
cells with L165041 (1 M) treatment. 
A significant activation (p < 0.001) with PPAR ligand rosiglitazone (5 M) was 
confirmed (Figure 31). 
 
Additionally, lipid synthesis in SZ95 sebocytes was activated by PPAR ligand 
(WY14643). WY14643 enhanced neutral lipid synthesis (p < 0.01). L165041 and 
rosiglitazone did not show any effect on the lipid content in SZ95 sebocytes (data not 
shown).  
 
 
5.5.3 PPAR ACTIVATION BY FATTY ACIDS AND PHOSPHOLIPASE A2 
 
As a control, SZ95 sebocytes transfected with the „‟empty‟‟ pSG5 vector were treated 
with arachidonic acid, linoleic acid and compounds like Botmo GF 11-101, Botmo GF 
11-117, honey bee PLA2 and Naja mossambica mossambica snake venom PLA2. 
This experiment determined the effect of the compounds on endogenous PPAR in 
SZ95 sebocytes. Only linoleic acid significantly increased luciferase activity (p < 0.05) 
in transiently transfected SZ95 sebocytes.  
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Figure 32 - Identification of endogenous PPAR activation in transiently transfected SZ95 
sebocytes.  
SZ95 sebocytes were seeded at a density of 200,000 cells/well in a 12-well plate and incubated 
overnight. On the next day cells were transfected with pSG5 expression vector and incubated with (-) 
medium (untreated SZ95 sebocytes), arachidonic acid (AA) (50 M), linoleic acid (LA) (100 M), 
Botmo GF 11-101 (1 g/ml), Botmo GF 11-117 (1 g/ml), honey bee sPLA2 (PLA2 bee) (100 M) and 
Naja mossambica mossambica sPLA2 (PLA2 naja m.) (100 M). Data are shown as mean ± standard 
deviation of triplicates (n = 9). These data were analyzed by two-tailed Student's t test, where 
(p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
 
SZ95 sebocytes were transiently transfected with PPAR isotypes. Arachidonic acid 
and linoleic acid, as well as Naja mossambica mossambica sPLA2 stimulated an 
increase in luciferase activity for endogenous PPAR activation. However, only linoleic 
acid (100 M) activated endogenous PPAR elements in SZ95 sebocytes significantly 
(p < 0.01) (Figure 32).  
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Figure 33 - Identification of ligands for PPAR, , 2 in transiently transfected sebocytes. SZ95 
sebocytes were seeded at a density of 200,000 cells/well in a 12-well plate and incubated overnight. 
On the next day cells were transfected with PPAR, , 2 and incubated with (-) medium (untreated 
SZ95 sebocytes), (+) corresponding PPAR ligand (WY14643 (100 M), L165041 (1 M) and 
rosiglitazone (5 M)), arachidonic acid (AA) (50 M), linoleic acid (LA) (100 M), Botmo GF 11-101  
(1 g/ml), Botmo GF 11-117 (1 g/ml), honey bee sPLA2 (PLA2 bee) (100 M) and Naja mossambica 
mossambica sPLA2 (PLA2 naja m.) (100 M). Graph A shows SZ95 sebocytes transfected with 
PPAR, graph B PPAR transfected SZ95 sebocytes and graph C PPAR2 transfected SZ95 
sebocytes. Data are shown as mean ± standard deviation of triplicates (n = 6). These data were 
analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
 
After PPAR activation with PPAR ligands a significant relative luciferase activity 
(p < 0.001) was measured. PPAR activation was 5 to 10 times higher compared to 
PPAR2 or PPAR.  
As shown in Figure 33, arachidonic acid, linoleic acid, GF 11-117 and snake sPLA2 
significantly induced (p < 0.001) PPAR activation in SZ95 sebocytes. 
PPAR was significantly activated by linoleic acid (p < 0.01); a low relative luciferase 
activity was measured with arachidonic acid and snake sPLA2 (p < 0.01). A significant 
activation of PPAR2 was observed with arachidonic acid (p < 0.001) and linoleic acid 
(p < 0.001); a low significant activation was caused by GF 11-117 (p < 0.05). 
Treatment with Botmo GF 11-101 leads to no PPAR activation. SZ95 sebocytes 
treated with Naja mossambica mossambica sPLA2 activated PPAR with high 
significance (p < 0.001), PPAR (p < 0.01) and PPAR2 (p < 0.05). In comparison to 
the snake sPLA2, sPLA2 from honey bee venom showed no PPAR activation. 
 
In summary the transient transfection method was for the first time applied and 
adapted to SZ95 sebocytes. The PPAR reporter gene assay for SZ95 sebocytes was 
created to determine whether Botmo GF 11-101 or 11-117 could activate PPAR like 
PPAR ligands. For Hela and COS/7 cells the used transient transfection reagent was 
lipofectamine. For SZ95 sebocyte transfection, superfect was used instead. Chen et 
al. reported that sebocytes produce more lipids when they were cultured with 
medium without fetal bovine serum [19]. Fetal bovine serum inactivates 
lipofectamine. Additionally, superfect reagent has some more advantages compared 
to lipofectamine making the transient transfection faster and more reliable.  
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The PPAR receptor gene assays with SZ95 sebocytes demonstrated PPAR 
activations with arachidonic acid and linoleic acid treatment. Linoleic acid (100 M) 
led to an unspecific activation of all PPAR subtypes. Arachidonic acid (50 M) only 
activated PPAR and 2. In SZ95 sebocytes only Botmo GF 11-117 and Naja 
mossambica mossambica sPLA2 showed significant PPAR activation (Table 16). 
 
Table 16 - Results overview of transiently transfected SZ95 sebocytes 
 
Treatment NL PL PPARE PPAR PPAR PPAR2 
AA  *** - 137% - 378%  *** 138% - 260% *** 
LA *** - 267%  * 795%  *** 250%  ** 205%  *** 
Botmo GF11-101 ** * 100%  - 94%  - 94% - 108% - 
Botmo GF11-117 *** * 116%  - 486%  *** 107% - 108%  - 
PLA2 naja m. *** - 155%  - 306% *** 166%  * 127%  * 
Legend: NL neutral lipids, PL polar lipids, (-) no significant effect, AA arachidonic acid (50 M), LA 
linoleic acid (100 M), Naja mossambica mossambica sPLA2 (PLA2 naja m.) (100 M). PPAR 
activation is calculated in % compared to PPAR transient transfected sebocytes treated with medium. 
These data were analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
 
 
5.5.4 CYCLOOXYGENASE-2 AND LIPOXYGENASE INHIBITOR 
TREATMENT OF TRANSFECTED SZ95 SEBOCYTES 
 
Empty vector or PPAR, , 2 transiently transfected SZ95 sebocytes were treated 
with arachidonic acid, general LOX inhibitor (NDGA), COX-2 inhibitor (NS398) and in 
combinations arachidonic acid and NDGA as well as arachidonic acid and NS398. 
We started with a control experiment which determined the effect of LOX and COX-2 
inhibitors on the empty expression vector transiently transfected SZ95 sebocytes. 
NDGA as well the combination NDGA with arachidonic acid significantly increased 
luciferase activity (p < 0.001) in expression vector transfected SZ95 sebocytes.  
NS398 showed a low, not significant reduction of luciferase activity. Additionally, 
arachidonic acid and NS398 demonstrated signal suppression compared to 
sebocytes treatment with arachidonic acid.  
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Figure 34 - NDGA and NS398 activation of endogenous PPAR in transiently transfected 
sebocytes. SZ95 sebocytes were seeded at a density of 200,000 cells/well in a 12-well plate and 
incubated overnight. On the next day cells were transfected with pSG5 expression vector and 
incubated with arachidonic acid (AA) (50 M), NS398 (10 M) and NDGA (10 M). Data are shown as 
mean ± standard deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t 
test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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Figure 35 - NDGA and NS398 activation of PPAR, , 2 in transiently transfected sebocytes. 
SZ95 sebocytes were seeded at a density of 200,000 cells/well in a 12-well plate and incubated 
overnight. On the next day cells were transfected with PPAR, , 2 and incubated with (-) medium 
(untreated SZ95 sebocytes), (+) corresponding PPAR,  or 2 ligand (WY14643 (100 M), L165041 
(1 M) and rosiglitazone (5 M)), arachidonic acid (AA) (50 M), NS398 (10 M) and NDGA (10 M). 
Graph A shows SZ95 sebocytes transfected with PPAR, graph B PPAR transfected SZ95 
sebocytes, and graph C PPAR2 transfected SZ95 sebocytes. Data are shown as mean ± standard 
deviation of triplicates (n = 3). These data were analyzed by two-tailed Student's t test, where (p < 
0.001 ***; p < 0.01 **; p < 0.05 *). 
 
SZ95 sebocytes were transfected with PPAR luciferase reporter plasmids specific for 
PPAR, , 2. After transfection, sebocytes were treated with PPAR ligands, COX-2 
inhibitor, NS398 and a general LOX inhibitor, NDGA. It was hypothesized that 
blocking COX-2 and LOX enzyme activities inhibits PPAR activation by fatty acids 
and their metabolites. 
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The known inhibitor of LOX, NDGA, was selected to block general LOX activity in 
SZ95 sebocytes. Figure 35 shows a highly significant increase of luciferase activity 
for PPAR activation and a significant increase of PPAR and 2 activation after 
general LOX inhibitor NDGA treatment. Treatment with arachidonic acid and NDGA 
demonstrates a synergetic PPAR,  and 2 activation. 
Additionally in this sebocyte transfection study, COX-2 inhibitor NS398 was tested for 
PPAR activation (Figure 35).  
In comparison to transfected sebocytes treated with arachidonic acid, combined 
arachidonic acid and COX-2 inhibitor treated SZ95 sebocytes were able to inhibit 
PPAR activation. Figure 35 shows still a highly significant PPAR activation and a 
low PPAR2 activation after arachidonic acid and COX-2 inhibitor treatment. NS398 
alone shows no activation of PPAR,  and 2. 
 
In summary the LOX inhibitor NDGA activated all PPAR (p < 0.001). The combination 
treatment NDGA and arachidonic acid demonstrated a synergetic, unspecific PPAR 
activation (p < 0.001). However, NDGA did not activate lipid synthesis in SZ95 
sebocytes. NS398 exhibited no effect on any PPAR, but NS398 inhibited arachidonic 
acid activated PPAR (Table 17). 
 
Table 17 - Results overview of cyclooxygenase-2 and lipoxygenase inhibitor treated PPAR, , 
2 transiently transfected SZ95 sebocytes  
 
Result NL PL PPARE PPAR PPAR PPAR2 
AA  *** - 137%  - 378%  *** 139%  - 200% *** 
NDGA - - 490% *** 319%  *** 300%  * 418%  *** 
NDGA+AA n.d. n.d. 531%  *** 375% *** 787%  ** 1067% *** 
NS398 - - 99% - 88%  - 78%  ** 146%  - 
NS398+AA n.d. n.d. 119%  - 294%  *** 105%  * 103%  - 
Legend: NL neutral lipids, PL polar lipids, (-) no significant effect, (n.d.) no data, (AA) arachidonic acid 
(50 M), NS398 COX-2 inhibitor (10 M), general LOX inhibitor NDGA (10 M). PPAR activation is 
calculated in % compared to PPAR transient transfected SZ95 sebocytes treated with medium. These 
data were analyzed by two-tailed Student's t test, where (p < 0.001 ***; p < 0.01 **; p < 0.05 *). 
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5.6 VISUALISATION AND IDENTIFICATION OF SEBACEOUS LIPIDS 
 
5.6.1 PHASE CONTRAST MICROSCOPE IMAGING OF SZ95 SEBOCYTES  
 
SZ95 sebocytes were treated with linoleic acid, an unspecific neutral PPAR ligand, 
and arachidonic acid, a neutral PPAR ligand. Both compounds increased neutral 
lipid accumulation in cells (Figure 36, Figure 37, Figure 38). 
In contrast to untreated sebocytes, cell structure was different and cell size of linoleic 
acid and arachidonic acid treated SZ95 sebocytes was increased. Furthermore lipid 
accumulation was stimulated with fatty acid treatment. 
 
 
Figure 36 - Cultured SZ95 sebocytes. Cells 
(20,000 cells/chamber) were seeded in chamber 
slides and cultured for 48 h (200-times 
magnified). 
 
 
 
Figure 37 - Cultured SZ95 sebocytes treated 
with linoleic acid. Cells (20,000 cells/chamber) 
were seeded in chamber slides and cultured for 
24 h. Then SZ95 sebocytes were treated with 
linoleic acid (0.1 mM) for 24 h. In cytoplasm more 
lipid droplets were detected (200-times 
magnified). 
 
 
Figure 38 - Cultured, differentiated SZ95 
sebocytes treated with arachidonic acid. Cells 
(20,000 cells/chamber) were seeded in chamber 
slides and cultured for 24 h. Then SZ95 
sebocytes were treated with arachidonic acid 
(5x10
-5
 M) for 24 h. The cell morphology showed 
a late differentiation phase. Cell membrane 
shape became round and showed a lot of lipid 
droplets inside (200-times magnified). 
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5.6.2 CONTENT OF LIPIDS IN SZ95 SEBOCYTES INCUBATED WITH 
LINOLEIC ACID  
 
Cells stained with Nile Red and Hoechst 33342 point out cell structures. This 
technique allows to visualize accumulated neutral lipids (yellow, Nile Red), 
membrane lipids (red, Nile Red) and the nucleus (blue, Hoechst). Three images were 
taken and overlayed (Figure 39). 
 
A B
C
 
Figure 39 - Fluorescence staining of SZ95 sebocytes. Cells (20,000 cells/chamber) were seeded in 
chamber slides and cultured for 24 h. Then SZ95 sebocytes were treated with linoleic acid (0.1 mM) 
for 24 h. Neutral lipids (yellow) (485 / 555 nm), polar lipids (red) (544 / 620 nm) and DNA nucleus 
(blue) (385 / 420 nm) were visualized by fluorescence microscopy. (A) Staining of the nucleus was 
done with Hoechst 33342, (B) Nile Red stained polar and neutral lipids, (C) Overlay of picture A and B. 
 
Lipid synthesis in the cells was stimulated with linoleic acid. Many cytoplasmic lipid 
droplets were on the cell surface, explaining why phase contrast microscopy could 
not resolve every individual lipid droplet. SZ95 sebocytes were also monitored by 
confocal microscopy. This method scanned sebocytes in many layers allowing a 
complete view of the cells and all cytoplasmic droplets. These data were documented 
in a video sequence. This video showed that SZ95 sebocytes are surrounded by lipid 
drops (data not shown). 
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5.6.3 FLUORESCENCE MICROSCOPE IMAGING OF SZ95 SEBOCYTES 
 
Immortalized human SZ95 sebocyte differentiation is characterized by the 
intracellular accumulation of neutral lipids in the cytoplasm [199]. The lipid synthesis 
in SZ95 sebocytes was inhibited by hydrocortisone, retinoids and estrogens. It was 
increased by fatty acids and androgens [191].  
 
 
5.6.3.1 VITEX AGNUS CASTUS EXTRACT INHIBITED LIPID SYNTHESIS 
 
Only fresh Vitex agnus castus plant extract was able to inhibit lipid synthesis in SZ95 
sebocytes. This extract was not stable and lost its activity after about 3 days at 4°C. 
This experiment worked only reliably with freshly diluted Vitex agnus castus extract.  
SZ95 sebocytes were treated with hydrocortisone and Vitex agnus castus extract. 
The morphology of the cells and the cytosolic neutral lipids were documented by 
means of fluorescence microscopy. In contrast to untreated SZ95 sebocytes, cell 
size remained unchanged and smaller lipid droplets were visualized in the 
hydrocortisone and Vitex agnus casus retreated cells. However hydrocortisone and 
Vitex agnus casus extract treatment inhibited neutral lipid synthesis (Figure 40) 
(Figure 41). 
 
 
Figure 40 - SZ95 sebocytes under hydrocortisone treatment. SZ95 sebocytes were cultured for 24 
h in chamber slides to 100% confluence. One day later SZ95 sebocytes were incubated with 
hydrocortisone (0.1 mM) for 24 h. Neutral lipids (yellow) (485 / 555 nm) and polar lipids (red) 
(544 / 620 nm) were visualized by Nile Red fluorescence staining. The control showed the intrinsic 
lipid production by SZ95 sebocytes which can be inhibited by hydrocortisone. 
 
 
Control Hydrocortisone 0.1 mM 
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Control Vitex agnus castus 10 μl/ml
 
Figure 41 - SZ95 sebocytes under Vitex agnus castus water extract treatment. SZ95 sebocytes 
were cultured for 24 h in chamber slides to 100% confluence. One day later SZ95 sebocytes were 
incubated with Vitex agnus castus water 10 l/ml extract for 24 h (200-times magnified). Neutral lipids 
(yellow) (485 / 555 nm) and polar lipids (red) (544 / 620 nm) were visualized by Nile Red fluorescence 
staining. The control showed the intrinsic lipid production by SZ95 sebocytes which can be inhibited by 
Vitex agnus castus extract. 
 
 
5.6.3.2 BOTHROPS MOOJENI VENOM GEL FILTRATION FRACTION 15 
STIMULATED LIPID PRODUCTION  
 
After treatment of SZ95 sebocytes with linoleic acid or Botmo GF 15 for 24 h, 
morphology of the sebocytes and the neutral and polar lipid synthesis was 
documented by means of fluorescence microscopy. In comparison with untreated 
SZ95 sebocytes, cell sizes of treated SZ95 sebocytes seemed to be increased. 
Furthermore, lipid accumulation was enhanced in linoleic acid and Botmo GF 15 
treated cells (Figure 42) (Figure 43). 
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Control Linoleic acid 0.1 mM
 
Figure 42 - SZ95 sebocytes under linoleic acid treatment. SZ95 sebocytes were cultured for 24 h 
in chamber slides to 50% confluence. One day later SZ95 sebocytes were incubated with linoleic acid 
(0.1 mM) for 24 h (200-times magnified). Neutral lipids (yellow) (485 / 555 nm) and polar lipids (red) 
(544 / 620 nm) were visualized by Nile Red fluorescence staining. The control showed the intrinsic 
lipid production by SZ95 sebocytes which can be additionally stimulated by linoleic acid treatment. 
 
 
Control Botmo GF15 1 μl/ml
 
Figure 43 - SZ95 sebocytes under Botmo gel filtration fraction 15 treatment. Cells (20,000 
cells/chamber) were seeded in chamber slides and cultured for 24 h. Then SZ95 sebocytes were 
treated with Botmo GF 15, 1 g/ml for 24 h (200-times magnified). Neutral lipids (yellow) (485 / 555 
nm) and polar lipids (red) (544 / 620 nm) were visualized by Nile Red fluorescence staining. Control 
cells showed the intrinsic lipid production by SZ95 sebocytes which can be additionally stimulated by 
Botmo GF15 treatment. 
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6 DISCUSSION 
 
The normal function of sebaceous glands is to produce and secrete sebum, a mixture 
of cell debris and lipids including triglycerides, fatty acids, wax esters, squalene, 
cholesterol esters, and cholesterol [31, 106, 126, 161]. Sebum lubricates the skin to 
protect the skin surface against outside influences and dehydration.  
The sebaceous glands consist of sebaceous gland cells, also called sebocytes. 
Sebocytes differentiate from the outer margin to the center of the sebaceous gland, 
increasing their size and lipid content until they burst and die. With advancing age the 
size of differentiating sebocytes tends to decrease, while their number remains 
approximately the same throughout life [190]. Sebocytes show an age-related 
reduced secretory output, which results in a decrease in the surface lipid levels [34, 
122] – which is one of the typical signs of aged skin [89]. 
 
 
6.1 APPROACH TO IDENTIFY NEW ACTIVE COMPOUNDS 
INTERFERING WITH LIPID SYNTHESIS 
 
For this thesis a SZ95 sebocyte screening model was developed to search for new 
active compounds as described in chapter 4.2.3. The aim was to identify new lipid 
regulating compounds and gain more insight into regulation of lipid synthesis. Neutral 
and polar lipids were measured by direct staining of SZ95 sebocytes with Nile Red. 
At the same time cell viability was monitored by fluorescein diacetate staining. This 
screening method allows the measurement of multiple parameters in a single well. 
Two hundred samples from plant extracts, snake venom fractions, microorganism 
extracts, and synthetic peptides were screened in two different concentrations. Plants 
and peptides were chosen based on literature research. Criteria for the literature 
research were plants known in traditional medicine and peptides involved in wound 
healing, hormone regulation, and lipid regulation. Microorganism samples (Marine 
microbial mats) came from French Polynesian islands. Until now, there are no data 
available which show how marine microbial mats act on human skin cells. These 
substances have to be identified and tested for their pharmaceutical activity. 
The size exclusion chromatography of Bothrops moojeni crude venom resulted in 18 
protein fractions named Botmo GF fraction 1 - 18 (Figure 44) [115]. The potential use 
of Bothrops moojeni venom may be interesting for pharmaceutical effects [74]. 
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Figure 44 - Gel filtration chromatogram of crude Bothrops moojeni venom. Size exclusion 
chromatography of Bothrops moojeni crude venom performed on a Superdex 75 column resulted in 18 
fractions named Botmo GF fractions  1-18 (cf. chapter 4.2.1.4) [115, 116]. 
 
After SZ95 sebocyte screening 26 compounds showed significant lipid regulating 
effects either up- or down-regulating of neutral lipids in SZ95 sebocytes. Out of 26 
compounds, fractions, extracts, and peptides, which showed interesting results, the 
Bothrops moojeni snake venom gel filtration fractions (Botmo GF) were selected for 
further evaluation. Botmo GF stimulated highly significantly neutral lipid synthesis in 
SZ95 sebocytes without cytotoxicity or apoptotic effects (Figure 16). 
Other elements of this work were experiments with glycyl-histidyl-lysine derivatives 
and the Vitex agnus castus extract which demonstrated significant neutral lipid 
suppression. These investigations were only a side project in this work and are 
discussed in the appendix. 
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Figure 45 - Focal points to identify new active compounds. This matrix provides a view into the 
proceedings of this work. Legend: Glycyl-histidyl-lysine (GHK), Lactatedehydrogenase (LDH), 
Peroxisome proliferator-activated receptors (PPAR), Phospholipase A2 (PLA2), Cyclooxygenase 
(COX), Lipoxygenase (LOX). 
 
Figure 45 displays the approach of this work. With this SZ95 sebocyte screening 
model, new compounds which regulate neutral and polar lipid synthesis in SZ95 
sebocytes were identified. For this work Bothrops moojeni venom gel filtration 
fractions were chosen for up-regulation and Vitex agnus castus as well as GHK and 
GHK derivatives for down-regulation of neutral lipid synthesis in SZ95 sebocytes. 
As mentioned before, Botmo GF fractions stimulated lipid production in SZ95 
sebocytes and exhibited no apoptotic and cytotoxic effects in the concentrations 
applied. Additionally cytokine release by Botmo GF fractions treated SZ95 sebocytes 
was examined, which was statistically not significantly different than the untreated 
cells.  
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After identification of sPLA2 type IIA in Botmo GF, it was suggested that PLA2 could 
activate the arachidonic acid metabolism in SZ95 sebocytes. Products of the 
arachidonic acid metabolism like arachidonic acid and linoleic acid increase the lipid 
production in sebocytes. Both fatty acids are natural PPAR ligands [4, 129, 132, 191]. 
  
In order to investigate how Botmo GF fractions stimulated sebocyte lipids, a new 
PPAR transient transfection method for SZ95 sebocytes was developed. The result 
of sPLA2 activation may increase substrates for cyclooxygenase (COX), 
lipoxygenase (LOX) as well as for platelet-activating factor (PAF) pathway (Figure 46) 
[33]. In this model, Botmo GF fractions, comparable sPLA2, arachidonic acid, linoleic 
acid, COX-2 and LOX inhibitors were tested for activating PPAR in SZ95 sebocytes. 
To obtain more information about the lipid signaling pathway, COX and LOX 
inhibitors were used to block PPAR activation in arachidonic acid activated, PPAR 
transiently transfected SZ95 sebocytes. Furthermore, COX-, LOX- and PLA2 
inhibitors were tested on how they act on SZ95 sebocyte lipid content or cytokine 
expression. Their biological actions may be interesting for the investigation of 
lipogenesis and lipolysis, which may be essential for therapeutic agents for both dry 
and oily skin. 
 
 
6.1.1 STIMULATION OF LIPID SYNTHESIS BY BOTHROPS MOOJENI 
PROTEIN FRACTIONS  
 
In this work Bothrops moojeni snake venom showed lipid regulatory actions in SZ95 
sebocytes. Bothrops moojeni snake venom was mostly evaluated for inhibiting blood 
coagulation [74]. This was the first time Bothrops moojeni protein fractions were 
tested on SZ95 sebocytes. Surprisingly, these water-soluble fractions significantly 
increased neutral lipid synthesis in SZ95 sebocytes. 
Increased cell volume and accumulation of lipid droplets in the cytoplasm are 
phenomena indicating terminal differentiation for sebocytes. This differentiation state 
indicates holocrine secretion and cell death [173]. Interestingly, no toxic and 
apoptotic effects were observed in SZ95 sebocytes with the applied compound 
concentrations (Figure 16). 
All tested Botmo GF fractions 1 - 18 (Figure 44; Table 14) led to the activation of lipid 
synthesis in SZ95 sebocytes. Botmo GF fractions were further purified using RP-
HPLC and analyzed by diverse transversal techniques [115]. The resulting HPLC 
chromatogram showed that Botmo GF fraction still contained a lot of compounds 
which were again tested for lipid activation in SZ95 sebocytes. MALDI-TOF MS 
analyses revealed in the HPLC subfractions the presence of many compounds in the 
PLA2 mass range, while immunometric assay for detection of type IIA sPLA2 allowed 
for characterization of enzymatically active and non-active members of the PLA2 
family [135]. 
Botmo GF 15-81 to 84 as well as Botmo GF 11-101 and Botmo GF 11-117 increased 
neutral lipid production in SZ95 sebocytes (Figure 18 and Figure 20). Because of the 
amount of material and the measured lipid synthesis activation, two Botmo GF 11 
PLA2-containing subfractions were selected for further evaluation of their potential on 
the stimulation of lipogenesis in SZ95 sebocytes. These were Botmo GF fraction 11-
101 and 11-117, deprived of PLA2 enzymatic activity or possessing it, respectively. 
HPLC fractions Botmo GF 11-101 (150%) and Botmo GF 11-117 (310%) stimulated 
significantly neutral lipid production in SZ95 sebocytes (Figure 20).  
* 
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These findings on enzymatically active or inactive PLA2, which were detected in the 
low molecular weight fractions of Bothrops moojeni crude venom, are supported by 
several previous studies that identified many PLA2 in this snake venom [52, 115, 
116].  
PLA2 catalyses the hydrolysis of the sn-2 fatty acyl bond of phospholipids yielding a 
free fatty acid and a lysophospholipid [22]. The interest in PLA2 arose due to their 
unusual adaption for catalysis at the surface between aqueous and lipid phases 
[142]. 
 
 
 
Figure 46 - Interaction and interconvertibility of lipid signaling pathways. Phospholipase A2 
(PLA2), cyclooxygenase (COX), lipoxygenase (LOX), cytochrome P-450 2C (CYP2C), 
hydroxyeicosatetraenoic acid (HETE), hydroxyperoxyeicosatetranoic acid (HPETE), eicosatrinoic acid 
(EETs); acetyl-CoA lyso platelet-activating factor actyltransferase (lyso PAF AT), platelet-activating 
factor (PAF) [33] 
 
Figure 46 describes the interactions of the PLA2 lipid signaling pathway. This 
pathway can be subdivided into the arachidonic acid and lysophosphatidylcholine 
metabolism [35]. 
The release of arachidonic acid from membrane phospholipids is believed to be a 
key step in the control of eicosanoid production and involvement of inflammatory 
signaling [10, 22, 24, 47]. Fatty acids such as arachidonic acid are converted into 
eicosanoids through the action of a variety of prostaglandin and leukotriene synthesis 
mediated by cyclooxygenase, cytochrome P450 and lipoxygenase (Figure 46) [44, 
63].  
Lysophosphatidylcholine is metabolized to the platelet-activating factor (PAF). PAF is 
a potent phospholipid mediator that is produced by a variety of tissues and cells [21, 
39, 124]. High levels of platelet-activating factor acetylhydrolase II, which play a role 
in the lysophosphatidylcholine metabolism, are expressed in sebaceous glands and 
in SZ95 sebocytes [94].  
 
Data of this work indicate that Botmo GF 11-101 and Botmo GF 11-117 increase lipid 
synthesis in human SZ95 sebocytes. Surprisingly, stimulation of lipid synthesis was 
independent from PLA2 enzymatic activity in Botmo GF 11 subfractions [136]. 
So far, there may be different mechanisms which can cause lipid stimulation in 
sebocytes after Botmo GF 11-101 and Botmo GF 11-117 treatment. Both mentioned 
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pathways, acachidonic acid and lysophosphatidylcholine, may influence the fatty acid 
production. Fatty acids can be released from phospholipids, sphingomyelin, 
ceramide, lysophospholipid, phosphatidic acid, lysophosphatidic acid, diacrylglycerol, 
ceramide-1-phosphate, platelet-activating factor, and sphingosylphosphorylcholine by 
the action of PLA2. Many studies confirm that fatty acids activate neutral lipid 
production in SZ95 sebocytes [4, 87, 173]. 
It is known that PLA2 are largely involved in skin changes like lipogenesis and 
inflammation. Botmo GF 11-101 and Botmo GF 11-117 may be interesting tools for 
the investigation of sebaceous lipogenesis and may be of help in developing 
therapeutic concepts to treat age-related skin dryness. 
 
 
6.1.2 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS 
ACTIVATION BY PHOSPHOLIPASE A2 PRODUCTS 
 
To identify how Bothrops moojeni PLA2, Botmo GF 11-101 or Botmo GF 11-117 
stimulated lipid production in SZ95 sebocytes, different experiments were performed. 
To confirm the hypothesis that Bothrops moojeni PLA2 fractions activate the fatty acid 
production which can act as PPAR ligand, Botmo PLA2 fractions were tested for 
PPAR,  or 2 activation in PPAR transiently transfected SZ95 sebocytes. 
Additionally, cytokine expression and release were tested in order to obtain more 
information about the inflammatory response after SZ95 sebocyte treatment with 
Botmo GF 11-101 or Botmo GF 11-117.  
Botmo GF 11-101 and GF 11-117 led to different effects. Interestingly, with 
enzymatically inactive Botmo GF 11-101 no PPAR activation was detectable in SZ95 
sebocytes. However, Botmo GF 11-117 was a significant PPAR activator (486%) in 
transiently transfected SZ95 sebocytes compared to control (100%) (Figure 33).  
Furthermore, Botmo GF 11-101 and Botmo GF11-117 fractions did not express 
cytokines in significant amounts in SZ95 sebocytes.  
 
Previous studies described that cPLA2 is able to activate gene expression through 
PPAR and  activation and binding to the PPAR response element in HepG2 cells 
[55, 113]. Other data indicated that sPLA2 IIA released from rat mesangial cells by 
TNF- stimulates its own expression via an autocrine loop involving cPLA2 and 
PPAR [12]. However, there are no other data available so far suggesting a role of 
PLA2 IIA in the process to activate PPAR. Additionally, the detailed mechanisms for 
their actions and the regulation of the key eicosanoid-forming enzymes in cells are 
not well understood. 
Various sPLA2, when added exogenously to rat mesangial cells, can dramatically up-
regulate the expression of sPLA2 IIA [12]. The role of exogenous sPLA2 group IIA in 
regulating PLA2 expression
 has been linked to cPLA2 activation by sPLA2. Activation 
of cPLA2
 by various sPLA2 has also been reported in many other cells [9, 73, 80]. 
That involves cPLA2 and intracellular lipid mediator formation to activate the nuclear 
receptor PPAR. In detail, these cPLA2 activate arachidonic acid pathways which 
can further metabolize and produce eicosanoids. These resulting eicosanoids such 
as fatty acids, leukotrienes and prostaglandins are natural PPAR ligands [12, 20, 26, 
33, 75, 182]. An additional study confirmed that sPLA2 IIA has no influence to 
activate cytokine transcription [113]. 
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However, various PLA2 forms may play different roles in cell lipid metabolism and in 
the regulation of cell functions in various cells types. As mentioned before several 
cell culture models revealed that more than one PLA2 is involved in cellular regulation 
and lipid messenger formation.  
 
In this work both emphasized Botmo GF 11-101 and Botmo GF 11-117 activate lipid 
production in SZ95 sebocytes by obviously different biological pathways. 
Interestingly, the enzymatically inactive Botmo GF 11-101 was not able to activate 
PPAR. Enzymatically inactive Botmo GF 11-101 may stimulate lipid synthesis on a 
not yet investigated mechanism. However, enzymatically active Botmo GF 11-117 
and Naja mossambica mossambica PLA2 activate PPAR.  
 
 
6.1.3 COMPARISON BETWEEN BOTMO GEL FILTRATION FRACTION, 
HONEY BEE AND NAJA MOSSAMBICA MOSSAMBICA 
PHOSPHOLIPASE A2 
 
Since first unexpected results identified PLA2 in Bothrops moojeni venom gel filtration 
fractions showing lipid synthesis stimulation in SZ95 sebocytes, two different sPLA2 
(comparable snake Naja mossambica mossambica and honey bee) were tested for 
PPAR activity in transiently transfected SZ95 sebocytes. The aim was to investigate if 
the functions found with Botmo GF could also be achieved with other sPLA2. 
Naja mossambica mossambica sPLA2 increased neutral lipid synthesis and polar 
lipid synthesis (Figure 22). Naja mossambica mossambica sPLA2 showed a high 
significance of PPAR (306%) and a low significance of PPAR (166%), PPAR 
(127%) induction in transiently transfected SZ95 sebocytes (Figure 33). SZ95 
sebocytes treated with Naja mossambica mossambica sPLA2 released 10% more IL-
8 compared to control cells which was not significant (Figure 26). Although honey 
bee PLA2 stimulated lipid production in SZ95 sebocytes, no PPAR activation was 
observed. 
Secreted PLA2 can be divided in five different classes based on sequence criteria. 
Four classes share the catalytic activity but the fifth class of sPLA2 group contains 
sPLA2-like proteins [93]. These proteins bear 80% of structural homology towards 
class I/II enzymes but they are catalytically inactive due to one or more amino acid 
substitutions [142]. 
Class I and II enzymes are abundant in snake venom, human exocrine pancreas and 
human spermatozoa. Honey bee sPLA2 belongs to class III. Compared to its class I/II 
relatives [74, 115], bee venom sPLA2 is relatively insensitive [142]. This may explain 
the low lipid accumulation and no affinity to PPAR binding in SZ95 sebocytes by bee 
venom sPLA2. 
As mentioned before Botmo GF 11-101 is a non enzymatically active PLA2 which 
may belong to sPLA2 group V. Interestingly, a sPLA2 from Naja nigricollis venom 
inhibited the prothombinase complex by non enzymatic mechanisms. Additionally, 
those special snake venom proteins without detectable enzymatic activity inhibited 
blood coagulation [74]. These observations of another PLA2 isolated from a snake 
may prove the activity on lipid synthesis in sebocytes by a non enzymatic mechanism 
of Botmo GF 11-101 action. 
Botmo GF 11-117 and Naja mossambica mossambica sPLA2 lead to comparable 
results. The SZ95 experiments suggested that enzymatically active PLA2 Botmo GF 
11-117 is able to activate lipid synthesis in these cells by utilizing or activating the 
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arachidonic acid metabolism. Enzymatically active sPLA2 IIA like Botmo GF 11-117 
and Naja mossambica mossambica sPLA2 showed a significant PPAR activation in 
SZ95 sebocytes. These enzymatically active PLA2 may activate directly the 
arachidonic acid pathway and mediators which activate PPAR. The lipid synthesis 
and PPAR activation of PLA2 in SZ95 sebocytes seem to be sPLA2 class dependent. 
 
 
6.1.4 INHIBITION OF PHOSPHOLIPASE A2 IN SZ95 SEBOCYTES  
 
PLA2 activated significantly neutral lipid synthesis in SZ95 sebocytes. Recently it was 
hypothesized that the role of sPLA2 group IIA in regulating PLA2 expression
 has been 
linked to cPLA2 activation by secreted PLA2. To get more knowledge about the 
mechanism of lipid stimulation, which was suggested to involve the arachidonic acid 
pathway including cPLA2, we tried to block the activation by a cPLA2 inhibitor 
(AACOCF3).  
The inhibitory function of AACOCF3 on PLA2 activity resulted in suppression of the 
arachidonic acid release by cPLA2 and the unspecific reduction of 5-LOX [36-38]. 
Furthermore, earlier studies showed that specific cPLA2 inhibitors suppressed 
eicosanoids and PAF biosynthesis [16, 43, 170].  
 
The cPLA2 inhibitor AACOCF3 was tested on SZ95 sebocytes to control lipid 
synthesis and reduce cytokine expression. AACOCF3 treatment had no significant 
influence on the lipid content of SZ95 sebocytes. In addition, AACOCF3 was not able 
to significantly suppress linoleic acid pre-stimulated lipids in SZ95 sebocytes (Figure 
22). In Naja mossambica mossambica PLA2 pre-stimulated SZ95 sebocytes 
AACOCF3 reduced neutral lipid synthesis by about 5%.  
However, this study demonstrated a significant reduction of IL-6 (12%) and IL-8 
(31%) expression by PLA2 inhibitor AACOCF3 in linoleic acid pre-stimulated SZ95 
sebocytes (Figure 28).  
Additionally, in another study AACOCF3 reduced oleic acid induced IL-8 production 
[144]. AACOCF3 inhibits production of lipid mediators, which stimulate the cytokines 
IL-6 and IL-8 [80]. These studies confirm our observations, which demonstrated 
significant IL-6 and IL-8 reduction.  
 
In conclusion our results showed SZ95 sebocytes treated with AACOCF3 did not 
block lipid synthesis but reduced cytokine expression, which is supported by several 
previous studies [144]. This experiment shows that AACOCF3 is a very potent 
cytokine IL-6 and IL-8 suppressor in human SZ95 sebocytes.  
 
 
6.1.5 5-LIPOXYGENASE INHIBITOR TREATMENT OF SZ95 SEBOCYTES 
LEADS TO A STRONGER REDUCTION OF CYTOKINE RELEASE 
THAN A GENERAL LIPOXYGENASE INHIBITOR 
 
As a comparison to the general lipoxygenase (LOX) inhibitor (NDGA), the 5-
lipoxygenase (5-LOX) inhibitor MK886 was tested in the context of lipid production 
and cytokine expression. NDGA treatments led to low, statistically not significant 
activation of lipid synthesis. MK886 slightly stimulated neutral lipid synthesis.  
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In general, LOX inhibitor (NDGA) treated sebocyte cytokine expression was not 
relevant compared to positive control (Biolip P51) treated cells. In comparison to 
NDGA, MK886 significantly reduced the release of the cytokines IL-6 (12%) and IL-8 
(13%) expression in SZ95 sebocytes (Figure 28). 
 
It has been reported that significant amounts of 5-LOX and low levels of 15-
lipoxygenase (15-LOX) are expressed in SZ95 sebocytes both at the mRNA and 
protein level [4, 188]. The binding of leukotriene B4 (LTB4) to LTB2-receptors 
activates 5-lipoxygenase in sebaceous gland cells, whereas 15-lipoxygenase-2 will 
not be activated by 15-hydroxyeicosatetraenoic acid (15-HETE) [148]. 
These activities include effects of LOX products which act directly as PPAR ligands, 
but may also act indirectly by modulation of MAP kinase phosphorylation of PPAR 
[79]. The LOX products, including LTB4 [69], activate PPAR [179].  
 
Generally, LOX inhibitors reduce LOX catalyzed reactions. MK886 reduces 
leukotriene syntheses LBT4 [95, 195]. In an in vivo study, 5-LOX inhibition reduced 
inflammatory effects, which correlated with reduction of the sebaceous gland lipid 
content and the reduction of free fatty acids. However, leukotriene B4 amounts in skin 
surface lipids were unchanged [184].  
The observations of cytokine expression made with NDGA and MK886 treated SZ95 
sebocytes correspond to results from in vivo studies which consider 5-LOX inhibition 
on human skin. In our in vitro experiments MK886 stimulated neutral lipid synthesis. 
This result is contrary to in vivo observations. 
Both inhibitors did not block neutral and polar lipid synthesis in sebaceous gland 
cells. However, MK886 treatment of SZ95 sebocytes led to a stronger reduction of 
cytokine release than NDGA. MK886 significantly reduced IL-6 and IL-8 effects in 
SZ95 sebocytes. The 5-LOX inhibitor suppression effect of cytokines is supposed to 
be mediated by PPAR. These results suggest that MK886 may be more effective on 
SZ95 sebocytes compared to NDGA.  
 
 
6.1.6 LIPOXYGENASE INHIBITOR ACTIVATES TRANSIENTLY 
TRANSFECTED PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTOR ISOFORMS 
 
PLA2 activates the arachidonic acid metabolism which results in production of LOX 
and COX enzymes. These enzymes and fatty acid and their metabolites activate 
PPAR isotypes. Nordihydroguaiaretic acid (NDGA) was used as a non specific 
inhibitor for lipoxygenases. NDGA was reported to inhibit the hormonally induced 
differentiation in primary rat adipocytes [107, 150] and it was demonstrated that the 
glucose uptake stimulated by arachidonic acid in cells was blocked by NDGA [82, 
107], 
Surprisingly, NDGA as well as the combination of NDGA with arachidonic acid led to 
a significant activation of endogenous PPAR in empty expression vector transfected 
SZ95 sebocytes (Figure 34). Additionally, NDGA activated all PPAR, , 2 
significantly in transiently transfected SZ95 sebocytes. A combination treatment with 
NDGA and arachidonic acid showed a synergetic PPAR activation compared to 
NDGA treatment alone. PPAR showed the strongest activation. This ligand binding 
study suggested that NDGA binds or interacts directly to PPAR, , 2 in transiently 
transfected SZ95 sebocytes (Figure 35).  
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Data from Thuillier et al. confirm that the general LOX inhibitor NDGA directly binds 
to PPAR [163]. When NDGA was tested on primary keratinocytes, NDGA blocked 
PPAR activity and differentiation of the cells. The reported reduction of PPAR activity 
induced by NDGA [163] contradicts the SZ95 sebocyte results. During SZ95 
sebocyte experiments NDGA unexpectedly stimulated PPAR, , 2 activities. A 
notable observation by Yu et al. was that the general LOX reducing agent NDGA 
actually promotes LOX reactivity. The LOX products such as hydroxyeicosatetraenoic 
acid (HETE) and 15(S)-hydroperoxyeicosatetraenoic acid (HPETE) [177] may 
unspecifically trigger PPAR [177, 178] which may confirm the PPAR activation in our 
SZ95 sebocyte experiments. 
 
The remaining PPAR activity thus might be triggered by other arachidonic acid 
metabolites such as LTB4 and 15-HETE. In conclusion lipoxygenase products which 
rise after NDGA treatment may stimulate unspecifically PPAR, , 2.  
 
 
6.1.7 INHIBITION OF CYCLOOXYGENASE IN ARACHIDONIC ACID 
ACTIVATED PEROXISOME PROLIFERATOR-ACTIVATED 
RECEPTOR, , 2 TRANSIENTLY TRANSFECTED SZ95 
SEBOCYTES 
 
NS398 is a selective COX-2 inhibitor. PPAR,  or 2 transiently transfected SZ95 
sebocytes treated with arachidonic acid induced significant PPAR and PPAR2 
activation. The treatment with NS398 alone did not activate PPAR in transiently 
transfected sebocytes, but NS398 inhibited and abolished arachidonic acid activated 
PPAR,  and 2. The strongest PPAR inhibition induced by NS398 was observed in 
PPAR transiently transfected SZ95 sebocytes (Figure 35). 
 
Data presented by Iwana et al. affirmed an increased formation of intracellular lipid 
synthesis after treatment with the COX-2 inhibitor NS398. This inhibitor reduces 
PGF2 and PGE2 levels but increases ∆15-PGJ2 production and triacylglycerol 
synthesis which is connected to the augmentation of lipid droplet formation in 
sebocytes [56, 63, 188]. 
Additionally, NS398 was suggested to be associated with an increase in 
diacylglycerol acyltransferase activity in hamster sebocytes [63]. Diacylglycerol 
acyltransferase is involved in the lipogenesis pathway [149]. The involvement of 
prostaglandins in the formation of intracellular lipid droplets and the COX-2 
depending pathway in hamster sebaceous glands were investigated. 
In addition arachidonic acid induced accumulation of lipids in SZ95 sebocytes which 
activate PPAR [63, 173]. We observed that NS398 partially reduced a part of the 
arachidonic acid activated PPAR,  and 2 in SZ95 sebocytes, which may result 
from decreased PGF2 and PGE2 levels [63]. Two studies confirmed the inhibition of 
PPAR [176] and PPAR by NS398 [123].  
 
In summary, the NS398 does not act on PPAR in SZ95 sebocytes. NS398 treatment 
of arachidonic acid activated PPAR in PPAR, , 2 transiently transfected SZ95 
sebocytes showed a suppression of PPAR activation, while still showing more 
activation than control cells. Since NS398 is a known PGF2 and PGE2 inhibitor, it 
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can be assumed that this effect is caused by PGF2 and PGE2 reduction. The 
inhibition of the PPAR ligand PGF2 and PGE2 may reduce PPAR, , 2 activation as 
demonstrated by the results presented in this work. 
PPAR inhibition by NS398 in this study was more powerful than that of PPAR and 
2. This provides evidence that the inhibition of the lipogenesis pathway, which 
exhibits proinflammatory activities and activation of PPAR [4, 63, 188] is highly 
interesting for further research manipulating the prostaglandin pathway to regulate 
PPAR activation. 
 
 
6.1.8 ACTIVATION OF TRANSIENTLY TRANSFECTED PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTORS, , 2 
 
Empty vector transfections were control experiments. No activation of empty vector 
transiently transfected sebocytes were expected. Interestingly, significant 
endogenous PPAR and 2 activation was observed in empty vector transiently 
transfected SZ95 sebocytes.  
As observed in previous studies endogenous PPAR, , and  genes were expressed 
in sebocytes and sebaceous glands [19, 30, 132, 167]. One study described PPAR 
as the predominant isoform in freshly isolated and cultured preputial rat sebocytes. 
PPAR and  were also activated but to lower levels [72]. PPAR/ seems to be 
more important in the terminal differentiation stage of sebocytes [19, 72], Additionally, 
Alestas et al. observed PPAR and 1 are the predominantly activated PPAR 
isotypes in SZ95 sebocytes, while the expression of PPAR and 2 was very low [4].  
 
Furthermore, linoleic acid led to an unspecific activation of all transiently transfected 
PPAR subtypes whereas arachidonic acid only activated PPAR and 2. These data 
suggest that fatty acids like arachidonic acid and linoleic acid are unspecific PPAR 
ligands. Although the PPAR subtypes overlap in ligand recognition, there was a clear 
preference of the PPAR subtype for arachidonic and linoleic acid treated SZ95 
sebocytes observed. Both fatty acids activated PPAR to the same extent as the 
specific PPAR ligand WY14643. Additionally, the activation of PPAR by linoleic or 
arachidonic acid was similar in both transiently transfected COS/7 cells and SZ95 
sebocytes (Figure 30) (Figure 33). Linoleic acid and arachidonic acid significantly 
stimulated neutral lipid production in SZ95 sebocytes. 
Numerous studies described linoleic acid as a non specific natural PPAR and / 
ligand [129, 191]. Arachidonic acid is reported to be a natural PPAR ligand [4, 191]. 
Arachidonic acid derivatives like leukotriene and prostaglandin are the PPAR 
agonists of PPAR, /, and  isoforms [61, 71, 77]. However, data from Kersten, 
Wahli and Krey et al. confirm that these fatty acids are potent activators of all three 
PPAR and they observed a clear preference for the PPAR subtype activation [71, 
77]. Fatty acids have been shown to regulate gene expression through direct 
interactions with PPAR [27, 77, 129]. 
 
This study confirmed that arachidonic and linoleic acid, which activate PPAR and 2, 
stimulated lipid production in SZ95 sebocytes [137]. Studies of Rosenfield 
corroborated that PPAR and  activators were found to stimulate lipid droplet 
accumulation in cultured immature sebocytes [130-132]. PPAR mediates early 
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lipogenic steps to sebocyte function, and PPAR may play a role in stimulating 
sebocyte lipogenesis. PPAR/ may contribute to lipid biosynthesis in sebocytes 
under certain circumstances, like in response to the high concentration found in 
sebum, which was synthesized by sebocytes [129].  
 
In short, these data suggest that fatty acids unspecifically activate PPAR in a dose-
dependent manner. Structurally diverse fatty acids may have the capacity to act 
directly on gene expression by binding to and activating PPAR, / and 2 [77]. The 
fact that linoleic and arachidonic acid act as unspecific ligands of PPAR nuclear 
receptors in SZ95 sebocytes reveals that both may activate the PPAR pathway via 
the same mechanism. Possibly these fatty acids activate eicosanoid metabolism and 
the resulting products such as LTB4, prostaglandin and 15-HETE activate PPAR. 
 
 
6.1.9 CONCLUDING REMARKS  
 
Data presented in this work revealed that Bothrops moojeni venom fractions GF 11-
101 and GF 11-117 contain sPLA2, which were identified for lipid regulating or 
stimulating activity in SZ95 sebocytes. Surprisingly, the newly identified fractions 
included both enzymatically active and inactive PLA2 proteins. 
The mechanism how sPLA2 Botmo GF 11-101 or Botmo GF 11-117 activate and 
regulate lipid synthesis in SZ95 sebocytes is not completely understood. 
Interestingly, the enzymatically inactive Botmo GF 11-101 was not able to activate 
PPAR. Botmo GF 11-101 may stimulate lipid synthesis on a not yet investigated 
mechanism. 
The PPAR activation of enzymatically active Botmo GF 11-117 suggests that Botmo 
GF 11-117 activates PLA2, which induces eicosanoid and PAF production, followed 
by lipid stimulation and PPAR activation.  
An important remaining question concerns the identification of the early cellular 
events that are used by the different sPLA2. It is speculated that sPLA2 activates 
cPLA2. This cPLA2 may move to the interior of the cell and activates the arachidonic 
acid or lysophosphatidylcholine metabolism. The resulting molecules of the 
metabolisms are COX, LOX, PAF and metabolites which stimulate lipid synthesis and 
PPAR [12]. Interestingly, cPLA2 inhibitor AACOCF3 was not able to block significantly 
PLA2 or linoleic acid induced lipid stimulation in SZ95 sebocytes. 
However, the exact pathway is still not identified. Botmo GF 11-101 and 11-117 
might be interesting tools for the investigation of sebocyte lipogenesis and may be 
helpful to the development of therapeutic concepts for the treatment of age-related 
skin dryness. 
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7 OUTLOOK 
 
This sebocyte screening model has been proven to be an excellent alternative to cell 
culture models using animal cells. Moreover, the composition of intracellular lipids 
from hamster sebaceous gland-derived cells is similar to that of human sebocytes 
with the exception that hamster sebocytes do not contain the human sebocyte-
specific lipids, squalene and wax esters [62]. Cultured SZ95 sebocytes maintained 
properly preserve the major characteristic properties of human sebocytes in vivo and, 
therefore, the human sebocyte culture model is closer to the human in vivo situation 
[46, 185, 197]. 
The number of tests which have been carried out and the number of results produced 
show that this SZ95 sebocyte cell culture model is reliable, fast and usable to quickly 
run series of substance screenings [197].  
The data presented in this work indicate that Botmo GF fractions 11-101 and 11-117 
can increase lipid synthesis in human SZ95 sebocytes. Surprisingly, stimulation of 
lipid synthesis was independent of PLA2 enzymatic activity in Botmo GF 11 
subfractions. 
 
To gain better insight into age-related lipid behavior of Botmo GF 11-117 and Botmo 
GF 11-101 treated sebocytes, the compounds should be tested on another SZ95 
sebocyte model. A newly developed sebocyte culture model by Makrantonaki et al. 
[83, 85] may deliver information about lipid regulation in hormonally aged SZ95 
sebocytes. During life IGF-1, GH, 17-estradiol, progesterone, DHEA and 
testosterone levels in women and men decline. In vitro sebocytes treated with 
hormones that can be found in a 60-year old woman produce a lower level of lipids 
than those treated with a hormone cocktail of a 20-year old woman [83, 85]. It would 
be interesting to test Botmo GF 11-101 and 11-117 on these hormonally aged SZ95 
sebocytes to determine whether Botmo GF 11-117 or Botmo GF 11-101 can activate 
lipid synthesis in “young” respectively “aged” sebocytes without cytotoxicity or 
apoptotic effects in equal measure. 
Botmo GF 11-101 and Botmo GF 11-117 might be interesting subjects for the 
investigation of sebocyte lipogenesis and may be helpful to the development of 
therapeutic concepts for the treatment of age-related skin dryness.  
Additionally, analysis of secreted or accumulated lipids from SZ95 sebocytes could 
provide insight into lipid composition and associated effects. It is reported that photo-
oxidized lipids of sebocytes are inflammatory mediators. Sato et al. described a 
method to analyze the intracellular lipid content of sebocytes. Lipids were collected 
and then subjected to an automatic thin-layer chromatography Iatroscan [121, 134, 
146]. 
 
In conclusion, sebocyte culture models provide new chances for further research on 
sebaceous gland disorders, dry skin and aged skin effects. They are useful tools for 
understanding the pathophysiological mechanisms of these skin effects. They also 
facilitate the search for biologically active ingredients, new pharmaceuticals and 
cosmetics for anti-ageing, seborrheic and dry skin treatment. 
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8 APPENDIX 
 
 
8.1.1 LIPID INHIBITION BY GLYCYL-HISTIDYL-LYSINE 
 
Glycyl-histidyl-lysine (GHK) is a liver like growth factor derived from parathyroid 
hormone. It is a very rare sequence in human proteins, mainly existing in 
inflammation-associated proteins and proteins of the extracellular matrix. This 
tripeptide has a high affinity to Cu2+ [29, 120]. In human plasma and wound areas, 
GHK is likely to exist as a mixture of GHK and GHK Cu2+. GHK and GHK Cu2+ were 
investigated for wound healing effects and anti-inflammatory actions. These peptides 
heal broken and damaged skin and improve the quality of intact, undamaged skin 
[119]. 
Due to known actions of GHK on skin and hair follicles this copper peptide is used in 
cosmetic skin, hair care and dermatological skin renewing products. Formulations 
containing GHK Cu2+ increase skin elasticity, reduce wrinkles, and result in the 
removal of skin imperfections, such as sun damage marks, while producing an 
increase in subcutaneous fat cells [118].  
 
Hydrocortisone is identified for wound healing effects, as well as suppression of 
neutral lipid content and cytokine release in SZ95 sebocytes [145]. For this reason, it 
was hypothesized that the wound healing properties of GHK may reduce neutral lipid 
synthesis and may suppress cytokine release in SZ95 sebocytes. 
The results in this work document for the first time a lipolytic effect which was initiated 
by GHK. All tested GHK derivatives with and without Cu2+ showed a suppression of 
the lipid content in confluently grown SZ95 sebocytes. Only GHK demonstrated a 
significant activity in pre-stimulated SZ95 sebocytes, but not in non-stimulated SZ95 
sebocytes. Treatment with GHK significantly inhibited the content of neutral lipids by 
15%, but not of polar lipids which are representing cell membrane lipids in linoleic 
and arachidonic acid pre-stimulated, lipid accumulating SZ95 sebocytes. 
Cell viability and proliferation remained unchanged for all data sets. Additionally, in 
this study GHK showed an inhibition of cytokine release, IL-6 by 13% and IL-8 by 
15% [138]. 
 
Our results correspond to in vivo observations which have documented that GHK 
derivatives can show healing effects. The inflammatory response simulated with the 
pre-treatment of linoleic acid or arachidonic acid resulted in lipid increase as well as 
cytokine expression in SZ95 sebocytes. GHK treatment inhibited both inflammatory 
cytokines. Another study showed that the morphology of experimental wounds 
treated with GHK and GHK Cu2+ regenerated wound edge. The wound area was 
filled with hair follicles and sebaceous glands [109, 119]. The observed cytokine 
suppression was monitored by GHK Cu2+ treatment which has an inhibitory effect on 
IL-1 in rat pancreatic islets [171]. Also in cell culture experiment GHK Cu2+ reduces 
the secretion of TGF-1 in normal fibroblasts [92].  
Until know, the mechanism of action of GHK and its derivatives is not identified. GHK 
insert their hydrophobic moieties on the external bilayers of liposomes leaving the 
tripeptide on the surface of vesicles. This behavior has no influence on the motion of 
phospholipid polar heads but reduces the penetration of other molecules, this way 
increasing the stability of the vesicles. The binding of GHK to phospholipid bilayers 
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was determined. Moreover, the influence of these peptidolipids on several 
physicochemical properties of liposomes was studied. Binding experiments indicate a 
high affinity of these peptidolipids for lipids ordered in liposomes [6]. 
 
In conclusion, the mechanism how GHK and GHK derivatives regulate lipid synthesis 
or cytokine expression is not fully identified. GHK negatively affects lipid synthesis 
when added to SZ95 sebocytes and reduces inflammatory cytokines in numerous 
experiments. These biological activities of GHK might be interesting for treatments to 
normalize skin lipid synthesis and against inflammations. 
 
 
8.1.2 REDUCTION OF NEUTRAL LIPID PRODUCTION BY VITEX AGNUS 
CASTUS EXTRACT 
 
Vitex agnus castus extracts showed a significant suppressing effect on neutral lipid 
production in SZ95 sebocytes. This experiment worked only reliably with freshly 
diluted Vitex agnus castus extract (100% water extract). This extract was not stable 
and lost its activity after about 3 days at 4°C.  
 
In the traditional herbal pharmacology Vitex agnus castus extracts were used for the 
treatment of premenstrual syndromes. That suggests that compounds in the Vitex 
agnus castus extracts may be hormonally active.  
A cell culture study revealed an estrogen action of Vitex agnus castus extract on 
steroid release. Jarry et al. identified the flavonoid apigenin, a selective 
phytoestrogen, which was recognized to act on ER [86]. Another study described 
the expression of ER and ER in human SZ95 sebocytes [86]. This suggests that 
phytoestrogen may reduce neutral lipid synthesis in sebocytes. However, both 
mentioned studies worked with 68% ethanol extract which means that they isolated 
more phytoestrogen from Vitex agnus castus than we can with a water extract. 
 
Up to know it has not been investigated how Vitex agnus castus water extract 
suppressed the neutral lipid synthesis in sebocytes. Neither the mechanism nor the 
exact compounds which act on the lipid production have been identified. Vitex agnus 
castus extracts may be interesting for further investigations to suppress lipid 
synthesis in sebaceous glands or SZ95 sebocytes. 
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